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Solubility is the solution

Abstract
The validation of small molecule inhibitors identified by high throughput
screening requires a set of robust assays for interaction analysis. Here I
describe the implementation of three methods: bioluminescence resonance
energy transfer (BRET) for the analysis of protein/protein interaction in
cells, surface plasmon resonance (SPR) for the measurement of binding
kinetics in vitro and capture compound mass spectrometry (CCMS) for the
determination of binding specificity in proteome.
All the methods described were tested on cytohesins, a family of guanine
nucleotide exchange factors. The very recent discovery of their additional
role in the regulation of receptor tyrosine kinases (RTKs) signalling and the
availability of specific small molecule inhibitors (the Secins) made them an
interesting target.
BRET was applied to the analysis of a possible binding of the cytohesin
ARNO to the RTK EGF receptor (EGFR). Two strategies were devised: a
direct, where the interaction of ARNO and EGFR was monitored, and an
indirect, which followed the changes in the EGFR/EGFR interaction upon
overexpression of ARNO.
Two SPR approaches were developed to analyse the interaction between
ARNO and the EGFR on the one hand, and to determine the kinetic pa-
rameters of binding of ARNO to its inhibitor Secin16 on the other hand.
For CCMS, a photoreactive affinity based SecinH3 probe (SecinH3-TPD)
was synthesised and its ability to specifically label ARNO was shown, al-
though the labelling yield was limited by low solubility. A protocol for the
enrichment, digestion and MS-analysis of the labelled proteins was estab-
lished.
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1Introduction
Small G proteins, or GTPases, are switches which regulate protein activity and local-
isation by cycling between an inactive guanosine diphosphate (GDP)-bound and an
active guanosine triphosphate (GTP)-bound conformation. In their GTP-bound state
they interact with effector proteins to induce downstream signalling events (Fig. 1.1).
The GDP-GTP cycle is highly regulated by various classes of proteins. Guanine
nucleotide exchange factors (GEFs), for example, induce the release of bound GDP,
which is then replaced by GTP, more abundant in the cell, while GTPase-activating
proteins (GAPs) provide essential catalytic groups for GTP hydrolysis1.
G G
GDP
GDPGTP
GTP
GEF
GAP
Effector
G
GTP
Effector
Figure 1.1: Regulation of GTPases - Small G proteins cycle between an inactive
GDP-bound and an active GTP-bound state. Exchange of GDP for GTP is catalysed
by guanine nucleotide exchange factors (GEFs), while GTPase-activating proteins (GAPs)
induces hydrolysis of GTP back to GDP. In the active state, GTPases interact with effectors
molecules to trigger downstream signalling.
GTPases are ubiquitously present and involved in various essential cellular pro-
cesses, thus their disregulation is often cause of serious medical conditions. Indeed,
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Ras, after which the Ras superfamily of small G proteins is named, was found to be
aberrant in ∼33 % of the human tumours2.
The more than 150 members of the Ras superfamily are divided in five major fam-
ilies and are key regulators of several aspects of normal cell growth and malignant
transformation. While the members of the Ran family are responsible for nuclear
import/export, nuclear envelope formation and spindle formation, Ras GTPases are
mainly associated with transcription, cellular differentiation and proliferation. Rho
family members control cell shape, cytoskeleton and cell migration, and Rab and Arf
small G proteins are involved in vesicle-associated processes1. The adenosine diphos-
phate (ADP)-ribosylation factors (ARFs) family is of interest for this project and is
presented in detail in next section.
1.1 ARF GTPases
ARFs were first described as a cellular activity required for cholera toxin to ADP-
ribosylate an heterotrimeric G protein and exerts its toxic effect3 but it was then
readily identified as a GTP-binding protein4 and its primary role in the regulation of
vesicular transport is now well established5.
The 6 members of the ARF family are divided in three classes. Class I comprises
ARF1-3 and is involved in the assembly of vescicle coat complexes, ARF4-5 are part of
Class II and the unique member of Class III, ARF6, regulates endocytosis, cytokinesis
and cytoskeletal actin assembly5,6. While the class I and II ARFs are concentrated in
the Golgi, ARF6 associates with the plasma membrane and a subset of endosomes at
the cell periphery5.
1.1.1 Structural features
ARFs have a mirystoylated N-terminal amphipathic helix, necessary for membrane
binding, and two switch regions, which are responsible of binding of the effectors7.
GDP-bound ARF is mainly cytosolic, while ARF-GTP is bound to the membrane.
Indeed, exchange from GDP to GTP changes the conformation of the switch regions
moving the interswitch away from the GTP-binding site and displacing the N-terminal
helix from a hydrophobic pocket7,8 (Fig. 1.2). This promotes insertion of the helix into
the adjacent bilayer and assures that activation can exclusively occur at a membrane7.
2
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Figure 1.2: Structures of the ARF6
GDP- and GTP-bound states - Bind-
ing of GTP causes the interswitch (red)
to move away from the switch regions
(blue) The resulting displacement of the
amphiphatic helix (green) favours its in-
teraction with an adjacent lipid bilayer.
Reprinted by permission from Macmillan Pub-
lishers Ltd: EMBO Reports (Ref. 8), copyright
2002.
Figure 1.3: The Sec7 domain
- Structure of the Sec7 domain of
ARNO. The helices contributing to
hydrophobic groove are shown in
blue. The glutamic acid residue
of the glutamic finger is shown in
ball-and-stick representation. Image
based on Protein Data Bank entry
1R8Q (Ref. 9).
Figure 1.4: The ARF1-Sec7 complex -
Structure of the complex of full length GDP-
ARF1 (ribbons) and the Sec7 domain of a
BFA-sensitive ARNO mutant (space-fill pre-
sentation) in the presence of BFA (not shown).
GDP is shown in ball&sticks representation,
Mg 2+ in green. The conformational changes
induced by ARNO binding on ARF, brings
the glutamic finger (shown in ball&sticks)
of ARNO in the nucleotide binding pocket
of ARF, leading to displacement of the nu-
cleotide. Since a BFA inhibited complex is
shown, the glutamic finger does not reside in
the binding pocket. Image based on Protein
Data Bank entry 1R8Q (Ref. 9).
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Table 1.1: ARF GEFs families and their localisation.7
Family Class Sec7 domain Localisation
GBF1 large yes Golgi
BIG large yes Golgi
PSD small yes Plasma membrane
IQSEC small yes Endosomes, cell periphery
Cytohesins small yes Plasma membrane
FBX08 small yes
Sec12 small no ER, Golgi
1.1.2 ARF activation
Almost all ARF GEFs share a Sec7 domain with, in particular, a conserved hydropho-
bic groove and a glutamic finger which is necessary for catalysis5–7 (Fig. 1.3). In the
ARF/ARF GEF complex the switch 2 inserts in the hydrophobic groove while the
switch 1 contacts the C-Terminus of the Sec7 domain. This induces substantial confor-
mational changes in ARF that allow the glutamic finger to access the nucleotide-binding
site and displaces the coordinating Mg 2+ and the phosphate of the bound GDP10–12.
This way, the glutamic finger extrudes the GDP from the binding pocket. The impor-
tance of the glutamic acid is confirmed by the fact that charge reversal at the glutamate
residue reduces the exchange activity to background levels11.
1.1.3 Guanine nucleotide exchange factors for ARFs
The ARF GEFs are divided in two major classes and 7 families based on sequence
similarities and functional differences, as shown in Table 1.1.
1.1.3.1 GEF inhibitors
Due to their important regulatory functions, GEFs are interesting drug targets. How-
ever, up to now only few GEF inibitors are known2. The fungal toxin brefeldin A
(Fig. 1.5), for example, inhibits ARF1 activation and therefore blocks many transport
steps13,14. Brefeldin A (BFA) is an interfacial inhibitor which acts only on large GEFs
and does not inhibit ARF6. It leads to loss of organelle identity, as for example the
rapid disassembly of the Golgi complex and the redistribution of resident Golgi markers
into the ER15.
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Figure 1.5: ARF GEF inhibitors - Structure of known small organic molecule ARF
GEF inhibitors. Brefeldin A (Refs. 13 and 14) and LM11 (Ref. 16) are both interfacial
inhibitors which bind the ARF/Sec7 complex. SecinH3 (Ref. 17) is a cytohesin specific
inhibitor.
The second ARF GEF inhibitor, LM11 (Fig. 1.5), was identified only very recently
by structure based screening, taking the BFA inhibition mechanism as model16. LM11
binds at the ARF1-Sec7 interface and inhibits both BFA-sensitive and -insensitives
GEFs but does not inhibit ARF6.
1.2 Cytohesins
Up to very recently, no specific small GEF inhibitor was known. Thus, some years
ago, our group took the BFA-insensitive cytohesin ARF GEF family as target for the
development of new inhibitors which would allow the study of the functions of this
protein class.
1.2.1 Structural features and functions
Cytohesin-1, cytohesin-2/ARNO∗, cytohesin-3/Grp1 and cytohesin-4, the four known
members of the cytohesin family, are highly homologous. The ∼47 kDa multidomain
proteins have a coiled-coil (CC) amino terminal domain, which is thought to facilitate
the interaction with cellular-binding partners, and a central Sec7 domain, which bears
the GEF function18. The pleckstrin homology (PH) domain and the C-terminal region,
which contains a large proportion of basic amino acids (polybasic region, PBR), are
important for the regulation of association to the membrane by binding to inositol
phospholipids18 and were recently shown to autoinhibit the exchange activity of the
∗ARNO: ARF nucleotide-binding site opener
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Sec7-domain19 (Fig. 1.6). In the polybasic region lye also protein kinase C (PKC) sites
which are specifically phosphorylated in response to phorbol ester stimulation 20,21
N C
CC Sec7 PH PBR
• interaction with  adapter proteins• dimerisation
• GEF activity• interaction with  integrin β2 chain
• binding to phospho-  lipids (membrane  association)• binding to GTP-ARF  and -Arl4
• membrane  association• autoinhibition• phosphoryl-  ation sites
Figure 1.6: Cytohesins conserved domains and their function - CC: coiled-coil;
PH: pleckstrin homology; PBR: polybasic region.
Additionally to their function as ARF GEFs, cytohesins were shown to interact
with a variety of cell surface proteins, such as the β2 integrin LFA-122, the HHV8
protein kaposin A23, the V-ATPase V0 complex24 and the A2A adenosine receptor
25,
and are involved in MAPK signalling and in the phosphatidylinositol 3-kinase (PI3K)
cascade18.
1.2.1.1 Autoregulation of cytohesins
In the last years, a new level of regulation of exchange of cytohesins on ARF was discov-
ered. In 2007, DiNitto et al. revealed the important role of the C-terminal polybasic
region of cytohesins in their autoregulation19. Indeed, under resting conditions the
docking site of the ARF switch regions on cytohesins is blocked by the linker region
between Sec7 and PH-domain and by the C-terminal amphipathic helix. The resulting
inhibition can be released by phosphoinositides-dependent binding of active ARF6 to
the PH domain-PBR and makes thus activation of cytohesins dependent on plasma
membrane recruitment19 (Fig. 1.7).
The results above, together with the discovery that the cytohesin PH-domain binds
the activated forms of ARF6 and Arl4 (Refs. 28–31), lead to the development of a new
model for the mechanism of activation of ARF by ARNO26. According to this model,
the requirement of binding of both anionic lipids (e.g. PS and PIP2
∗) at the plasma
membrane and ARF-GTP to release cytohesin autoinhibition impedes unlocalised ac-
tivation. Then again, activation by ARF-GTP triggers a positive feedback cycle in
∗PS: phosphatidylserine; PIP2: phosphatidylinositol 4,5-bisphosphate
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Figure 1.7: First model for autoregulation of cytohesins - After phosphoinositides-
dependent plasma membrane recruitment of cytohesins, lateral association with ARF6-
GTP simultaneously enhances membrane partitioning and shifts the equilibrium toward
the catalytically competent conformation. Other mechanisms, including phosphorylation
of PKC sites in the polybasic motif of cytohesin-1, may be required for full activation.19
Reprinted from Molecular Cell (Ref. 19), copyright 2007, with permission from Elsevier.
which ARNO activity is stimulated by its own product and allows a quick response to
stimulating events26 (Fig. 1.8).
1.2.2 The cytohesin inhibitor SecinH3
By mean of a newly developed aptamer displacement screening, which looked for small
organic molecules capable of efficiently compete the specific binding of the aptamer M69
(Ref. 32) to the Sec7 domain of cytohesin-1, the cytohesin inhibitor SecinH3 (Fig. 1.5)
was identified17,33.
SecinH3 was shown to be selective for cytohesins and to inhibit the exchange of
ARNO on ARF1 with an half maximal inhibitory concentration (IC50) of ∼11 µM
(Refs. 17 and 34). More importantly, SecinH3 allowed to discover new roles of cyto-
hesins.
1.2.3 Newly discovered roles of cytohesins
Application of SecinH3 in cell culture, mice and flies revealed the involvement of cyto-
hesins in insulin signalling17,35.
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Figure 1.8: Structural and functional aspects of ARNO activation on lipid
membranes - a. Proposed conformational changes in ARNO at the surface of lipid mem-
branes. The switch to an active membrane-bound conformation depends not only on the
presence of anionic lipids (e.g. PS + PIP2) but also on the presence of a free ARF-GTP
molecule. b. Model of ARNO response. In resting cells, ARNO remains inert because
no membrane contains both anionic lipids and free ARF-GTP. Notably, the plasma mem-
brane, which contains PS and PIP2, might not be suitable for ARNO activation when
active ARF species (e.g. ARF6) are engaged in interaction with classical effectors and for
constitutive functions. Ignition of ARNO requires a burst of active ARF6 or Arl4 at the
plasma membrane that exceeds the buffering capacity of effectors. After this initiation
step, ARNO is engaged in a sustained self-activating pathway through the feedback effect
of newly formed ARF-GTP molecules (e.g. ARF1) and remains active even if some initial
inputs disappear. The proposed circuit is not restricted to ARF6 and ARF1 and could
also apply when ARNO is activated by a different ARF subtype (e.g. Arl4).26 Reprinted
from Journal of Biological Chemistry(Ref. 26), copyright 2011 The American Society for Biochemistry
and Molecular Biology.
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Figure 1.9: Cytohesins in the insulin-signalling cascade - Through formation of
a complex with the insulin receptor and ARF6, cytohesins facilitate phosphorylation of
IRS and the following signalling cascade. Reprinted by permission from Macmillan Publishers Ltd:
Nature (Ref. 27), copyright 2006.
1.2.3.1 Regulation of insulin signalling
The insulin receptor is a receptor tyrosine kinase which upon binding of insulin un-
dergoes autophosphorylation on cytoplasmic tyrosine residues and stimulates phospho-
rylation of the insulin receptor substrate proteins (IRS). These, in turn, stimulate
the conversion of PIP2 to PIP3 (phosphatidylinositol 3,4,5-trisphosphate) by the phos-
phatidylinositol 3-kinase (PI(3)K) and lead to the activation of a number of downstream
targets including FOXO1, a factor that regulates the expression of insulin-sensitive
genes17,27 (Fig. 1.9).
The effect of SecinH3 in cell culture, mice and flies was very similar to that obtained
by impairment of the insulin receptor and it was shown that, although cytohesins do not
affect insulin receptor phosphorylation, they still act very far upstream in the signalling
pathway, probably by facilitating the binding of IRS to the insulin receptor17,35. This
results showed for the first time that cytohesins play an essential role in insulin signalling
and described a new ARF-dependent role of cytohesins.
1.2.3.2 Involvement in EGFR signalling
At the time when this project was started, preliminary results indicated that cytohesins
are involved also in the regulation of ErbB receptor signalling. In her Diploma thesis,
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A. Bill showed that SecinH3 treatment reduces the stimulation dependent activation of
the ErbB receptor in cell culture and SecinH3-dependent inhibition was also observed
in the downstream signalling cascade36. Moreover, inhibition of cytohesins led to a
reduction of the proliferation of the lung cancer cell line H46036. This results suggested
an important role of cytohesins in receptor tyrosine kinase signalling.
1.3 Receptor tyrosine kinases - The ErbB receptor family
Cell surface receptors regulate the proliferation of cells by recognising extracellular
growth factors and transducing the signals across the cell membrane37. Receptor tyro-
sine kinases (RTKs) are a main class of cell surface receptors that catalyse the transfer
of the γ phosphate of ATP to the hydroxyl groups of tyrosine residues on target pro-
teins. Inactive RTKs exist as monomers in the cell membrane. They are activated
by ligand-induced dimerisation resulting in autophosphorylation of their cytoplasmic
domains, which then can act as a platform for the activation of signalling molecules fur-
ther downstream38. RTKs are important regulators of fundamental cellular processes
like metabolism, proliferation and differentiation. Aberrant signalling of the normally
tightly controlled RTKs results in deregulated activity of downstream kinases and is a
common feature of malignant transformations39.
1.3.1 ErbB receptors dimerisation and activation
The members of the epidermal growth factor receptor family (EGFR or ErbB family)
are typical RTKs with an extracellular ligand binding domain connected by a single
transmembrane helix to the cytoplasmic domain38. The latter contains the protein ty-
rosine kinase (PTK) core and the carboxy-terminal tail with tyrosine autophosphoryla-
tion sites40. The phosphorylated residues serve as docking sites for signalling molecules
that are responsible for the downstream transmission of the signal41.
Upon binding to a ligand, the four ErbB family members EGFR/ErbB1/HER,
ErbB2/HER2, Erb3/HER3 and ErbB4/HER4 can form homo- and heterodimers with
any other ErbB receptor40. The formation of heterodimers is especially essential for
ErbB2 and ErbB3, because, while no activating ligands are known for ErbB2, ErbB3
lacks intrinsic kinase activity. Therefore, both receptors are unable to support signalling
as homodimers. Together, however, they form the most potent dimer in this receptor
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class40. The potency of the transduced signal depends on the cellular context, the
specific ligand, and the ErbB dimer40.
However, it was reported that dimerisation can occur also in absence of ligand42.
Thus, an additional level of regulation is necessary to avoid ligand independent ac-
tivation of EGFR signalling. In fact, dimerisation alone is not sufficient to activate
the ErbB receptors. The EGFR kinase domain is normally found in an autoinhibited
conformation, similar to that first seen in the cyclin-dependent kinase 2 (CDK) and
the Src family kinases41,43. Activation of the kinase requires the formation of an asym-
metric dimer between the bottom of the C-lobe of one kinase monomer, which acts as
a cyclin-like allosteric activator, and the top of the N-lobe of the other41,43 (Fig. 1.10).
Figure 1.10: Model of the activation mechanism of the ErbB receptors - All the
members in the family can act as the cyclin-like activator for the kinase-active members
(EGFR, ErbB2, and ErbB4) after ligand-induced homo- or heterodimerization.41 Reprinted
from Cell (Ref. 41), copyright 2006, with permission from Elsevier.
Downregulation of EGFR signaling is regulated by internalization, dephosphory-
lation and degradation of the activated receptors43. Additionally, the mechanism of
action of MIG6 (mitogen-induced gene 6), a feedback inhibitor which binds directly to
the cytoplasmic region of the ErbB receptors, was recently described. MIG6 binds to
the bottom of the kinase C-lobe, far away from the active site and blocks the EGFR
kinase domain in the CDK/Src-like inactive conformation, preventing the formation of
the active asymmetric dimer43,44.
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2Aims of the project
The validation of small molecule inhibitors identified by high throughput screening
requires robust assays for interaction analysis. The goal of this project was to establish
a set of suitable assays to investigate both protein/small molecule and protein/protein
interactions.
Cytohesins have been found to have a dual function as guanine nucleotide exchange
factors (GEFs) on one side and ErbB receptor activators on the other side. Accord-
ingly, the small molecule inhibitor SecinH3, which was developed as a GEF inhibitor
acting on the cytohesins Sec7 domain, proved to be able to inhibit ErbB receptors’
activation as well. This interesting characteristic offered the opportunity to develop
both types of assays on the same target protein and at the same time to elucidate these
distinct activities of cytohesins and better understand the mechanism of action of their
inhibitors.
Three methods were chosen for implementation: bioluminescence resonance energy
transfer (BRET) for the analysis of protein/protein interaction in cells, surface plas-
mon resonance (SPR) for the measurement of binding kinetics in vitro and capture
compound mass spectrometry (CCMS) for the determination of binding specificity in
proteome.
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3Bioluminescence resonance
energy transfer
Preliminary results showing inhibition of ErbB receptor signalling by SecinH336 sug-
gested cytohesins interact with ErbB receptors during their activation. To analyse this
interaction and its possible function for receptor activation, a method for the analysis
of protein-protein interaction was required. The use of Bioluminescence Resonance En-
ergy Transfer (BRET) to study the interaction between RTKs and their downstream
effector proteins in living cells had recently been reported by Tan et al.37 and seemed
to be an appropriate method for our purposes.
3.1 Principle of BRET
BRET, like FRET (Fluorescence Resonance Energy Transfer), involves the nonradia-
tive (dipole-dipole) transfer of energy from a donor (an enzyme or fluorophore) to a
complementary acceptor fluorophore, which usually emits fluorescence of a different
wave length45,46. The efficiency of the energy transfer depends on the spectral overlap,
the relative orientation of the dipoles, and the distance between the donor and acceptor
fluorophores45. The efficiency of energy transfer is inversely proportional to the sixth
power of this distance and RET effectively occurs when the donor and acceptor are 10-
100 A˚ apart45,47. As this distance is comparable to the dimensions of macromolecular
protein complexes and proteins can easily be expressed with a fluorescent tag, RET is
a suitable method to analyse protein-protein interactions46.
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In BRET, the donor fluorophore of the FRET technique is replaced by a luciferase45,
an enzyme that oxidizes a substrate, such as coelenterazine, to emit light. Thus, BRET,
not needing external excitation, avoids some of the problems associated with FRET,
such as photobleaching, autofluorescence and simultaneous excitation of both donor
and acceptor fluorophores45,46.
Dependent on the substrate used, the luciferase reaction has emission peaks be-
tween 395 and 475 nm (Ref. 46), and the acceptor fluorophore, usually a GFP (green
fluorescent protein) variant, has to be chosen accordingly. For this project a BRET2
combination consisting of Renilla luciferase (RLuc) with the coelenterazine derivative
DeepBlueC substrate as donor and GFP2 as acceptor fluorophore48 was used. The ad-
vantage of this combination is the superior separation of donor and acceptor emission
peaks and thus a reduction of the background signal46,49 (Fig. 3.1), while the drawbacks
are the low quantum yield and rapid decay of DeepBlueC, with the resulting need of
more cells and highly sensitive instruments to achieve sufficiently high luminescence
levels for BRET detection49.
Figure 3.1: Schematic representation illustrating the overlap of normalized
Rluc emission spectrum with normalized GFP excitation and emission spectra,
together with a typical filter combination. - a. Overlap of Rluc emission spectrum
with Class 1-3 GFP excitation spectra when using DeepBlueC. b. Lack of overlap of Rluc
emission spectrum with GFP2 emission spectra when using DeepBlueC. A typical filter
set for the BRET2 combination is shown. Adapted by permission from Macmillan Publishers Ltd:
Nature Methods (Ref. 46), copyright 2006.
To investigate protein-protein interactions by BRET, it is necessary to express the
proteins of interest fused to RLuc and GFP2, respectively. For BRET analysis in living
cells, cell populations coexpressing both fusion proteins are needed. To correct for RLuc
emission at GFP wavelength, a control cell population expressing the donor-tagged
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protein only is used. For both samples, light emission at both the short- (RLuc em.)
and long-wavelength (GFP em.) is measured directly after addition of the substrate.
The BRET signal, or BRET-ratio, is defined as the acceptor emission relative to the
donor emission subtracted by the light detected at long-wavelength which is contributed
by the donor emission (em.)46,49:
BRET-ratio =
GFP em.
RLuc em.
− GFP em. of donor-only transfected cells
RLuc em. of donor-only transfected cells
. (3.1)
This way, a high BRET-ratio generally indicates interaction between the two proteins.
Analysis of the data with this formula controls also for variation in substrate and sample
concentration46.
There is no absolute correlation between BRET-ratio and strength of binding, thus
the BRET signal of different proteins pairs can not be compared and can only be
ascribed to binding by adequate control experiments, as described in the next section.
3.2 Results and discussion
The BRET assay offers two complementary approaches for the investigation of the
ARNO-receptor interaction: binding of ARNO to the receptor can be measured directly,
using luciferase tagged receptor and GFP labelled ARNO, or indirectly, by coexpressing
non-labelled ARNO with luciferase and GFP tagged receptors. Both strategies were
used in this project as described below.
3.2.1 Direct interaction analysis
To investigate the EGFR-ARNO interaction directly, two fusion proteins shall be ex-
pressed. Since ARNO can bind the EGFR only in its cytoplasmic region, the EGFR was
constructed to carry Renilla luciferase (RLuc) at its C-terminus (EGFR-Luc), while
ARNO was C-terminally fused to GFP (ARNO-GFP). The GEF inactive ARNO mu-
tant ARNO-E156K11, was used to verify if the interaction EGFR-ARNO is dependent
on ARNO GEF activity.
As control, two proteins known to interact were needed. Thus, expression vectors
for glutathione S-transferase (GST), a constitutively dimerised protein, fused to either
RLuc (GST-Luc) or GFP (GST-GFP) were constructed. The same constructs can be
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used to check for unspecific interaction when coexpressed with EGFR-Luc or ARNO-
GFP.
The fusion proteins were transiently expressed by transfection of HEK cells. DNA
of the GFP-tagged proteins was used in 60-times excess since this ratio showed the
best results in preliminary exeriments. To avoid interference with the fluorescence
readout, growing medium without phenol red was used. After ∼36 hours, the cells
were harvested and transferred in a microplate. The plate reader was set up to inject
the luciferase substrate (DeepBlueC) immediately before measurement. The BRET-
ratio was calculated as described in Equation 3.1, p. 17.
Figure 3.2: ARNO-EGFR interaction and GST controls - EGFR-Luc or GST-Luc
were transiently coexpressed with either ARNO-GFP, ARNO-E156K-GFP or GST-GFP in
excess in HEK cells. The BRET-ratio is given. The GST-Luc/GFP pair gave, as expected,
a strong signal. While the EGFR-Luc/GST-GFP control showed no signal, a relatively
high BRET-ratio was detected when GST-Luc was coexpressed with the ARNO mutants.
Since the signal for the investigated pair (EGFR-Luc/ARNO-GFP) was lower than that
of the negative control, it could not be attributed to specific interaction. n = 5 (E156K: n
= 3).
As shown in Figure 3.2, the positive control cells, transfected with both GST con-
structs gave a strong BRET signal, supporting the experimental procedure used. How-
ever, the BRET-ratio obtained for the EGFR-ARNO pair was much lower. In fact,
the negative control sample, where GST-Luc and ARNO-GFP were coexpressed, re-
sulted in higher signals. This result speaks against a detection of specific binding in
the EGFR-ARNO pair.
A second possibility to check specificity in a BRET system is to perform a compe-
tition assay where the RLuc and GFP tagged proteins are coexpressed with unlabelled
protein46. This competes for interaction with the tagged protein, reducing the signal.
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Trying to carry out this experiment with untagged ARNO as competitor, revealed one
of the biggest problems of the experimental design. Indeed, the fluorescence signals
detected were generally quite near to the background. Since calculation of the BRET-
ratio involves quotients of these signals, a low signal to noise ratio gravely affects the
results. This problem was particularly evident in the competitions experiments, since
the amount of fluorescent protein was limited by the maximal quantity of DNA ac-
cepted by the cells. For the same reason, it was not possible to add the competing
protein in excess, making competition per se more difficult. Hence, the results of the
competition experiments were quite variable and difficult to interpret. Concurrently,
the ARNO-GFP construct was not functional (A. Bill, J. Theis, unpublished results),
therefore these experiments were suspended in favour of the indirect method.
3.2.2 Indirect interaction analysis
Monitoring the effects of ARNO on the BRET signal of the RLuc/GFP receptor pair
offers the opportunity to observe the ARNO-EGFR interaction indirectly. For this
strategy a second EGFR construct, carrying GFP at the C-terminus (EGFR-GFP),
was needed. Additionally a second BRET pair with HER2 as donor (HER2-Luc) and
HER3 as acceptor (HER3-GFP) was used.
Figure 3.3: Receptor-receptor interaction and GST controls - Receptor-Luc or
GST-Luc were transiently coexpressed with either receptor-GFP or GST-GFP in excess in
HEK cells. The BRET-ratio of the EGFR pair and the HER2/3 pair were higher than for
the negative controls. EGFR: n = 4, HER2/3: n = 2.
First, the BRET signal of both systems was measured. Since part of the receptors
is expected to be in the dimeric form under the growing conditions used, detection of
a significant BRET-ratio was anticipated. The same control system as in the direct
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method (Section 3.2.1, p. 17) with DNA donor:acceptor ratio of 1:20 was used. Indeed,
both the EGFR and the HER2/3 pair resulted in BRET-ratios higher than that of
the scrambled (receptor-GST) pairs (Fig. 3.3). A competition experiment could not be
performed because of the very low expression of the unlabelled receptor (EGFR-Stop,
data not shown) but the available controls were convincing enough to move to the
analysis of ARNO effect.
3.2.2.1 Influence of ARNO on the receptors BRET-ratio
In this experiment, the effect of coexpression of ARNO in the above systems was
investigated. Figure 3.4 shows that ARNO increased the BRET-ratio of both receptor
pairs. No effect was detected on the GST pair. The GEF inactive ARNO-E156K
mutant did not influence the EGFR BRET-ratio (Fig. 3.5).
Since BRET is very sensitive to both distance and orientation changes, the increase
of BRET signal could be due to both enhanced dimerisation or changes in the relative
conformation of the receptors. To get a first hint on the mode of action of ARNO, its
impact on the constitutive dimeric RTK Insulin-Like Growth Factor Receptor (IGFR)
was tested.
Coexpression of ARNO with the IGFR BRET pair lead to an increase of the BRET-
ratio (Fig. 3.6), as already observed for the EGFR and HER2/3 pairs. Since the IGFR
is constitutively dimerised, this effect can only be attributed to conformational change
or receptor clustering. As superresolution light microscopy showed that cytohesin inhi-
bition by SecinH3 does not alter the EGFR cluster size50, ARNO is most probably not
inducing receptor clustering. These results suggest, that ARNO regulates the ErbB
receptors by inducing a conformational change of already dimerised receptors.
The analysis above assumes that the expression ratio of RLuc and GFP labelled re-
ceptor is constant within a single experiment. In fact, titration of ARNO implies trans-
fection of at least three different plasmids per sample, making it difficult to comply with
this condition. An additional difficulty is presented by ARNO activity itself. Indeed, by
stimulating ErbB receptor phosphorylation, ARNO contemporaneously induces endo-
cytosis, which can likely change the proportion of donor and acceptor species. SecinH3,
as an ARNO inhibitor, offers a possibility to circumvent at least the first problem.
20
3.2 Results and discussion
Figure 3.4: ARNO increases the BRET-ratio of the receptor pairs. - Increasing
amounts of ARNO DNA were cotransfected with the BRET-pairs DNA in HEK cells.
Expression of ARNO enhanced BRET between receptors. No effect was detected on the
GST pair. EGFR: n = 11, HER2/3: n = 4, GST: n = 7.
Figure 3.5: ARNO-E156K does not influence the
EGFR BRET-ratio - Either ARNO or ARNO-E156K were
transfected in 2-times excess over the BRET pair. While ARNO
increased by almost 40 % the BRET-ratio of EGFR, the GEF
inactive mutant ARNO-E156K had no effect. Indeed the vari-
ation of 10 % is comparable to the effect of ARNO on the GST
control system. ARNO-E156K: n = 6, ARNO: see Fig. 3.4.
Figure 3.6: ARNO increases the BRET-ratio of IGFR - a. IGFR-Luc or GST-Luc
were transiently coexpressed with either IGFR-GFP or GST-GFP in excess in HEK cells.
The BRET-ratio of the IGFR pair was higher than for the negative controls. n = 1. b.
Increasing amounts of ARNO DNA were cotransfected with the BRET-pair DNA in HEK
cells. Expression of ARNO enhanced BRET between IGFRs. n = 4.
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3.2.2.2 Effect of SecinH3
The use of the small molecule SecinH3 allows the use of the same transfection mix
for all samples in an experiments, limiting variation in donor and acceptor protein
expression ratio. Since SecinH3 was known to be autofluorescent, I had to rule out
possible interferences with BRET before using it. From the spectra in Figure 3.7 is
clear that SecinH3 is excited and emits at shorter wavelengths than those used in my
BRET-system (Fig. 3.1) and the filter set used excludes any interferences. Thus, the
small molecule can be used without concern.
Figure 3.7: SecinH3 absorption and fluorescence spectra - Autofluorescence of
SecinH3 does not interfere with BRET measurements (BRET2: short-wavelength emission
at 405 nM, long-wavelength emission at 510 nM). Absorption spectrum was measured with
1 mM SecinH3 in DMSO. Fluorescence spectra were measured with 15µM SecinH3 in
DMSO or 1 % DMSO/water with excitation at 334 nM.
The handling of cells for the BRET measurements was quite different as for our
standard western blot analysis, by which inhibition of ARNO by SecinH3 was shown.
While for Western blot the cells were stimulated adherent and then harvested on ice,
cells for BRET were harvested, transferred into a 96-well plate and stimulated and
measured in suspension at 37◦C. Thus, I looked for BRET compatible conditions for
which inhibition was detectable by western blot were to be defined. Unfortunately, no
such condition was found and BRET inhibition with SecinH3 was not achieved.
3.2.2.3 Effect of stimulation on BRET signal
An important experiment to validate my BRET system, was the analysis of the effect
of receptor stimulation on the BRET signal. Indeed, the EGF induced dimerisation
of EGFR, should be manifest as an increase of BRET-ratio. Thus, HEK cells were
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transfected with RLuc and GFP labelled EGFR, harvested after 36 hours and trans-
ferred into a microplate. EGF was added to a final concentration of 10 nM 5 minutes
before DeepBlueC injection and measurement. Since no effect of the EGF stimulation
was detected, various transfection amounts, EGF concentrations and stimulation times
were tested, but no condition gave the expected results.
The experiments described above, were all performed with EGFR DNA constructs
lacking the exon 4, which codes for an extracellular fragment of the receptor, part of the
EGF binding domain51,52. A possible explanation of my results was therefore that the
receptor constructs used had impaired EGF binding and were therefore not stimulat-
able. To check this hypothesis, new expression vectors coding for the complete EGFR
were cloned (EGFRwE4). Western blot analysis of stimulation showed indeed that the
new constructs had a much higher phosphorylation level after stimulation (Fig. 3.8).
The stimulation dependent phosphorylation detected up to then in cells transfected
with the original constructs, was probably to ascribe to endogenous receptor.
Figure 3.8: Phosphorylation of the EGFR con-
structs lacking exon 4 is impaired - HEK cells were
transfected with expression plasmids of both EGFR iso-
forms. Stimulation was performed with 10 nM EGF for 5
min. After separation on a 7.5 % SDS-PAGE and Western
blotting, the phosphorylated receptor was detected with
phosphospecific antibodies. Hsc70 was used as loading con-
trol.
The analysis of the effect EGF stimulation was then repeated with the EGFRwE4
BRET pair. The BRET-ratio of aliquots of transfected cells was measured at increas-
ing stimulation times. A reduction of BRET-ratio was detected some seconds after
stimulation (Fig. 3.9a), but analysis of the cells expressing EGFRw4-Luc only revealed
high variability of the background BRET-ratio (Fig. 3.9b), undermining the results
in a. Indeed it turned out, that EGF stimulation affected luciferase activity in the
EGFRwE4-Luc receptor. Since this effect was not seen with GST-Luc, it is probably
due to a conformational change of the receptor which influences substrate uptake, or
variation in the physiological milieu of the luciferase for example because of receptor
internalisation. In this set up, as in the direct strategy, I was generally dealing with
very low GFP signals. Thus, changes in bioluminescence had a relevant influence on
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the GFP signals, altering the resulting BRET-ratios. All this, together with the points
discussed in the next section, made interpretation of the data unreliable. Experiments
in this direction were therefore temporarily discontinued.
Figure 3.9: Effect of stimulation on BRET-Ratio - HEK cells were transfected with
either the EGFRwE4 BRET pair (a) or EGFRwE4-Luc alone (b). The BRET-ratio was
measured at the indicated time after EGF addition and is plotted without subtraction of the
background BRET-ratio, to allow visualisation of the results of the donor only samples. A
decrease in BRET-ratio in the first minutes after stimulation is visible in a, but variability
in the same magnitude was detected in cells expressing the donor only (b). n = 5.
3.2.3 Discussion
With the intent to elucidate the mechanism by which ARNO activates the EGFR,
BRET between EGFR-Luc and ARNO-GFP was analysed. Using GST-Luc and GST-
GFP as controls, it was shown that the BRET signal measured in cells coexpressing the
EGFR/ARNO BRET pair, was not result of specific binding (Fig. 3.2). Yet, in our re-
cently published work50, we showed that ARNO directly interacts with the EGFR. The
discrepancy between these results is explained by experiments conducted in parallel to
the BRET assay, which showed that the ARNO-GFP fusion protein was not functional
(A. Bill, J. Theis, unpublished results). To my knowledge the use of ARNO-GFP is
not reported in literature. However, various groups successfully worked with the N-
terminal chimera GFP-ARNO29–31,53–59. Thus, BRET experiments with GFP-ARNO
could possibly allow to detect binding of ARNO to the EGFR.
Analysis of the results was complicated by the very low signals detected. As for
GFP, it is possible that the problem would be solved by the use of GFP-ARNO, since
interaction between the BRET pair is expected to increase the GFP signal. However,
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the RLuc signal can only be improved by increasing the transfection amounts or the
number of cells per sample. Unfortunately, none of these options was applicable with
the experimental conditions of this project.
Competition experiments, in which unlabelled protein is coexpressed with the BRET-
pair, are often used as a control of specificity49. Yet, for my system the control was
unsatisfying for two main reasons. First, I could transfect the cells with only very
limited amount of untagged protein DNA and, second, transfection with up to four
different plasmids lead to variable ratio of RLuc- and GFP-protein expression. The use
of cells stably expressing the donor and acceptor proteins would minimize these prob-
lems. Possibly, higher expression of the unlabelled protein could be achieved and, at
the same time, the expression ratio of the two BRET-proteins should be less variable.
Because the establishment of stable cell lines is particularly work intensive, this would
be an interesting option only if further experiments are planned with the cell line.
As a second strategy, an indirect interaction analysis was performed. In this set
up, donor and acceptor proteins were both receptor chimeras and the effect of ARNO
overexpression was monitored. In both the EGFR-Luc/GFP and HER2-Luc/HER3-
GFP expressing cells BRET-ratios higher as for the controls were measured. Interest-
ingly, the EGFR BRET-pair gave a BRET signal almost 3-times higher than that of
the HER2/HER3 pair (Fig. 3.4) and similar to that of the constitutive dimeric IGFR
(Fig. 3.6). Even if the absolute BRET-signal is usually not comparable between differ-
ent BRET-pairs (since energy transfer is dependent also on the relative position and
orientation of the fluorophores dipoles, which vary from pair to pair) the structural
similarity of the receptors studied is tempting to speculation. Indeed, the finding that
the EGFR isoform used can actually not be stimulated (Fig. 3.8) because it lacks the
exon 4, which is involved in EGF binding, suggests that the energy transfer observed
could be a measure of dimerised EGF receptor. This hypotesis is supported by a very
recent publication which reports identification of an exon 4-deletion variant of EGFR
in gliomas, ovarian cancer tissues and prostate cancer tissues52. This mutant displayed
minimal EGF binding activity and underwent ligand-independent autophosphorylation
and self-dimerisation.
Founding on these results, it is interesting to note that overexpression of ARNO
increased BRET between the EGFR pair. This implicate an effect of ARNO on already
dimerised receptors, as we could show later with other methods50. Nevertheless, these
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results must be taken with caution, since they are only valid under the assumption
that the expression ratio of RLuc and GFP labelled receptor is constant within a single
experiment. In fact, this experiment again requires transfection of at least three differ-
ent plasmids, a condition which can lead to variations in expression ratio. Moreover,
the activity of ARNO itself affect EGFR expression, since activation of the receptor by
ARNO overexpression enhances endocytosis.
Experiments were performed to analyse the effect of EGFR stimulation on BRET
between EGFR-Luc and EGFR-GFP. With the current knowledge about the charac-
teristics of the exon-4 deletion variant of the EGFR (Fig. 3.8 and Ref. 52), it is clear
that no stimulation influence could be detected. With respect to the new constructs
EGFRwE4, which were shown to be stimulatable, the analysis is more complicated.
Indeed, at first glance, one could interpret the results in Figure 3.9a as stimulation
dependent change of BRET-ratio. The fact that the ratio is decreasing and not in-
creasing, as one would intuitively expect, can be explained by conformational changes
in the EGFR C-terminus, and consequent changes in the fluorophores relative orienta-
tion, which overwhelm the effect of dimerisation (a similar result was shown by Yang
et al. in a luciferase fragment complementation assay60). In fact, analysis of the raw
data showed a high variability in the luciferase and GFP signals upon EGF stimulation
without detectable trends. Again, having to deal with very low signals increased the
gravity of these random variations. Additionally, it was observed that the RLuc sig-
nal observed for aliquots of the same cell population decreased rapidly with the time.
This was caused by deterioration of the DeepBlueeC solution in the instrument. Thus,
for comparable luminescence, repeated priming of the instrument was needed during a
measuring series. Still, the BRET2 system used was not adequate for the analysis of
stimulation. Ideally, one would monitor the changes of BRET after stimulation in a
single sample. Unfortunately, luminescence induced by DeepBlueC is very short lived
and allows only a single measurement per sample. The use of BRET1 or eBRET, in
which the substrates Coelenterazine h or EnduRen, respectively, allow detection for up
to one to several hours49, would therefore be more appropriate.
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As an alternative method to investigate a possible interaction of cytohesins and ErbB
receptors, surface plasmon resonance (SPR) bioanalysis was chosen because it offers the
chance to follow binding events in real time and thus determine a range of interaction
characteristics, like association and dissociation rates. These experiments are described
in Section 4.3.1.
The small molecule SecinH3 allowed the identification of new roles of cytohesins17,50,
which, in turn, generated interest in SecinH3 derivatives with improved activity and
solubility. In Section 4.3.2, the establishment of an SPR based platform for the analysis
of the binding properties of these new compounds is described.
Although SPR has been used since the early Nineties for the analysis of biomolecular
interactions, still various misconceptions are diffused. Thus, I will start with a detailed
introduction to the theory of SPR (Section 4.1) and its application in affinity biosensors
(Section 4.2).
4.1 Physics of surface plasmon resonance
Surface plasmon resonance is a phenomenon that occurs in planar metal-dielectric
waveguides, as for example a metal/water interface61. Surface plasmons are electrons
oscillations which propagate parallel to the interface and are usually generated by means
of a prism coupler and the attenuated total reflection method61. Our device is using
the Kretschmann geometry, in which the metal film is evaporated directly onto the
prism61,62. When illuminated, the metal film reflects part of the light back into the
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prism while a part of the light propagates in the metal as a so-called evanescent wave
(an inhomogeneous electromagnetic wave which decays exponentially in the direction
perpendicular to the prism-metal interface)61. If the metal film is sufficiently thin, the
evanescent wave penetrates through it. For each wavelength, a single angle of incidence
leads to excitation of surface plasmons at the outer boundary of the metal film via the
evanescent wave field. As a result, SPR is seen as a drop in the intensity of the reflected
light (Fig. 4.1)61,62.
Figure 4.1: The SPR angle - At a certain combination of wavelength and angle, the
incident light excites plasmons in the gold film. As a result, a characteristic absorption of
energy via the evanescent wave field occurs and SPR is seen as a drop in the intensity of
the reflected light.62 Reprinted from Biacore - Sensor surface handbook (Ref. 62), copyright 2005-2007
GE Healthcare Bio-Sciences AB.
Application of the perturbation theory to the electromagnetic theory of optical
waveguides demonstrate that the propagation of surface plasmons is highly sensitive
to changes in the refractive index at the boundary61, such as those resulting from
adsorption of molecules to the metal surface. This is the property which is exploited
in optical sensors based on surface plasmons63, such as Biacore62.
Our instrument, a Biacore 3000, is an SPR sensor with angular modulation. That
is, it uses monochromatic light for excitation and monitors the reflected light intensity
at multiple angles of incidence. Resonance is thus detected as a dip in the intensity of
the reflected light (Fig. 4.1a) and the sensor output is the angle of incidence yielding
the lowest intensity (Fig. 4.1b)62,63. Changes in this angle are expressed in Resonance
Units (RU).
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4.2 SPR affinity biosensors
Since the Nineties commercial SPR based sensor devices for the analysis of biomolecular
interactions are available. SPR affinity biosensors carry biorecognition elements which
are able to interact with a selected analyte. Binding of analyte molecules to the affinity
elements produce an increase in the refractive index at the sensor surface an thus a
change in SPR63.
The first and best known commercial SPR instrument is the Biacore, commercialised
by Pharmacia Biosensor AB (now GE Healthcare Bio-Sciences AB). For this project a
Biacore 3000 was used, whose principal characteristics are described in the next section.
4.2.1 The Biacore system
The principal parts of Biacore 3000 are the detector unit, an interchangeable sensor
chip and the microfluidic system. The sensor chip is composed of a glass slide with a
thin layer of gold where SPR take place. The gold surface is derivatised, as described
in Section 4.2.3.1 (p. 31), to allow immobilisation of the biorecognition element. The
sensor chip is pressed against a semi-cylindrical glass prism and light from a diode
is focused on to the sensor surface, covering a fixed range of incident and reflected
angles62. On the opposite side, the chip is pressed on the flow cell block, so as to form
a wall of the flow cells and the gold layer is thus in direct contact with the flowing
buffer (Fig. 4.1b). The four flow cells allow analysis of up to three ligand in parallel
(the fourth cell is usually used as reference to correct for bulk refractive index changes
in the sample). The flow cell block is part of the Integrated Microfluidic Cartridge
(IFC), which consists of a series of channels and valves and, together with the pump
system, is responsible for precisely controlling the delivery of sample and buffer. The
use of two pumps assure a continuous buffer flow even during sample preparation and
injection62,64.
4.2.2 Measuring approach and terminology
To enhance comprehension, some basic terminology is explained here. In Biacore exper-
iments, one interacting partner (the ligand) is immobilised on the surface of a sensor
chip while a solution with the second interaction partner (the analyte) is flown over
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the surface along four flow cells (Fc). The sample is carried in a continuous flow of
buffer, the running buffer.
The resonance units (RUs) quantify the response, which is directly proportional
to the concentration of biomolecules on the surface and is acquired in real time. The
progress of the interaction is displayed on a sensorgram, a plot of response against
time. In a typical cycle a baseline is collected while running buffer is flowing. Then,
association is observed during sample injection, followed by dissociation when run-
ning buffer is again flown on the chip. Regeneration, that is removal of bound analyte
from the surface without damaging the ligand, is achieved by injection of a regeneration
solution with composition dependent from the investigated interaction. Typical regen-
eration solutions are high salt and acidic buffers and detergent containing solutions.
After regeneration a new cycle with a different analyte concentration is measured. The
sensorgram of a typical cycle is displayed in Figure 4.2, but before discussion of the most
important characteristics of a simple binding curve, some details of the experimental
design are presented.
Figure 4.2: Schematic illustration of a sensorgram - The bars below the sensorgram
curve indicate the solutions that pass over the sensor surface. Reprinted from Biacore - Sensor
surface handbook (Ref. 62), copyright 2005-2007 GE Healthcare Bio-Sciences AB.
4.2.3 Experimental design
Acquiring SPR data is easy, generating high quality data is an art form and takes some
effort65. In particular, it is important to start with good quality reagents (this include
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chemically and conformationally pure ligand and analyte, since in order for data to
fit a simple bimolecular reaction model, the analyte and ligand must be monomeric
in solution and form a 1:1 complex when mixed66). A critical point is selecting the
interaction partner to immobilise and the immobilisation procedure, as discussed below.
4.2.3.1 Immobilisation
Although initially immobilisation was based on simple physical adsorption of proteins to
an active metal surface, unmodified gold is usually not a suitable surface for biomolec-
ular interactions. This is because of its high tendency for adsorption of proteins and
other molecules, the possible loss of activity of these molecules upon adsorption, and
the instability of this type of surface binding67. Thus, to protect the biological sample
from contact with the gold and at the same time provide a mean of attachment of a sur-
face matrix, the gold on almost all Biacore sensor chips is covered with a self-assembled
monolayer of alkanethiol molecules62,67.
On most sensor chips, such as the CM5/CMDP∗, the surface is additionally cov-
ered with a matrix of carboxymethylated dextran, a flexible unbranched carbohydrate
polymer forming an approximately 100 nm thin hydrogel-like polymer layer which pro-
vides high flexibility and water solubility. Additionally, the dextran matrix offers
a defined chemical basis for covalent attachment of biomolecules to the surface and
the negatively charged carboxyl groups allow electrostatic concentration of positively
charged molecules, enabling efficient immobilization from dilute ligand solutions62 (see
Section 4.5, p. 33). Moreover, the three-dimensional structure increases the binding
capacity several-fold in comparison with a flat surface and extends the region where
interactions occur to match with the penetration depth of the evanescent wave62,67.
Carboxymethylated dextran derivatised chips are compatible with all the three main
strategies for immobilising biomolecules on the sensor chip surface shown in Figure 4.3,
namely covalent coupling, non-covalent capture and lipid layers mediated coupling.
With respect to covalent coupling, the carboxylic acid residues of the carboxymethy-
lated dextran derivatised chips can be either reacted with amines or other nucleophilic
groups, or converted for use in coupling chemistries based on, e.g., aldehyde and car-
boxylic acid condensations and thiol reactions. In fact, the formation of a covalent
∗Sensor chips were bought from two companies. The first name always refers to the Biacore chips
and the second one to the Xantec chips (see Materials and methods, p. ??).
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Figure 4.3: Strategies of biomolecules immobilisation - The ligand can either be
chemically coupled to accordingly derivatised surfaces or immobilised by binding to a cap-
ture molecule such an antibody or streptavidine. As a third method, hydrophobic carrier
such as a lipid monolayer or bilayer can be attached to the sensor chip surface through
hydrophobic adsorption and offer, e.g, a matrix for insertion of membrane-associated pro-
teins. Reprinted from Biacore - Sensor surface handbook (Ref. 62), copyright 2005-2007 GE Healthcare
Bio-Sciences AB.
amide bond between the carboxylic acid and the amine group in lysine residues is the
most common immobilisation method in Biacore experiments67. The coupling is usu-
ally performed directly in the instrument and in two steps: the carboxylic group is
activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) before the lig-
and is passed on the surface, to avoid reaction between the carbodiimide and the ligand.
Since the reactivity of the first step intermediate in aqueous solutions is so high that
water hydrolysis would rapidly transforms it back to carboxylic acid, a mixture of EDC
and N -hydroxysuccinimide (NHS) is used to form a more stable active ester derivative
(Fig. 4.4)67.
Figure 4.4: Activation of carboxymethyl dextran with EDC/NHS - The car-
boxylic group is activated with EDC. To avoid rapid hydrolysis, NHS is present in the
coupling solution to give reactive succinimide esters which react spontaneously with amines
and other nucleophilic groups. For simplicity the dextran chains are omitted. Reprinted from
Biacore - Sensor surface handbook (Ref. 62), copyright 2005-2007 GE Healthcare Bio-Sciences AB.
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Traditionally, coupling of active esters is done under slightly alkaline conditions
where a normal alkylamine nucleophile is close to its pKa and can compete with water
hydrolysis and this is the preferred method for coupling of organic molecules and small
peptides67. However, for immobilization of proteins, where high-density modifications
are desirable, electrostatic preconcentration is usually used. This method takes ad-
vantage of the unreacted carboxylic groups on the EDC/NHS activated surface. As
these leads to an overall negatively charged environment, under low ionic strength light
acidic buffer conditions positively charged proteins are attracted resulting in a high
local surface concentration, which in turn favours protein coupling over water hydrol-
ysis (Fig. 4.5)67. This methods leads to high-density surfaces and has the additional
advantage that coupling occurs under conditions where only a small fraction of the
nucleophilic groups on the protein are reactive and thus the very few immobilization
points increase the likelihood of preserving activity67. Additional methods of covalent
coupling include the formation of disulfide bonds and thioether linkages, and coupling
to aldehyde groups and will not be discussed here.
Figure 4.5: Preconcentration of the ligand - The ligand is concentrated on the surface
through electrostatic attraction when the pH lies between the isoelectric point (pI) of the
ligand and the pKa of the surface. If the pH is too low or too high, the ligand will not
be concentrated on the surface62. Reprinted from Biacore - Sensor surface handbook (Ref. 62),
copyright 2005-2007 GE Healthcare Bio-Sciences AB.
Where covalent coupling does not work, capture-based coupling can be used. In
this technique a capture molecule, often an antibody, with high affinity for the ligand
of interest is coupled to the chip and the ligand is then immobilised through binding
to the capture molecule. The advantage of this setup is the possibility of removing
the ligand after analysis. This step is analyte independent but new ligand must be
captured for the next assay cycle, thus higher amounts of ligand are needed. Moreover,
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one should take care that the affinity of ligand and capture molecule is sufficient to
avoid loosing ligand during the measurement67.
Antibodies specific for tagged recombinant proteins are often immobilised as cap-
ture molecule, but also organic molecule can be used for this scope. An example is
nitrilotriacetic acid (NTA) which in complex Ni 2+ ions is routinely used in affinity pu-
rification of polyhistidine tagged proteins68. Accordingly, His-tagged proteins can be
immobilised by chelation on NTA derivatised sensor chips. A particular advantage of
this strategy is the easy removal of ligand by sequestering the nickel ions with chelating
agents such as EDTA (ethylenediaminetetraacetic acid).
The third strategy, hydrophobic attachment of membrane-associated proteins through
lipid monolayers and bilayers, is not relevant to this project and is therefore not pre-
sented in more detail.
4.2.3.2 Data processing
Especially when measuring small signals, a careful data processing is necessary to get
rid of system artifacts. In fact, the noise from the injection needle, bulk refractive
index changes, washing steps, and instrument drift can be similar in magnitude to the
binding signal. If not stated otherwise, we applied double referencing (i.e. both the
signal of a reference cell, as well as a the signal of blank injections were subtracted
from the binding signal) as described by Myzska66 (see Section 7.1.6.2, p. 133, for more
details). Global analysis was then applied, as described in next section.
4.2.4 Data analysis
The ability of SPR biosensors to detect complex formation in real time makes it possible
to obtain quantitative information about binding interactions, including the rates of
association and dissociation. The binding constants are usually determined by either
kinetic or equilibrium analysis. Below, the evaluation models and the requirements to
the data are presented.
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4.2.4.1 Kinetic analysis
Biacore is best suited for kinetic analysis of simple bimolecular interactions of the type
A + L
ka−−⇀↽−
kd
AL , (4.1)
where A is the analyte, L the ligand and ka and kd the association and dissociation
rate constants, respectively. When the number of analyte molecules is higher than the
amount of ligands, the surface concentration of the complexes γ formed per unit time
t is described by the Langmuir equation for interactions at a surface in contact with
reactants in solution (pseudo first-order reaction)69
dγ
dt
= ka α0 (β − γ)− kd γ , (4.2)
where β is the surface concentration of ligands and α0 the analyte initial concentration.
Its solution is a single exponential function with an asymptote corresponding to the
equilibrium fulfilling equation69
KA =
ka
kd
=
γeq
α0 (β − γeq) . (4.3)
This condition is respected by Biacore 3000, where the concentration of free analyte
is controlled by the solution flown in the cell and can be either increased or decreased
stepwise. Thus, an SPR sensorgram encompasses an association phase (beginning with
the sharp increase of the free analyte concentration to a constant value α0) followed
by a dissociation phase (when the free analyte concentration is suddenly reduced to
zero)69. Both association and dissociation phase have an exponential progress, as shown
in Figure 4.6A-F.
The best way to accurately estimate the binding constants is to perform global
analysis. That is, all responses of a data set (i.e. responses of a wide range of con-
centrations) are fitted simultaneously using the same set of constants (ka, kd, γmax).
The fitting procedures of analysis softwares like BiaEvaluation, base on minimization of
the chi-squared value χ2, given by the difference between simulated and experimental
data. For this, the initial parameter estimates are adjusted iteratively as long as χ2
can be improved. As global analysis is particularly stringent, it provides a method to
discriminate between different reaction models70.
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The model described above premises uniform analyte concentration distribution in
the flow cell. In fact, the concentration profile is dependent on analyte diffusion and
binding. When the binding rate is equal or faster than the diffusion of analyte to the
ligand surface, mass transport must be considered in the evaluation model70.
Mass transport limitation
A 1:1 binding reaction influenced by mass transport can be described by the equation
A0
kM−−⇀↽−
kM
A + L
ka−−⇀↽−
kd
AL (4.4)
with the mass transport coefficient kM characterising the rate of analyte A0 diffusion
to and from the reaction surface70.
The effect of mass transport limitation on a typical sensorgram is shown in Fig-
ure 4.6F. Since slow analyte transport causes a concentration decrease when it is bound
during the association phase and an increase when it is released during the dissociation
phase, both reactions are slowed down69. Typically, mass transport introduces a linear
component at the beginning of the injection phase and makes the dissociation phase
non-exponential65.
Since laminar flow, as found in a Biacore flowcells, is very ineffective in transporting
analyte to the sensor surface, translational diffusion (i.e diffusion along a concentration
gradient, in this case perpendicular to the chip surface) is particularly important in the
vicinity of the active sensor layer69. The diffusion coefficient D, which expresses the
proportionality between the rate of diffusion and the concentration gradient, decreases
as the size of the molecule increases and is dependent on temperature and viscosity
of the medium. For typical biomolecules in aqueous medium, D is usually between
10−7 cm2 s−1 and 10−6 cm2 s−1 (Ref. 69).
In the simplified model of mass transport limitation for a pseudo first-order reaction,
the average concentration of complexes 〈γ〉(t) is described by
d〈γ〉(t)
dt
= kefa (t)α0[β − 〈γ〉(t)]− kefa (t)〈γ〉(t) , (4.5)
where the effective rate constants
kefa (t) =
ka
1 + ka[β − 〈γ〉(t)]/kM and k
ef
d (t) =
kd
1 + ka[β − 〈γ〉(t)]/kM (4.6)
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are both space- and time-dependent and
kM ≈ 1.378
(
vmaxD
2
hl
)1/3
. (4.7)
Again, α0 and β are the analyte initial concentration and the ligand surface concentra-
tion, respectively. The maximum flow velocity vmax is found at the mid-point of the
cell height h (dimension perpendicular to the sensor surface) while l is the length of
the cell (dimension along the flow)69.
The effect of kM on the SPR response is estimated by the Damko¨hler number
Da = kaβ
(
vmaxD
2
hl
)−1/3
∼ kaβ
kM
, (4.8)
which is proportional to the ratio of the reaction velocity to the diffusion flux of the
analyte at the beginning of the association phase69.
For Da  1 the mass transport is much faster than the surface reaction itself and its
effect can therefore be ignored, while for Da  1 the reaction is completely controlled
by diffusion and is thus not possible to determine reaction rate constants from the
sensorgram69.
From Equation 4.8 is evident that both increasing vmax and decreasing the amount
β of coupled ligand reduce the Damko¨hler number. This is the motivation of the general
advice to use low ligand density surfaces and high flow rates when determination of
kinetics constant is the goal of an SPR experiment.
4.2.4.2 Equilibrium analysis
If the association phase is long enough, steady response levels are reached, visible as
plateau at the end of injection. If this is true for all concentrations (as it is the case
in Figure 4.6C and D), the whole data set can be used in an equilibrium analysis to
determine affinity65.
From the reaction in Equation 4.1 and the equilibrium dissociation constant defini-
tion
KD =
kd
ka
=
αeq βeq
γeq
and with γmax = βeq + γeq (4.9)
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the relation between steady state binding level and analyte concentration
γeq =
γmax
(1 +KD/αeq)
(4.10)
is derived. Thus, the KD can be determined by measuring the dependence of the
equilibrium response on the injected analyte concentration (binding isotherm)69.
4.2.4.3 How to recognise a good spectrum
Figure 4.6: Simulated binding responses - Panels A-F depict systems described by
simple exponentials and panels G-H depict problematic systems. A-C. Interactions having
the same ka but increasing kd across the series. D. An interaction that reaches equilibrium
within a few seconds of the start of the injection phase. E. Responses that, at higher analyte
concentrations, approach saturation of the ligand surface. F. A partially mass transport-
limited interaction. G, H. Interactions displaying complexity. I. Drifting responses. J.
Severely substandard responses, which often result from analyte aggregation/precipitation
and/or instrument maintenance issues65. Reprinted from Journal of Molecular Recognition (Ref.
65, p. 358), copyright 2008, with permission from John Wiley and Sons, Inc.
Now that the theory of SPR binding analysis is explained, the main features of the
sensorgrams in Figure 4.6 should be readily detectable. The sensorgrams A-C show
typical binding curves where both association and dissociation phase can be described
by a simple exponential. Across these three data sets the ka is kept the same but the
kd increased 100 fold to demonstrate how the kd affects the binding profile in both the
association and dissociation phases65. The square-shaped response in D is result of
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a very fast kd but can still be described by the standard mechanism in Equation 4.1.
The same is true for the data set E, where at high concentrations the analyte start
saturating the ligand surface65.
It is important to distinguish saturation from equilibrium. Indeed, saturation is
observed when the ligands on the surface are fully occupied with analyte. Under condi-
tions that approach saturation, the responses for increasing analyte concentrations have
nearly the same intensity at the end of association. This maximal response Rmax can
be used to determine the binding capacity of the surface and estimate the activity of
the immobilized ligand62,65. However, often the response continue to increase together
with analyte concentration. This non-specific binding is mostly due to heterogeneity
of the interaction partners and should not be interpreted as second type of binding.
Measurements should preferably be performed around the KD (∼ 0.1 to 10 fold) as
there is no absolute necessity to demonstrate saturation in a biosensor experiment65.
The sensorgrams in F are an example of a partially mass transport limited reac-
tion. Particularly evident is the linear initial binding rate and the non exponential
dissociation phase. As long as the binding reaction is not completely covered by the
mass transport effect, the kinetic parameters can easily be determined by application
of the right model (see Section 4.2.4.1). Nevertheless it is advisable to repeat the
measurements with lower surface density and higher flow rate to avoid mass transport
effects65.
Data sets G and H show complex binding profiles. This curves can not be described
by a simple exponential and are commonly referred as biphasic binding response. Al-
though this behaviour could be biologically relevant71, the fact is that once you get
biphasic data it becomes virtually impossible to resolve what actual event is leading to
the complex response. This is because biphasic data can be described equally well by a
multitude of models.65 Of course a more complicate model with an higher number of
variable will fit the data better, but this does not mean that the model is appropriate.
Therefore before trying to find a model which perfectly fit the results obtained, it would
be better to redesign the assay to see if one can get rid of the complex part65.
As last, I and J are examples of inappropriate experimental conditions. The drifting
baseline in I indicate inefficient coupling, as the ligand is detaching from the sensor
surface during the measurement, while the sensorgrams in J are a typical example of
measurement with a dirty instrument or bad quality reagents65.
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4.3 Results and discussion
As described above, to determine reliable kinetics parameters out of an SPR sensor-
grams set, high quality data, ascribable to a simple binding mechanism, are required.
Often, a careful evaluation of various coupling and buffer systems is required to get
data of the desired quality. The next sections give an overview of the optimisation
process for the analysis of ARNO/EGFR (Section 4.3.1) and ARNO/small molecule
(Section 4.3.2) interaction, describe some common challenges and present the obtained
binding results.
4.3.1 Analysis of ARNO/EGFR binding affinity
To start with, interaction of ARNO and EGFR was tested. Since expression and
purification of the receptor is quite more demanding, we preferred it as immobilised
partner, to limit the amount needed for analysis. Immobilisation on NTA/NiP chips
was the first method tested, because it allows loading of new, native, ligand whenever
necessary.
4.3.1.1 Immobilisation on nitrilotriacetic acid derivatised chips
A typical analysis cycle on NTA/NiP chips consists in loading the NTA with Ni 2+ by
flowing a NiCl2 solution on the flow cells (Fc). Then, the His-tagged protein binds
to the surface by chelation of the Ni ions. Binding analysis by injection of analyte is
followed by regeneration with either EDTA (which remove the ligand together with
the analyte, due to depletion of Ni 2+) or an appropriate regeneration solution (which
remove the bound analyte without affecting the ligand activity).
To get acquainted to the system, a protein pair known to interact was chosen. Thus,
interaction between His-ARNO-Sec7 (the purified Sec7 domain of ARNO carrying an
His-tag) and ARF6 carrying a strep-tag72 (strep-ARF6) was measured.
Interaction of ARNO and ARF6
First, the loading conditions were tested. All flow cells were rinsed with EDTA to get
rid of Ni 2+ and other contaminant ions and single Fcs were loaded with NiCl2 and at
the end the protein solution flown over all cells. Fc without Ni 2+ were used to check
40
4.3 Results and discussion
the requirement of Ni 2+ for His-tag protein immobilisation. In fact, some His-ARNO-
Sec7 was found to bind also in the Ni-free Fc 1 (Fig. 4.7). The initial assumption of
a damage of the IFC, leading to diffusion of Ni 2+ from Fc 1 to Fc 2, was discredited
by a system check which did not reveal any particular IFC failure. The effect was thus
ascribed to carry-over of NiCl2 after injection.
Two main tricks were applied to reduce the problem: 3 mM EDTA was added to the
dispenser buffer (connected to pump B and used for sample preparation and washing
of the injection needle) and another rinsing program was used. Indeed, the command
‘WASH IFC’ leads to increased risk of carry-over. The commands ‘EXTRACLEAN’
or ‘WASH Needle’ should be used instead. With this modifications carryover was
successfully avoided.
Figure 4.7: Carry-over of Ni ions leads unspecific binding of His-ARNO-Sec7 to
a Ni 2+-free flow cell - All flow cells were rinsed with EDTA and Ni 2+ was then loaded on
Fc 2 (green) and 3 (magenta) only. His-ARNO-Sec7 bound to Fc 1 (red), too. Fc 4 (blue)
was Ni 2+-free and no binding was detected. The problem was solved by use of a robuster
buffer system and special cleaning procedures. Responses are presented unreferenced.
For binding analysis the cells were loaded with either nothing (Fc 1), Ni 2+ (Fc 2),
Ni 2+ and His-ARNO-Sec7 (Fc 3), or Ni 2+ and His-PAZ∗ (Fc 4). When strep-ARF6
was injected, strong binding to the Ni 2+-loaded cell was detected (Fig. 4.8). Metal-
dependent, nonspecific protein adsorption to the biosensor surface was already reported
∗The purified PAZ domain of Argonaute 1 was used as negative control because it has similar size
and like the Sec7 domain carries a His-tag. Expression and purification of His-PAZ are described in
Refs. 73 and 74.
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by Willard and Siderovski75. Analysis is thus only possible when the reference cell has
the same surface concentration of protein as the Fc of interest (and comparable levels
of unspecific binding to exposed Ni 2+ is expected). Therefore, I always tried to couple
similar amounts (in RU) of proteins of comparable size on the two cells. Subtraction
of the signal measured in Fc 4 (immobilised His-PAZ) from that in Fc 3 (Sec7 domain)
gave a reasonable binding curve for 2 µM strep-ARF6 (Fig. 4.8b).
Figure 4.8: Metal dependent unspecific adsorption of non His-tagged proteins
to the Ni-NTA surface - This complication was already reported75. a. The raw response
data of four different cells (Ni-free (red) and loaded with Ni 2+ only (green), His-PAZ (blue)
and His-ARNO-Sec7 (magenta), respectively) are shown. The Ni-loaded Fc showed the
highest response over injection of 2 µM strep-ARF6. b. Referenced curves from a: in red
the response of the Ni 2+-loaded cell after subtraction of the Ni 2+-free cell is given. In
magenta the response of the ARNO loaded Fc after subtraction of the reference cell with
PAZ.
Acquisition of a complete data set showed concentration dependent binding of
strepARF6 on His-ARNO-Sec7 (Fig. 4.9). The control proteins GST, Rac1-strep and
Rac1-GST∗ did not bind even at high concentrations. However, the curve shapes did
not fit a simple 1:1 binding model. Because the responses also did not reach equilibrium,
it was not possible to determine the binding characteristics.
Since analysis of the ARNO-ARF6 interaction was only meant as training, we de-
cided not to invest time in optimisation and to directly test if the EGFR-ARNO inter-
action was better behaving.
∗Rac1-strep and Rac1-GST were kindly provided by Bjo¨rn Niebel.
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Figure 4.9: StrepARF6 bound immobilised His-ARNO-Sec7 in concentration
dependent manner - However, the responses could not be described by a simple binding
model. Controls proteins did not show binding. Data were referenced with the His-PAZ
signal.
Interaction of EGFR and ARNO
As described above, we were interested in immobilising the EGFR, thus a construct
consisting in the intracellular part of the EGFR (EGFR-ICD) with an His-tag (His-
EGFR) and a strep-tagged ARNO (strep-ARNO) were used.
His-EGFR was immobilised according to the method developed in the previous
section and His-PAZ was again immobilised on the reference cell. The responses ob-
tained by flowing strep-ARNO on the Fc were primarily concentration dependent but,
at times, outliers were observed (Fig. 4.10). GST did not bind to the receptor.
Figure 4.10: Sensorgrams for binding of ARNO to the coupled EGFR - The
responses were concentration dependent but outlier were observed. The negative control
GST was not binding. Data were referenced with His-PAZ.
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The receptor is bigger (> 60 kDa) than the PAZ (19 kDa) domain, which is there-
fore probably not an optimal negative control in this case (in particular with regards
of the problem of unspecific adsorption to Ni 2+). Looking for a more appropriate con-
trol protein, His-ERK (a 42 kDa His-tagged protein) was found∗. Unfortunately, the
immobilised His-ERK had very strange behaviour on the chip and could not be used
as reference and no better control was available.
Since the unspecific binding issue was difficult to keep under control, I tried direct
covalent coupling of the receptor on a CM5/CMDP chip.
4.3.1.2 Preconcentration on carboxymethylated dextran chips
Covalent coupling offers the advantage that, since coupling of the receptor is performed
only once, only a minimal amount of His-EGFR is needed and, more important, it
avoids the presence of Ni 2+ and the resulting unspecific binding. However, it as the
disadvantage that the ligand must withstand the coupling conditions (e.g. acidic pH)
and has to be regenerated after each analyte injection (i.e. one has to find conditions
to elute the analyte without denaturing the receptor).
As explained in Section 4.2.3.1, p. 33, proteins are usually coupled at pH comprised
between 3.5 and their pI, the range in which electrostatic attraction favours preconcen-
tration on the surface. His-EGFR was thus desalted in 10 mM NaOAc at pH 5.0 and
injected on a non activated CMDP chip to test preconcentration. Figure 4.11 shows,
that the response did not go back to the basis level in the washing phase: the receptor
could only be removed under harsh conditions. Sticking on the chip surface is probably
due to denaturation of the receptor under acidic conditions.
Beacuse of this problem, preconcentration was not possible. I thus decided to
combine NTA immobilisation with covalent coupling as described in next section.
4.3.1.3 Covalent coupling to nitrilotriacetic acid derivatised chips
NTA/NiP chips are obtained by derivatisation of CM5/CMDP chips. Since EDC/NHS
activation is never complete, free carboxyl groups are still present on the surface and can
be used to covalently bind the protein via standard amine coupling chemistry. Thus,
it is possible to take advantage of the binding of the His-tag to Ni-NTA to concentrate
∗His-ERK was kindly provided by Nicole Kra¨mer.
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Figure 4.11: Preconcentration of His-EGFR on a non activated CMDP chip
- a. The receptor was desalted in 10 mM NaOAc, pH 5.0 before injection (1160-1290 s).
The signal is not returning to basis level after injection: the receptor is probably sticking
on the surface due to denaturation. Unreferenced signal. b. Example of preconcentration
scouting results. Binding increases as the pH is reduced from 5.5 to 4.5. At pH 4.0, the
sensorgram is irregular and bound material does not dissociate from the surface at the end
of the injection, indicating that the protein is aggregating or denaturing. The optimum pH
for this protein is 4.5.62 Part b reprinted from Biacore - Sensor surface handbook (Ref. 62), copyright
2005-2007 GE Healthcare Bio-Sciences AB.
the receptor at the surface without need of acidic buffer. The surface can be activated
with EDC/NHS both before or after protein injection. The unreacted NHS-esters are
then deactivated by injection of ethanolamine.
The main advantage of this strategy is that Ni 2+ is only needed during the coupling
step: after deactivation it can be washed away with EDTA, avoiding that way the
unspecific binding problem. Two additional advantages are that proteins are coupled
in a directed way, since they are all binding to the surface through the His-tag, and
that untagged impurities are disfavoured. This results in a more homogeneous surface
and, possibly, simpler binding curves75.
The coupling procedure was successful with ∼1100 RU His-EGFR coupled on a
NiP chip (Fig. 4.12). The binding was stable and a stable baseline could be reached.
Preliminary analysis with NTA running buffers∗ detected binding of strep-ARNO-Sec7
when injected over the EGFR surface (Fig. 4.13). The negative control (GST) did not
bind. However, the curves were not fitting to a simple 1:1 binding model and showed
clear biphasic behaviour.
Other buffer systems were tested, such as HBS-P† , which was a good buffer for
∗NTA running buffer: 10 mM HEPES, pH 7.4, 300 mM NaCl, 50 µM EDTA, 0.005 % Tween-20;
NTA dispenser buffer: 10 mM HEPES, pH 7.4, 300 mM NaCl, 3 mM EDTA, 0.005 % Tween-20.
†HBS-P: 10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005 % Tween-20.
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Figure 4.12: Covalent binding of His-EGFR on a NiP chip - The surface was
first loaded with Ni 2+, activated with EDC/NHS and then the receptor was injected.
Ethanolamine was used for deactivation and Ni 2+ was washed away with EDTA. 1100 RU
of receptor were immobilized. Unreferenced response.
Figure 4.13: Comparison of the responses for ARNO and GST injected over
His-EGFR covalently coupled on an NiP chip - Analysis performed in NTA running
buffers. A clear signal is seen for ARNO but the shape of the curve is not simple exponential
indicating a complex binding behavior. The control protein GST did not bind. Referenced
with untreated Fc.
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the receptor but not for ARNO. Indeed, strep-ARNO-Sec7 aggregated/precipitated
in HBS-P during injection if diluted or during desalting in HBS-P. This was seen as
jumping and bumpy curves in Biacore and extensive cleaning was needed after injection
to get again sensible injection curves (data not shown).
In A-buffer∗ binding reached equilibrium and the dissociation phase was more sen-
sible (Fig. 4.14). Unfortunately, EGFR was not stable in A-buffer and binding ac-
tivity was completely lost after overnight incubation. Because of a delivery delay, no
NTA/NiP chip was available for a new immobilisation, thus, meanwhile, I tried a cou-
pling on CM5/CMDP chips without preconcentration.
Figure 4.14: Responses in A-buffer reach equilibrium - Injection of 5 µM strep-
ARNO-Sec7 in A-buffer over His-EGFR covalently coupled on an NiP chip was sufficient to
reach equilibrium in∼5 min. This buffer is unfortunately not suitable for the receptor which
completely lost its binding activity by prolonged incubation. Referenced with untreated
Fc.
4.3.1.4 Covalent coupling to carboxymethylated dextran chips without
preconcentration
In principle, it could be possible to immobilise sufficient protein on a CM5/CMDP
chip even without preconcentration and thus avoid the acidic conditions which are not
tolerated by the receptor.
As first, I tested if it is possible to get enough ligand at the surface. In HBS-P
buffer, the His-EGFR sticks on the chip after a simple injection without activation.
∗A-buffer: 50 mM Tris, pH 7.8, 300 mM NaCl, 50 µM EDTA, 0.005 % Tween-20.
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This is seen as an increase of the baseline level after injection (Fig. 4.15). Both chips
from Xantec and Biacore were tested.
Figure 4.15: His-EGFR in HBS-P buffer sticks on carboxymethylated dextran
surfaces - His-EGFR was injected over a non activated surface of a CMDP (left) or CM5
(right) chip (injection times: 250-840 s and 100-220 s, respectively). The receptor sticked
on the surface and could only be removed under harsh conditions. Unreferenced responses.
Thus, a second EGFR construct (GST-EGFR) tagged with GST instead of the His-
tag was tested. As GST-EGFR did not stick on the chip, it was used for coupling and
∼3400 RU receptor could be immobilized (Fig. 4.16).
Figure 4.16: Coupling of GST-EGFR to a CM5 chip - The chip was activated with
EDC/NHS solution (400-700 s) before injection GST-EGFR in HBS-P (850-1750 s) and
deactivation with ethanolamine (1950-2050 s). 3400 RU EGFR were coupled. Unreferenced
response.
Strep-ARNO-Sec7 bound in concentration dependent manner to immobilised GST-
EGFR (Fig. 4.17) while the negative control (GST) did not bind. The shape of
the curves showed some complexity (e.g., linearity at the end of the injection phase).
Nevertheless, a fit to a 1:1 binding model was tried (black lines in Figure 4.17). Since
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dissociation was slow, the acquisition time in the washing phase was too short to
obtain a curvature of the dissociation response, a condition necessary for a precise
determination of kd. Longer acquisition times in the dissociation phase could not be
achieved do to technical limitations. Thus, the binding parameters should be taken with
reserve, since kd values 2-3 times as high would still be compatible with the measured
data and affect both ka and KD.
Some variation is present in the replicates in Figure 4.17. This is because the
measurements shown were part of a data series where various regeneration conditions
were tested. The most promising solution was 0.1 % SDS/1 % Triton X-100 in HBS-P,
but still complete regeneration was not possible.
Figure 4.17: Binding of strep-ARNO-Sec7 to immobilised GST-EGFR - The
responses are concentration dependent but display some complexity, as evident from the
superimposed fit to a 1:1 binding model (shown in black). E.g., at the end of injection
the responses become linear. Due to slow dissociation and limited acquisition time in the
dissociation phase, kd (and thus KD) can not be determined precisely. The fit parameters
(ka = 1360 M
– 1s – 1, kd = 6.2 × 10−4 s – 1, KD = 450 nM, Rmax = 80 and χ2 = 7.3)
should therefore be taken with reserve. Responses referenced with untreated cell.
As a control, interaction of GST-MIG6, a known binding partner of the EGFR-
ICD44, and the receptor was analysed. The responses were concentration dependent
and, except for some complexity at the start of the washing phase, overall well described
by a simple binding model (Fig. 4.18). The KD was estimated to 5 µM with ka =
591 M−1s−1, kd = 3.0 × 10−3 s – 1, Rmax = 50 and χ2 = 0.4∗. Again, longer acquisition
of the dissociation phase would have allowed preciser determination of the binding
∗Errors are not reported because the parameters results from a single global fitting operation.
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parameters.
Figure 4.18: GST-MIG6 binding to immobilised GST-EGFR - The responses are
concentration dependent and the association phase is very well described by a 1:1 binding
model (black lines). Longer dissociation times would be needed to discern if the complexity
an the start of the dissociation phase is relevant and allow preciser determination of kd.
Fit parameters: ka = 591 M
– 1s – 1, kd = 3.0 × 10−3 s – 1, KD = 5 µM, Rmax = 50 and
χ2 = 0.4. Responses referenced with untreated cell.
The analyte binding capacity gives the maximal response (in resonance units) one
can expect from a surface saturated with analyte and is calculated as62
analyte binding capacity (RU) =
Mr(analyte)
Mr(ligand)
∗ immobilised ligand (RU) . (4.11)
In this case with the molecular weights Mr(GST-MIG6) = 32 kDa and Mr(GST-
EGFR) = 88 kDa, and ∼3400 RU immobilized EGFR, the theoretical analyte binding
capacity is ∼1240 RUs. However, the fit in Figure 4.18 estimates a maximal binding
capacity (Rmax) of 50 RUs which corresponds to only 4 % of the theoretical value. This
probably means that only a minimal part of the coupled receptor was able to bind
MIG6 and can have various explanations, as for example:
• some receptors loosed activity during the coupling, or binding was sterically hin-
dered (this could be the case, e.g., if the receptor was coupled nearby the binding
site)
• part of the receptors was already inactive in the stock solution
• the response from the coupling was not only given by the receptor but also by
impurities (either in the ligand or coupling solutions).
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In fact, the amount of coupled receptor was quite high for the conditions used
(concentration, pH and coupling time). To check for a possible presence of impurities
in the coupling solutions, a coupling in absence of protein was performed. Indeed,
mock coupling of a reference surface lead to a significant increase in the baseline signal,
i.e. the signal detected when flowing buffer (Fig. 4.19a). Up to then, coupling was
performed with in-house reagents. Comparison with the original reagents from the
‘Biacore coupling kit’ showed that the last affected the baseline to a much lower extent
(Fig. 4.19b). It is not clear what are the reasons for this difference, but it has to be
taken into account when estimating the analyte binding capacity.
Figure 4.19: Mock coupling of the reference surface - The surface of a CM5 chip
was activated with EDC/NHS solution, washed with coupling buffer, and deactivated with
ethanolamine. a. When in-house coupling reagents were used, mock coupling led to a
baseline increase of ∼1800 RU (∆bkg). b. Use of fresh ‘Biacore coupling kit’ increased the
baseline of only ∼180 RU. Reprinted from Ref. 76, p.42.
Injection of strep-ARNO-Sec7 on the mock coupled surface (in-house reagents) lead
to responses higher than on the GST-EGFR surface (Fig. 4.20). This, together with
the increase in baseline, suggests that the coupling reagents used were possibly con-
taminated and could lead to false positive signals. The chips used in Section 4.3.1.3
(Covalent coupling to nitrilotriacetic acid derivatised chips) were treated with the same
reagents and the results presented there are therefore also put in question. To confirm
the binding results obtained, the experiments described above should thus be repro-
duced with the new coupling reagents.
4.3.1.5 Discussion
The experiments in Section 4.3.1 focused on Biacore analysis of a possible ARNO/EGFR
interaction. Four different approaches for coupling of the receptor are described, with
51
4. SURFACE PLASMON RESONANCE
Figure 4.20: Unspecific binding of strep-ARNO-Sec7 to a mock coupled Fc -
The surface of a CM5 chip was mock coupled with in-house reagents (see Fig. 4.19) The
response of injection over the mock activated Fc (red) is higher than in the GST-EGFR
coupled Fc (green). No binding was detected on untreated surfaces (blue and magenta).
special emphasis on common problems encountered and viable solutions. Here, only
the results directly regarding the question if ARNO does bind the EGFR are discussed.
The first strategy was to immobilise His-tagged receptor on an NTA-derivatised
chip surface via Ni 2+ chelation. Since the high extent on metal-dependent, nonspecific
protein adsorption to the biosensor surface made analysis very challenging, the method
was discarded. Nevertheless qualitative results could already suggest an interaction.
The most promising method benefited of the enrichment of His-EGFR on an NTA
surface to covalently couple the receptor with amine-coupling chemistry. This strategy
qualitatively showed that ARNO and EGFR can interact. The complexity in binding,
which prevented a quantitative analysis, can probably be reduced by the use of other
buffers and new coupling reagents. Indeed, the screening of buffers already led to some
improvement of the curve shapes. Additionally, using lower concentrations of ARNO
could also significantly enhance the quality of analysis. Indeed, in Section 4.3.2.3 we
show that concentrations of ARNO above 1 µM leads to complex responses indepen-
dently of the coupled molecule. By now, we characterised the ARNO/EGFR interaction
by fluorescence polarisation with a KD of ∼1 µM50. It could therefore be difficult to
precisely determine the binding parameters with ARNO concentrations below 1 µM.
In case of interest in the binding rates of the interaction, one should therefore consider
the option of coupling ARNO instead of the receptor.
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Despite of some complexity in the responses and limited dissociation data avail-
ability, covalent coupling of GST-EGFR to carboxymethylated dextran chips allowed
to roughly estimate the binding parameters of ARNO and EGFR. Since dissociation
could only be determined very imprecisely, KD values 2-3 times as high as the obtained
value of ∼450 nM would still be compatible with the measured data and match well
with the dissociation constant determined by fluorescence polarisation. Analysis of the
interaction of GST-EGFR with the known binding partner GST-MIG6 gave a KD of
∼5µM, which lies in the reported range44,50.
For improvement of data quality, the same considerations as above are valid. The
finding of a possible contamination of the coupling reagents inducing unspecific binding,
could not be investigated in this project. Thus, the results described here should be
reproduced with new coupling reagents.
4.3.2 Analysis of ARNO/inhibitor binding affinity
In the second part of this study, we were interested in establishing a method to analyse
the binding affinity between the protein ARNO and its small organic molecule inhibitors
by surface plasmon resonance (SPR). Since the discovery of SecinH3 some years ago17
various derivatives were synthesised or identified by in silico screening, raising the need
for a method for the analysis of their binding properties on cytohesins.
4.3.2.1 The derivatives of SecinH3
With the goal to identify improved cytohesins inhibitors, the group of Prof. Bajorath
performed a virtual screening of chemical libraries formatted in silico and our group
was involved in the in vitro analysis of the identified compounds.
Starting from limited information out of the primary hits from the HTS screen-
ing which lead to the identification of SecinH317,33 and the subsequent structure-
activity-relationship (SAR) analysis, the virtual screening combined fingerprint sim-
ilarity searching and support vector machine modelling34. Activity analysis in vitro
of the 145 candidate compounds suggested by the virtual screening, identified 40 new
structurally diverse inhibitors. Of these, 26 compounds were more active than SecinH3
in at least one of the three different biological assays tested34. Secin16 and Secin132
(Fig. 4.21) were the only two compounds with improved inhibition in all three assays34.
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Since Secin16 had a better IC50 in the nucleotide exchange inhibition (3.1 ± 0.5µM
vs. 8.0± 0.1µM) we chose it for our SPR analysis.
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Figure 4.21: Structures of the virtual screening hit compounds - Secin16 and
Secin132 were more active than SecinH3 in all three biological assays34.
4.3.2.2 Measurements with immobilised protein∗
Since for SPR measurements one of the interacting partners has to be immobilised on
the chip surface, we had two possible experimental setups: either coupling the protein
or the compound. Both methods should give similar results and have advantages and
drawbacks.
On the one hand, coupling of the protein allows to measure several compounds on
the same surface and does not require their derivatisation. Then again, one has to
take into account the risk of loss of protein activity during the coupling process and
of protein deterioration in the course of the experiments. Additionally, the detection
of very low responses, as expected for this strategy because of the small dimensions of
the compounds, is posing higher requirements for the quality of the reagents and the
maintenance of the instrument.
On the other hand, coupling of small organic molecules usually requires their
derivatisation and thus implies a considerable synthetic effort to afford a compound
which retains its activity. All the same, a compound coupled surface offers the ad-
vantage of improved stability. As harsher conditions can be used, regeneration of the
surface is generally more effective and loss of binding capacity is less frequently a prob-
lem. Moreover, binding of protein is inducing a high change in surface density leading
to higher signal to noise ratios and easily detectable binding signals.
∗The experiments in this and the next section (Sections 4.3.2.2 and 4.3.2.3) were performed by my
master student Esteban Gutierrez.
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There are various strategies for coupling a protein to an SPR-chip, including non
covalent methods as well as covalent coupling with different chemistries. For our pur-
pose it was important to have a stable surface, since any drifting of the baseline (as it
occurs when protein dissociate from the chip) would additionally complicate our task of
detecting small responses. We therefore directly excluded non covalent methods. Cap-
turing biotinylated protein on streptavidine coupled chips is a non covalent approach
which offers, thanks to the high affinity of biotin for streptavidine, surface stability
similar to the covalent systems and has the advantage of being almost universally ap-
plicable. We still did not consider this approach as our first choice for two main reasons:
first, the biotinylation of ARNO would have added an extra step to the procedure with
additional risk of denaturation or loss of activity and, second, the streptavidine layer on
the surface would have lead to an higher distance between the surface and the binding
compound and reduced the sensitivity of the system further.
For these reasons, we decided to use EDC/NHS chemistry to covalently attach
our protein to a CM5 chip. The optimisation of the coupling conditions and buffer
system, as well as the measurements with various small molecules are described in detail
elsewhere76 and will not be reported here. Intensive control measurements showed that
this setup was not suitable for the analysis of protein-compound interaction and we
therefore went further to the second immobilisation approach.
4.3.2.3 Measurements with immobilised compound
To immobilise the compounds, we decided again to use NHS chemistry on CM5 chips.
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Figure 4.22: Derivatised Secin16 and control compounds - An amine derivatisation
was needed to couple the compounds to the CM5-chip. Secin16 (a) and the negative control
compound XH1009 (c) were synthesised with a propanolamine linker. The positive control
compound SecinH3 (b) was already available with an ethanolamine linker.
This approach offers the advantage of a stable surface, but the compounds need to be
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derivatised and the ideal linker length has to be determined experimentally. Secin16 and
the negative control compound XH1009 were synthesised with a propanolamine linker,
while an ethanolamine derivatised SecinH3 was already available and was coupled as
positive control (Fig. 4.22).
Binding affinity of ARNO-Sec7 for Secin16
Figure 4.23: ARNO-Sec7 binding to immobilised Secin16 - Secin16 was covalently
coupled to a CM5-chip and ARNO-sec7 at the indicated concentrations was allowed to
flow on it. Four distinct data sets (three of them are shown) were fitted independently
to a 1:1 binding mechanism and the average parameters used to simulate the expected
binding curves (continuous lines). Although the data were of good quality and showed
good reproducibility, the simulated curves are only poorly describing the measured ones.
The sensorgrams obtained by flowing ARNO-Sec7 on immobilised Secin16 were
of good quality and acceptable reproducibility. Additionally, a clear concentration
dependence of the responses was detectable. However, global analysis of the data
was not satisfactory. Each experiment (with 4-6 protein concentrations) was analysed
separately by global fitting and the mean of the kinetic parameters was taken to simulate
the expected curves. As visible in Figure 4.23, the simulated curves does not describe
adequately the experimental ones. A closer look to the curves shapes reveals that two
different binding behaviours are present. In fact, the curves at low concentrations (till
∼500 nM) are exponential and reach equilibrium before the end of the injection phase
(as expected from a 1:1 binding mechanism), while the ones at higher concentrations
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are not reaching equilibrium any more but instead the response increase linearly at the
end of the injection.
This is particularly evident when looking at Figure 4.24. In a the low concentration
curves of the same experiments as in Figure 4.23 are shown. In b the results of mea-
surements on a newly coupled chip are displayed. The four independent experiments
were again fitted separately and the mean of the parameters used to simulate the curves
in black. In this case, the simulation describes adequately the measurements. More-
over, the experiments on the different surfaces are described equally well. Since on the
second chip less compound was coupled, the absolute responses are not comparable and
this was taken into account for the simulation. The fact, that with different conditions
(the surface density on the two chips is different), the same parameters are obtained
confirms the quality of the data.
Figure 4.24: Analysis of ARNO-Sec7 binding to immobilised Secin16 at low
protein concentrations - Out of the measurements shown in Figure 4.23 only the data
with maximal protein concentration of 500 nM were taken for analysis. The measurements
were performed at different days (a) and on distinct chips (a, b) with the indicated pro-
tein concentrations. The dissimilar absolute response between a and b is due to different
compound densities on the two chips. The sensorgrams show good reproducibility and rea-
sonable curves shape. Data analysis was performed as in the previous figure. The simulated
curves are shown in black and describe the measurements adequately. The common binding
parameters are ka = (7 ± 1) × 103 M−1s−1, kd = (10±2) × 10−4 s−1,KD = 155 ± 53 nM,
n = 4. Data are given as mean ± SEM.
To better display the complex curve behaviour, these parameters were used to
simulate the expected response at high concentrations. As evident in Figure 4.25,
the responses at higher concentrations are surprisingly higher than expected. This
and the absence of a plateau of the curves suggest the presence of a second binding
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mechanism, which take place at high protein concentrations. It is thinkable that at
concentration above 500 nM, the Sec7 domain starts dimerising, leading to different
measuring conditions. Additionally aggregation on the surface or on already bound
protein could take place and be responsible for the non specific binding behaviour.
An additional problem of the high concentration curves is visible in the dissocia-
tion phase. In fact, the dissociation is not exponential, as expected for a 1:1 binding
model, but definitely biphasic: the dissociation, rapid in the first seconds, is quickly
slowing down and never complete. This is an additional reason to omit these data from
evaluation.
When taking into account only the low concentration measurements a KD of 155
± 53 nM was determined (ka = (7 ± 1) × 103 M−1s−1, kd = (10 ± 2) × 10−4 s−1, n
= 4).
Figure 4.25: High concentrations of ARNO-Sec7 result in complex interaction
with immobilised Secin16 - The data in Figure 4.23 are presented superimposed with
the simulated curves of Figure 4.24 (continuous). The difference between simulated and
acquired data, reveals that at higher protein concentrations the interaction does not behave
as expected for a simple 1:1 binding mechanism. No equilibrium is reached, the dissociation
is only partial and binding does not saturate.
Measurements with the positive control compound SecinH3
Binding of SecinH3 to ARNO had already been shown with other methods17,77. Thus
SecinH3 was an interesting positive control. Unfortunately, no sensible sensorgrams
were obtained on the SecinH3 surface (data not shown). Since already the buffer
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injections behaved unpredictably, it is more probable that the surface was not ideal for
SPR measurements, than this being caused by undesired interaction with the protein.
A possible cause of the problem, could be the different linker used for SecinH3
coupling. Since not available propanolamine derivatised, an ethanolamine derivatised
SecinH3 was coupled to the chip. This shorter linker could have impaired the properties
of the compound, leading to the strange response curves. A second linker was also tested
and in fact, even if still not good, the sensorgrams showed a different behaviour.
A second possibility is that the immobilisation, and therefore concentration, of
SecinH3 on the surface, can have lead to aggregation or other undesired interactions
between the molecules. This would change the surface properties and perhaps lead to
irregular responses. Because of this unexpected effects, the interaction between SecinH3
and ARNO could not be measured and quantified.
Measurements with the negative control compound XH1009
Figure 4.26: ARNO-Sec7 does not bind to the negative control compound
XH1009 - The negative control compound XH1009 was coupled on the same chip as in
Figure 4.24b and the sensorgrams acquired in parallel. The measurements on XH1009 are
shown in color, the sensorgrams for binding to Secin16 were measured at the same con-
centrations and are shown in black for reference. ARNO-Sec7 does not exhibit significant
binding to XH1009. The complex binding behaviour at high concentrations is visible in
this figure too, in form of a sudden increase of response at the highest concentration (b,
the same experiments as in a with all measured concentrations shown).
The compound XH1009, which has the same core structure as SecinH3 but has no
inhibitory activity and does not bind ARNO77 was used as negative control. ARNO-
Sec7 did not show any significant binding to XH1009 (Fig. 4.26a). In Fig. 4.26b is
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evident that at higher concentration (1.5 µM, yellow) the Sec7 behaves differently on
this surface, too.
Measurements with a negative control protein
Figure 4.27: The negative control protein GST shows unspecific binding - GST
was injected over covalently coupled Secin16. The sensorgrams for GST (in color) are
displayed superimposed to the ARNO-Sec7 measurements (black). The absolute response
is lower as for ARNO-Sec7, but the KD (220 nM) is comparable. GST proved not to be
an appropriate negative control, as discussed in the text (Section 4.3.2.4).
Having seen that ARNO-Sec7 is not binding to XH1009, we tested a negative control
protein. For this scope glutathione S-transferase (GST) was flowed over the Secin16
surface. The results obtained were contradictory: while the sensorgrams shown in
Figure 4.27 show binding of GST to Secin16, other data sets show no binding (data not
shown). The sensorgrams displayed were fitted to a 1:1 binding model and, although
some deviation are readily visible, the fit seems to almost adequately describe the
curves. Though the absolute response is lower, the KD obtained, 220 nM, is in the same
range as that obtained for ARNO-Sec7. It has to be noted that for this measurements
the concentrations of GST were higher than the acceptable ones for ARNO, while
the sensorgrams showing no binding were measured at lower concentrations. It is
questionable if GST is an adequate control, as discussed in detail in Section 4.3.2.4.
4.3.2.4 Discussion
Two different approaches were tested to evaluate the binding of small organic inhibitors
to the Sec7 domain of ARNO by surface plasmon resonance. The first one involved
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the covalent coupling of the protein to the chip surface and did not lead to biologically
significant data. For the second one the amine derivatised compounds were immobilised
and the protein flown on the surface. This setup led to sensible data but some artefacts
were detected at high protein concentrations.
High ARNO concentrations alter binding
ARNO-Sec7 shows complex binding behaviour at high concentrations Measurements
at different time points and on different surfaces showed a good reproducibility of the
data but at the same time made evident that at least two binding modes were observed.
The first one, seen at protein concentrations till ∼500 nM, has a standard 1 : 1 binding
mechanism with exponential binding and dissociation curves and equilibrium at the
end of the injection (Fig. 4.24). At higher concentrations unspecific binding seems
to get the upper hand: the binding curves increase linearly at the end of injection
and the dissociation curves becomes biphasic (Fig. 4.25). This effect is not surprising,
since complex behaviour of ARNO at high concentrations was also observed with other
methods, such as thermophoresis (A. Schmitz, unpublished data). This could be due to
a solubility issue which leads to aggregation and unspecific interaction of ARNO either
already in solution or on the surface (where the local concentration is even higher).
Moreover, such artefacts seems to be common in SPR analysis as explained by Rich
and Myszka: Sometimes, the response continues to increase (and may become more
complex) as the analyte concentration increases. Most likely this is due to heterogeneity
in the ligand, analyte, or both. Weakly binding material or higher levels of non-specific
binding is often observed at higher analyte concentrations.65. In their annual survey
of optical biosensor literature, they stress the importance of using adequate analyte
concentrations to avoid these artefacts65.
Secin16 interacts with ARNO-Sec7
Analysis of the measurement series at low concentrations reveals a dissociation con-
stant of 155 ± 53 nM for ARNO-Sec7 and Secin16, a value which lies in a reasonable
biological range. It is not possible to directly compare KD and half maximal inhibitory
concentration (IC50), amongst other because of the dependence of the IC50 from the
experimental conditions. Nevertheless, we can point out that this KD could account
for the IC50 of 3.1µM observed in the nucleotide exchange assay
34.
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Stumpfe et al. reported a KD of 5 and 7µM for the Sec7/Secin16 interaction de-
termined by SPR and microscale thermophoresis respectively34. However his results
can not be directly compared since different measuring approaches were used. Indeed,
for their SPR measurements Stumpfe et al. immobilised the protein instead of the
compound and used a special sensor chip with 3 D immobilization matrices (hydrogel
surface). Moreover the Sec7 domain of cytohesin-1 and not ARNO was used34. For
microscale thermophoresis ARNO-sec7 was used. However, there is no literature so far
showing comparison of KDs determined by SPR and thermophoresis. It is thus diffi-
cult to determine how far the measured KDs are influenced by the measuring approach
and the actual KD probably lies somewhere between the values reported here and in
Ref. 34.
Analysis of the absolute response
A surprising feature of these SPR measurements is the absolute response. For the
first chip, the amount of immobilised ligand was estimated as 2300 RUs. Inserting the
molecular masses of ligand (∼400 Da) and analyte (27 kDa), in Equation 4.11 gives a
theoretical maximal response of over 150 000 RU. The theoretical value can strictly only
be reached at infinite analyte concentration and contact time and the experimental
value is also dependent on other factors, such as the activity of the ligand and the
kinetics of analyte binding62. Nevertheless, the estimated maximal response of ∼17 RUs
(Fig. 4.25) is suspiciously low.
Still, the binding response is dependent on the amount of compound immobilised, as
depicted in Figure 4.24. In fact, the amount of compound coupled in a (2300 RUs) and
b (800 RUs), correlates pretty well with the respective experimental maximal binding.
Additionally, the equation above is actually only described for immobilised proteins
and it is not clear if the same relation is valid for small organic molecules. Because
of the quite different properties of these two type of molecule it would be reasonable
if a correction term is needed. In particular, the maximal response could be limited
by steric effects if the surface is densely modified with compound. Thus, although this
irregularity should be kept in mind, we believe that this is not enough to discredit the
data.
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SecinH3 sensorgrams are irregular
Unfortunately, measurements with the positive control compound SecinH3 were not
possible since no modified molecule with the right linker was available (the measure-
ments with SecinH3 with shorter linker lead to non evaluable data, see Section 4.3.2.3
for possible explanations). It would be interesting to test if the propanolamine deriva-
tised SecinH3 allows detection of binding data of quality comparable to that of the
Secin16 measurements.
In a previous work, the dissociation constant of SecinH3 and ARNO-Sec7 was mea-
sured by SPR and isothermal titration calorimetry (ITC) giving KDs of 748 ± 70 nM78
and 250 ± 5 nM17, respectively. Although, since the SPR measurements were per-
formed with a different approach and because of the dissimilar principle of ITC (where
both interacting molecules are in solution) it is not possible to directly transfer this
values to our system. Therefore, comparison of the binding affinity of Secin16 and
SecinH3 is not possible at this stage.
The negative control compound XH1009 does not bind the Sec7 domain
Because of the aggregation propensity of ARNO and the complex binding behaviour
observed, it was particularly important to have a good negative control. To exclude un-
specific binding of ARNO-Sec7, the interaction between ARNO-Sec7 and immobilised
XH1009 was analysed. As requested, no binding was detected (Fig. 4.26a). Interest-
ingly, at concentrations above 1 µM a sudden increase of response was detected (Fig.
4.26b). This supports the hypothesis of a complex behaviour of ARNO-Sec7 at high
concentrations.
GST is not an adequate negative control
As a cross check we analysed the behaviour of the completely unrelated protein GST on
the Secin16 surface, but the outcome of this experiment was not conclusive. In fact, two
different data sets, gave quite different results. In the first experiment GST concentra-
tions between 0.5 and 1.5 µM were used and, although the absolute response was lower
as that obtained for ARNO-Sec7, kinetic evaluation resulted in a KD of ∼200 nM (Fig.
4.27), which is comparable to the KD of the Sec7 domain. However, measurements
with lower concentrations, did not show binding.
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With the benefit of hindsight, we can say that GST is not an ideal negative control.
GST was chosen because it is unrelated but of similar size to the Sec7 domain and read-
ily available. Unfortunately, in our experiments these advantages were overwhelmed by
the drawbacks. One of these is the constitutive dimeric state of GST, which can cause
complex behaviour of the protein on the chip. Moreover, GST has not only a broad
specificity for its ligands but it is also reported to bind a broad spectrum of nonsub-
strate ligands79,80, a peculiarity for which it earned, at the time of its discovery, the
name ligandin81. It is probably this kind of unspecific binding that we detected in our
measurements, an observation corroborated by thermophoresis data where GST was
shown to bind to all binding partner tested (A. Schmitz, unpublished). All together, it
is now clear that the data acquired for GST can not be taken in consideration for our
evaluation and that a better negative control protein should be selected. Ideally this
protein should have similar size and isoelectric point as the Sec7 domain, be monomeric
in solution and do not show noticeable unspecific binding behaviour. E. Gutierrez’s cur-
rent measurements of additional control proteins seems to confirm the specificity of the
detected ARNO/Secin16 interaction.
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When a new active compound is identified, the question about its specificity for the
target protein directly arises. Traditionally, this is investigated in vitro with binding or
activity assays with more or less related proteins. Unfortunately, this process is not only
extremely time consuming but often leads to biologically non relevant data. Moreover
the number of proteins which can be tested is minimal compared to the proteome.
The interest on identifying possible side targets already at an early stage of com-
pound characterisation, led to the development of new methods in the last years. This
process was speeded up by the revival of whole-cells based screening for drug discovery,
since the target protein of active small molecules identified that way are unknown and
need to be identified in a successive stage82.
A very innovative method which allows the one-shot test of an entire proteome is
known as activity/affinity based protein profiling (ABPP) or capture compound mass
spectrometry (CCMS). Goal of this project, was to establish CCMS for our inhibitors
and SecinH3 was taken as model compound.
5.1 The concept of capture compound mass spectrometry
(CCMS)
Activity based probes (ABPs) were first developed as a tool to collectively monitor the
activity of enzymes with similar reaction mechanisms83. Their use was initially limited
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to irreversible inhibitors which covalently bind to the target protein (see Ref. 84 and
85 for review) but the method was soon adapted also to non covalent inhibitors86–88.
Figure 5.1: Activity/affinity based probes - a. Conventional activity based probe.
The irreversible inhibitor acts as reactive group and is covalently bound to the enzyme.
For detection and enrichment, reporter groups like biotin or fluorescent tags are used. b.
Photoreactive affinity based probe. Upon irradiation, the reversible inhibitor is covalently
bound to the interacting protein via the photoreactive group.
A conventional activity based probe is made up of three units: a reactive group, a
linker, and a reporter group. In the case of an irreversible inhibitor, the reactive group
is the ligand, which covalently binds to the enzyme (Fig. 5.1a). The reporter group
can be a biotin or a fluorescent tag and is needed for the detection of the modified
protein. Since the analysis is usually performed under denaturing conditions, e.g. gel
electrophoresis, the method could not be applied to reversible inhibitors. Adding a
photolabile unit to the probe, as first described by Hagenstein et al.86, is an elegant
solution to circumvent this limitation (Fig. 5.1b). This way, the inhibitor acts as a
Trojan Horse by recruiting the probe to the protein which is then irreversibly modified
by the photoreactive group upon irradiation86–88.
An important step toward the development of a powerful method was the combina-
tion of ABPP with mass spectrometry (MS)89–92. This association allows, not only to
readily identify the proteins modified by a probe, but also to determine their binding
site. As shown in Figure 5.2, the whole process, called CCMS93 when reversible ligands
are used, consist of 6 steps. First, the probes are incubated with the proteome till bind-
ing equilibrium is achieved. Upon UV irradiation (a), the probes binds covalently the
interacting proteins. A pull down with beads specific for the reporter group (b) allows
enrichment of the labelled proteins. Then, a proteolytic cleavage is performed directly
on the beads (c). Finally, the supernatant is analysed by liquid chromatography tan-
dem mass spectrometry (LC-MS/MS) (d) and the data obtained is compared with a
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protein database for identification (e). For the identification of the site of modification,
the labelled peptides can be eluted from the beads and analysed the same way with
LC-MS/MS.
Figure 5.2: Capture compound mass spectrometry - Work flow of a standard
CCMS experiment. The photoreactive probe is preincubated with the proteome. Upon
UV irradiation (a), the probe reacts and binds covalently the interacting protein. Labelled
proteins are enriched by pull down with streptavidine beads (b). Proteolytic cleavage is
performed directly on the beads (c). The supernatant is analysed by LC-MS/MS (d)
and the data obtained compared with a protein database for identification (e). Labelled
peptides can be eluted from the beads for identification of the site of modification.
5.2 Mass spectrometry in proteomics
The first measurement of the mass-to-charge ratio (m/z) of various gaseous ionised
atoms or molecules by Sir Joseph John Thomson signed the start of mass spectrometry
in 1910. Though great advancements of the method in the subsequent years, for the
first 80 years its application was essentially limited to small chemicals94. The break-
through was made at the end of the Eighties with the development of the soft ionisation
methods electrospray ionization (ESI)95 and matrix-assisted laser desorption/ionization
(MALDI)96,97. Allowing gentle ionisation of large non-volatile molecules, they extended
MS to protein analysis. This, together with the quick growth of protein sequences
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databases, thanks to the extensive genomics efforts, led to the rapid establishment of
MS as a standard method for protein identification and analysis98.
5.2.1 The working principle of a mass spectrometer
The three main components of a mass spectrometer are the ionization source, mass
analyzer, and detector.
The ionisation source is needed to introduce the sample in the system. It is at
this stage that the molecules are ionised and brought into (pseudo) gas phase. As MS
can only measure charged molecules, this is an important step, which was precluded
to proteins before the invention of MALDI and ESI. For MALDI96,97, the sample is
co-crystallised with a matrix which is then vaporised with UV laser pulses to liberate
the peptides or proteins as gaseous ions. In ESI95, the molecules are dissolved in liquid
which is sprayed under high voltage to form small charged droplets. Evaporation of
the solvents leaves singly and/or multi charged molecules which can enter the mass
analyser.98,99
There are various types of mass analyser (e.g. time-of-flight (TOF), quadrupole,
ion trap) which all rely on the application of electromagnetic fields to separate the ions
according to their m/z.
The detector measures the number of ions having the m/z ratio corresponding to
the applied fields. The display of ion intensity versus m/z is called a mass spectrum.
For this project, a mass spectrometer with ESI source and quadrupole ion trap
analyser was used.
5.2.2 Peptide sequencing by tandem MS
Tandem MS allows the acquisition of additional information by performing two subse-
quent mass analyses. In the first step, a mass spectrum is acquired and “precursor ions”
are selected for further processing. These ions are then fragmented and the resulting
“product ions” are again separated according to their m/z and recorded as an MS/MS
spectrum98.
Fragmentation is usually achieved by collision induced dissociation (CID), in which
the energy imparted by collisions with an inert gas (such as nitrogen, argon, or he-
lium) causes the peptide to break apart100. At low collision energies (10-50 eV), the
68
5.2 Mass spectrometry in proteomics
product ions are primarily formed by cleavage at the peptide bonds98. The Roepstorff-
Fohlmann-Biemann101,102 nomenclature of the possible ions is shown in Figure 5.3.
Ions are labelled as a, b, and c when the charge is retained by the amino-terminal
fragment and x, y, and z if the charge is retained on the C-terminal side. In ion trap
instruments y and b ions predominate100.
Figure 5.3: Product ions of collision induced dissociation - This figure shows
different possibilities of fragmentation for a tetrapeptide (top) and the produced fragment
structures (bottom). Ideal N-terminal fragments are computed by adding the mass of the
N-terminal group (H) and all amino acid nominal masses before the cleavage position. Ideal
C-terminal fragments are computed by adding the mass of the C-terminal group (OH) and
all amino acid nominal masses after the cleavage position. Each ion type is characterized
by an offset that represents the mass difference in Daltons between the observed mass and
the corresponding N- or C-terminal ideal fragment. For example, the b-ion type offset
is 0 (Da), because the mass of a b-ion type exactly corresponds to an ideal N- terminal
fragment, whereas an a-ion type offset is -28 (Da), because a-ions lose a carbonyl and an
oxygen atom compared to an ideal N-terminal fragment.98 Reprinted from Mass Spectrometry
Reviews (Ref. 98), copyright 2006, with permission from John Wiley and Sons, Inc.
As shown in Figure 5.4, in an ideal MS/MS spectrum each peptide fragment differs
from the neighbour by exactly one amino acid. The mass difference between two adja-
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cent peaks therefore theoretically allows to infer the amino acid sequence. In practice,
missing peaks and noise can highly complicate the analysis and de novo sequencing
rely on high quality data and an experienced eye. Indeed, even the leading de novo
algorithms are still unreliable100,103.
This problem was circumvented by the combination of database search with de novo
sequencing104, as described in the next section. This strategy takes advantage of the
fact that for most peptides short partial sequences are easily determined. Using this
“peptide sequence tags” for database matching allows rapid protein identification.
Figure 5.4: Mass-spectrometry traces - a. The total ion intensity from all the mass
spectra that were recorded during the LC-MS run is shown as a function of elution time
(total ion chromatogram). Shown in bold is the trace for the intensity of one particular
ion, which elutes within a 40-second window approximately 42.5 minutes into the gradient
(extracted ion chromatogram). The area under this curve represents the total signal of
this peptide. b. The mass spectrum of the peptides that were eluted 42.4 minutes into
the gradient. The insert shows the m/z values around the peptide ion of interest, which
are indicative of the resolution and allow the charge state to be derived. c. The MS/MS
spectrum of the peptide ion of interest (highlighted by a dashed box in part b). The
mass differences between this y-ion series indicate the amino-acid series, which is shown
below the spectrum. As this is a y-ion series, the sequence is written in the carboxy-to-
amino-terminus direction going from left to right.100 Adapted by permission from Macmillan
Publishers Ltd: Nature Reviews Molecular Cell Biology (Ref. 100), copyright 2004.
70
5.3 Results and discussion
5.2.3 Protein identification by database searching
The so called “top-down” strategy of protein analysis involves the ionisation of intact
proteins and his fragmentation inside the spectrometer. Although this approach allows
a more complete characterisation of protein isoforms and modifications105, its use is
still limited by the low throughput106, expensive instrumental set up, lower sensisitvity
and limited availability of specific bioinformatic tools107.
Widespread is the “bottom-up” strategy, which analyses peptides generated by
proteolytic digestion. Because of their smaller size and better solubility, peptides are
readily separated by chromatography and can be analysed on every MALDI and ESI
instrument107. Trypsin, a protease which cleaves at the carboxyl side of lysines or
arginines108, is routinely used in proteomic analysis because of the favorable length of
the obtained peptides. Moreover, every tryptic peptide carries at least two protonation
sites (the N-terminal amino group and the C-terminal lysine or arginine) for efficient
ionisation and detection109.
There are two main bottom-up approaches: peptide mass fingerprinting (PMF)110–114
and tandem MS based data base search104,115. In PMF the peptide masses obtained
experimentally are compared with the theoretical masses from in silico digest of a ref-
erence database. Since peptides with very similar masses can be derived from different
proteins, this method requires an accurate mass determination, a large number of pep-
tide matches and a high percentage of protein sequence coverage for a reliable protein
identification. The second approach relies on the possibility of deriving sequence in-
formation from CID spectra, as described in the previous section. The simultaneous
knowledge of peptide mass and (partial) sequence improves considerably the database
search as it is theoretically possible to correctly identify a protein with a single MS/MS
peptide match109.
5.3 Results and discussion
Capture compound mass spectrometry can be applied to any binding molecule for which
the necessary modifications are possible. This is particularly interesting for our group,
where new inhibitors discovered by high throughput screening need to be characterised.
The goal of this project was to establish a generally applicable CCMS protocol in our
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group. Our best known small molecule inhibitor, SecinH3, was chosen as molecule of
interest. The first step was thus the synthesis of a photoreactive SecinH3 probe.
5.3.1 Design and synthesis of a photoreactive SecinH3 probe
As described in Section 5.1 (p. 66), photoreactive affinity based probes are composed
of three elements: an affinity unit, in our case SecinH3, responsible for the interaction
with the target protein; a photoreactive moiety, which upon irradiation covalently binds
the probe to the enzyme; and a reporter group, for detection and enrichment of the
labelled protein.
Figure 5.5: Structures
of SecinH3, SecinH3-
TPD and BA103 -
In the photoreactive
probe SecinH3-TPD,
the thiophenyl group
is substituted by the
photo-activatable group
trifluoromethylphenyl di-
azirine (red). The reporter
group is desthiobiotin
linked at the 3-position of
the triazole ring (blue).
The non photoreactive
derivative BA103 serves as
negative control.
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An ideal photo-activatable group should be small, stable in the absence of light, as
well as highly and indiscriminately reactive upon irradiation at wavelengths which do
not damage the biological sample116. Commonly used photo-activatable groups include
aryl azides, benzophenones, and 3-aryldiazirines. Though the advantages of trifluo-
romethylphenyl diazirine (TPD)117 over the other photoactivatable groups were early
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recognised, its use in photoaffinity labelling was limited in the past by synthetic restric-
tions and limited availability of TPD derivatives with convenient reactive groups118,119.
The recent establishment of various diazirine compatible reactions118,120 and the in-
creasing commercial availability of TPD derivatives, now allows their more widespread
use. The exceptional reactivity at relatively long wavelength (∼360 nm), the supe-
rior properties, and its structure make of TPD an ideal photo-activatable group for
the modification of our small organic cytohesin inhibitor SecinH3. In particular the
lack of formation of slowly reacting isoforms, as observed for benzophenones and aryl
azides116,121,122, is an important advantage of TPD which make it suitable for binding
site identification experiments.
Structure-activity-relationship (SAR) studies on SecinH3 showed that the phenyl
group is necessary for inhibition but its modification does not seriously affect activity
and that the alkoxy substitutent is not essential (Ref. 77 and X. Bi, A. M. Hayallah and
M. Famulok, unpublished results). These results offered the terminal thiophenyl group
as an ideal target for effective substitution with the TPD moiety (Fig. 5.5) by amine
coupling reaction with commercially available 4-(1-Azi-2,2,2-trifluoroethyl)benzoic acid
(TPD-COOH).
Since extension of the methoxy group at the 3-position of the triazole ring is possible
without significant loss of inhibitory activity77, we decided to take it as anchoring point
for the reporter unit. For a straightforward enrichment of labelled protein at later
stage, we decided to use desthiobiotin, coupled through an aminoethoxyethanol spacer,
as affinity element (Fig. 5.5). The biotin analogue desthiobiotin binds less tightly to
streptavidin and can be easily displaced by biotin123. Thus, proteins labelled with
desthiobiotin can be recovered after enrichment.
5.3.1.1 Retrosynthesis
The photoreactive building block TPD-COOH is not only quite expensive, but it re-
quires also special care during handling (e.g. avoid exposition to light). Thus, we wanted
to develop a synthetic strategy where the TPD moiety could be inserted efficiently in
the last step.
Starting from the synthesis of the biotinylated SecinH3 precursor Bio-SecinNH2
described by X. Bi (Fig. 5.6, unpublished data), we formulated the retrosynthetic plan
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Figure 5.6: Biotin coupling - This procedure for the synthesis of the biotiny-
lated SecinH3 precursor Bio-SecinNH2 was reported By X. Bi (unpublished data): (i)
dichloromethane, TFA, 1 h, RT (82 %); (ii) D(+)-biotin, HBTU, N-ethyldiisopropylamine,
DMF, 30 min, RT (76 %).
in Figure 5.7 for the synthesis of SecinH3-TPD. Both TPD-COOH and desthiobi-
otin are coupled via peptide coupling reactions to BS-4. This can be obtained by
deprotection of BS-3, which was available in sufficient amount.
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Figure 5.7: Retrosynthetic path for the synthesis of SecinH3-TPD - Peptide
coupling is used to react TPD-COOH and desthiobiotin with BS-4, which is produced by
deprotection of BS-3.
In fact, the reaction of BS-4 with desthiobiotin (activated with HBTU and Hu¨nig’s
base) did not give the desired product: probably the reaction was not selective enough.
A new retrosynthetic analysis was therefore necessary. In the new retrosynthetic plan,
BA99 is obtained by hydrogenation of the nitrophenyl compound BA96. Desthiobi-
otin can selectively react with the free amine of BA94. Cyclisation of BS-1 leads to
the 1,2,4-substituted triazole ring in BA91.
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Figure 5.8: Retrosynthetic analysis for the synthesis of BA99 - Selective desthio-
biotinylation can be achieved on BA94. The 1,2,4-substituted triazole derivative BA91
is obtained by cyclisation of BS-1
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Figure 5.9: Synthesis of the photoreactive SecinH3 probe SecinH3-TPD -
(i) Nitrophenyldiazirine, EtOH, 80◦C, 8 h; (ii) Formic acid, 2.5 h; (iii) Desthiobiotin,
HBTU, N -ethyldiisopropylamine, DMF, 1 h; (iv) 10 % Pd/C, EtOH/THF, 9 bar H2,
2 h; (v) TPD-COOH, oxalylchloride, THF, DMF (catalytic), 2.5 h; (vi) BA99, N -
ethyldiisopropylamine, CH2Cl2, 2 h.
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5.3.1.2 Synthetic way
The synthesis of SecinH3-TPD is depicted in Figure 5.9. The 1,2,4-substituted triazole
ring BA91 was obtained by cyclisation of BS-3 (Ref. 77) with 4-nitrophenylhydrazine.
Deprotection of BA91 with formic acid lead to BA94, which was then coupled to
desthiobiotin by standard peptide coupling reaction. The desthiobiotinylated SecinH3
core BA99 was obtained by palladium catalysed hydrogenation of BA96.
The final coupling was optimised in a model reaction on a non photoreactive benzoic
acid: 4-ethylbenzoic acid was reacted to 4-ethyl-benzoyl chloride with oxalylchloride
and then coupled to BA96 to give the negative control compound BA103 (Fig. 5.5).
Analogously, the benzoic acid TPD-COOH was converted to the benzoyl chloride
before reaction with BA99 to give the final product SecinH3-TPD. All steps gave
the desired product with good purity and yield.
5.3.2 Determination of the labelling conditions in vitro
Having synthesised the photoreactive probe SecinH3-TPD, the ideal labelling conditions
had to be established. The amount of protein labelled upon UV irradiation correlates
directly with the portion of protein bound to the compound at equilibrium. Therefore,
to define the initial working concentrations for both protein and compound, I first
calculated the expected complex ratio at various concentrations.
5.3.2.1 Theoretical binding ratio at various compound and protein concen-
trations
Assuming a simple 1:1 binding behaviour, the amount x of protein:compound complex
at equilibrium depends from the initial concentration of protein ([P]) and compound
([C]), and the dissociation constant (KD) according to
x =
[P] + [C] +KD −
√
([P] + [C] +KD)2 − 4 [P] [C]
2
. (5.1)
Under assumption of a KD of 200 nM
17, the curves in Figure 5.10 were obtained for
the Sec7 domain of ARNO and SecinH3.
For the planned experiments it was important to maximise the portion of labelled
protein. So, with the intent to minimize unspecific interaction, minimal concentrations
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Figure 5.10: Simulation of the theoretical binding ratio for a KD of 200 nM -
The ratio of SecinH3:ARNO-Sec7 complex with respect to total ARNO-Sec7 concentration
is plotted against ARNO-Sec7 concentration. The results for 1-fold (red square), 5-fold
(blue diamond) and 10-fold (yellow triangle) compound excess are shown. Data points
which require compound concentrations above SecinH3 solubility are shown in grey. With
1 µM ARNO-Sec7, 5-fold excess SecinH3 is expected to lead to 95 % complexed protein at
equilibrium.
giving acceptable complex ratio were chosen. The preliminary labelling experiments
were therefore performed at [P] = 0.5µM and [C] = 2.5µM.photo-activatable group
5.3.2.2 Correction of the calculations for a KD of 15 µM
Later on, new binding data were obtained which estimated the dissociation constant of
ARNO-Sec7 and SecinH3 at ∼15µM (A. Schmitz, unpublished data). The corrected
curves in Figure 5.11 show that with the concentrations used above a maximal labelling
of only 20 % is possible. The easiest way to improve this ratio, would be increasing
the compound concentration. Unfortunately, SecinH3 was known to be only limitedly
soluble, though the exact solubility had not been determined. Thus, the solubility of
SecinH3 was measured.
5.3.2.3 Solubility of SecinH3
The solubility of small molecules was determined by measuring the absorption of com-
pound dilutions after centrifugation to remove possible aggregates/precipitates. The
solubility was defined as the concentration at which the linear correlation between
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Figure 5.11: Simulation of the theoretical binding ratio for a KD of 15 µM - The
ratio of SecinH3:ARNO-Sec7 complex with respect to total ARNO-Sec7 concentration is
plotted against ARNO-Sec7 concentration. The results for 1-fold (red square), 5-fold (blue
diamond) and 10-fold (yellow triangle) compound excess are shown. Data points which
require compound concentrations above SecinH3 solubility are shown in grey.
concentration and absorption is broken. Since SecinH3-TPD is not stable at the wave-
lengths used, the solubility tests were performed with SecinH3 instead.
Traditionally, the SecinH3 inhibition experiments in vitro and in cell culture were
performed in 0.4 – 10 % DMSO in aqueous solution. Though higher DMSO concentra-
tion could improve SecinH3 solubility, it is known that most proteins do not withstand
it. Hence, as an alternative to DMSO, diglyme (1-methoxy-2-(2-methoxyethoxy)ethane)
was tested. Diglyme is an organic solvent similar to glycerol, which has been shown to
be tolerated by various enzymes even at high concentrations124–126.
The absorption spectrum of SecinH3 in diglyme was measured and an absorption
maximum was found at 260 nM (Fig. 5.12). Since the absorption maximum in DMSO
was known to be at 280 nM, the measurements were performed at this wavelength.
Because of the high absorption at 280 nM, the solubility curves at high concentrations
were measured at 330 nM.
As visible in Figure 5.13a, SecinH3 has a solubility of ∼20µM both in 10 % DMSO
and diglyme. Desirably, the solubility in 40 % diglyme drastically increases to over
100µM. Even at 20 % diglyme, SecinH3 is soluble till 100µM (Fig. 5.13b).
Because no data about the tolerance of ARNO for diglyme were available, both
diglyme and DMSO were initially used for the labelling experiments.
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Figure 5.12: Absorption spectrum of SecinH3 in diglyme - Absorption of a 50µM
solution of SecinH3 in diglyme was measured
Figure 5.13: Diglyme increases SecinH3 solubility - SecinH3 dilutions in 10 %
(orange diamond), 20 % (red triangle) or 40 % (blue square) diglyme or 10 % DMSO
(yellow triangle) were centrifuged to remove non soluble compound. Absorption at
280 (a) or 330 (b) nm is plotted against SecinH3 concentration. The break-point in the
curves indicate the maximal solubility. The solubility of 20µM in 10 % DMSO is increased
to 100µM in 20 % diglyme.
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5.3.2.4 Analysis of the specificity of labelling
The most important question at this stage was whether the synthesised SecinH3 probe
would label ARNO-Sec7 and how specific this labelling would be. As SecinH3-TPD
carries a desthiobiotin tag, the proteins it reacts with can easily be detected on a
western blot by streptavidine. As a first test of specificity, labelling of the purified
PAZ domain of Argonaute1 was measured. This protein was chosen as negative control
from those available in the group, because it has similar size and carries the same tag
(His)73,74 as ARNO-Sec7, allowing easy comparison of the total protein in the assay.
Figure 5.14 shows that SecinH3-TPD labelled ARNO-Sec7 upon irradiation. No
signal was detected when the negative control compound BA103 (Fig. 5.5) was used.
Although the PAZ domain was slightly tagged by SecinH3-TPD, the binding was almost
completely competed by ARNO-Sec7. These results show that the designed SecinH3
probe retains its affinity for ARNO.
Figure 5.14: SecinH3-TPD binds and labels ARNO-Sec7 - SecinH3-TPD or the
negative control compound BA103 (2.5µM) were incubated with the indicated proteins
(0.5µM) for 15 min at RT before irradiation for 0, 2, or 5 min. After separation with 10 %
SDS-PAGE and Western blotting, the labelled proteins were detected with a horseradish
peroxidase streptavidin conjugate. The total amount of protein was detected with His5
specific antibody. S: ARNO-Sec7, P: PAZ-domain
Having seen that SecinH3-TPD binds to ARNO-Sec7, I tested if the labelling ef-
ficiency could be improved with higher compound concentrations. To allow the use
of concentrations higher than 20µM, diglyme was used as solvent. As reference, 20µl
SecinH3-TPD in DMSO was used. Diglyme increased dramatically the amount of la-
belled ARNO-Sec7. As indicated by the bands intensities in Figure 5.15, the amount of
modification was improved even at equal compound concentration as in DMSO (20µM).
Increasing the concentration to 80µM had a less prominent effect.
80
5.3 Results and discussion
Two additional main differences are evident in the diglyme samples. First, the
appearance of additional bands: the presence of bands at around the double mass of
ARNO-Sec7 was observed also in other experiments and seems to be quite condition
dependent. Second, a band shift in the irradiated samples (His-tag detection): the
expected mass difference in case of single labelling (∼700 Da) is not a sufficient expla-
nation, in particular because the band shift is not present in the DMSO samples. A
possible interpretation, which would also account for the higher labelling observed at
20µM, is that diglyme lead to multiple labelling of a single ARNO molecule. Taken
together with the fact, that diglyme hinders the nucleotide exchange of ARNO-Sec7
on ARF1 in vitro (A. Bill, unpublished data), diglyme does not seem to be compatible
with the ARNO-Sec7 activity.
Figure 5.15: Diglyme increases ARNO-Sec7 labelling by SecinH3-TPD - The
labelling experiments were performed in 20 % diglyme or 10 % DMSO as indicated. The
proteins (1µM each) were incubated for 15 min at RT with the given concentrations of
inhibitor and then either irradiated for 10 min (UV) or kept in the dark (-). After separation
on 12.5 % SDS-PAGE, detection was performed as in Figure 5.14. S: ARNO-Sec7 (J),
P: PAZ-domain (<)
5.3.2.5 Labelling efficiency of ARNO domains and mutants
At this point, only labelling of a truncated form of ARNO, namely ARNO-Sec7, had
been investigated. Yet, although SecinH3 was selected against the Sec7 domain, its bio-
logical activity imply that SecinH3 is successfully inhibiting the native protein. There-
fore I was interested in finding out how the different ARNO domains influence SecinH3
binding. Additionally to the full length ARNO (FL), constructs lacking the pleckstrin
homology and coiled coil domains (∆PH and ∆CC, respectively) were used. Moreover,
I made a new construct lacking the polybasic region at the C-terminus (∆PBR). As
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described in Section 1.2.1.1, p. 6, this region is responsible for autoinhibition of the
exchange activity of the Sec7 domain and its excision restores the activity in purified
proteins19. Figure 5.16 shows that SecinH3-TPD labelled ∆PBR much better than
ARNO-Sec7. Although the actual concentration of the different domains in the assay
was quite variable, ARNO-Sec7 and ∆PBR were present in comparable concentrations.
Figure 5.16: ∆PBR is more efficiently labelled than ARNO-Sec7 - The proteins
(1µM) were incubated with 20µM SecinH3-TPD for 10 min on ice before irradiation
(10 min). After separation on a 12.5 % SDS-PAGE and Western blotting, the labelled
proteins were detected with a NeutrAvidin DyLight 800 fluorescent conjugate. The total
amount of protein was detected with His5 specific antibody. The abbreviations are defined
in the text. -: non irradiated; UV: irradiated for 10 min.
Molecular docking experiments performed in the group of Prof. Bajorath (Depart-
ment of life science informatics, University of Bonn), revealed a possible binding site of
SecinH3 on ARNO-Sec7. On this basis, four point mutants which should affect SecinH3
binding were designed (Fig. 5.17). Though the mutants were functional in the exchange
assay, the activity was too low to permit the measurement of a significant inhibition
assay (Caroline Kubaczka, unpublished data). Thus, the inhibition (ergo binding) of
SecinH3 of this mutants could not be tested that way. A more direct approach to anal-
yse their binding to SecinH3 was the use of the photoreactive SecinH3. Surprisingly,
none of the mutants showed a reduced binding. Yet, for the mutant L148A (M1) the
labelling was even increased (Fig. 5.16).
Detection with His5 antibody revealed that the actual concentration of the different
proteins in the assay was not comparable. However, the relative concentrations in the
repetitions of the assay were not constant. This excludes an error in the estimation
protein concentration. To check if aggregation or coating to the vial were the causes
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Figure 5.17: Mutants 1-4 of ARNO-Sec7 - A possible binding site of SecinH3 on
ARNO-Sec7 was detected with the help of docking experiments in silico. The four point
mutants which were designed to disrupt the interaction are shown in color in the model of
the ARNO-Sec7 domain. Yellow: M1, L148A; green: M2, L153A; red: M3, M164A; blue:
M4, F243A. Image based on Protein Data Bank entry 1PBV (Ref. 11).
of variability, the samples were centrifuged before loading on the gel. Both the super-
natant, containing the soluble proteins, and the pellet, containing aggregated proteins,
were analysed. Figure 5.18a shows that most of the protein was actually found in the
pellet, demonstrating a solubility issue.
5.3.2.6 Effect of detergent on solubility and labelling
Figure 5.18: Triton X-100 is necessary to keep ARNO in solution - Quantifi-
cation of total protein is displayed. The experiments were performed as in Figure 5.16,
with the difference that after irradiation the samples were centrifuged to separate soluble
(supernatant, green) from aggregated (pellet, blue) proteins. a. Labelling under standard
conditions b. 0.005 % Triton X-100 added to the labelling buffer.
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Figure 5.19: The amount of labelled ARNO in the supernatant is increased by
Triton X-100 - Quantification of labelled protein found in supernatant in the experiment
in Figure 5.18.
With the intent to improve solubility, 0.005 % Triton X-100, a nonionic surfactant
which is often used to solubilise proteins, was added to the labelling buffer. Indeed, the
detergent improved the solubility dramatically and most of the protein was found in
solution (Fig. 5.18b). As expected, the amount of labelled protein in the supernatant
was also increased (Fig. 5.19). Under this conditions, the labelling of ∆PBR was 5-times
higher than ARNO-Sec7 labelling. The higher background signal for non irradiated
∆PBR is due to non specific recognition of ∆PBR by NeutrAvidin.
5.3.3 Establishment of the mass spectrometric analysis
Having proved that SecinH3-TPD can be crosslinked to ARNO, the next step was to
define suitable conditions for the mass spectrometric analysis of ARNO. Since there
was no know-how about protein analysis on MS in the group, we decided to start with
a model sample before moving to more complex mixtures.
The whole procedure from the labelled protein, through LC-MS/MS analysis, till
peptide identification involves various steps like denaturation, digestion, HPLC (high
pressure liquid chromatography) and MS. Hence, we decided to synthesise a peptide
which would allow to train all these techniques.
The ideal peptide, would be similar to those expected for digested ARNO and carry
at least one cleavage site for trypsin. Thus, the following 27 amino acids long sequence
was chosen out of ARNO-Sec7 sequence (“‖” denotes a tryptic cleavage site):
H2N− FVAMNR ‖ GINEGGDLPEELLR ‖ NLYDSIR− CO2H
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5.3.3.1 Synthesis of a reference peptide
The synthesis was carried out on a peptide synthesiser by Fmoc solid-phase peptide
synthesis. Deprotection was achieved in 82.5 % TFA, 2.5 % DTT, 5 % water, 5 % phenol
and 5 % thioanisol as described in Section 7.1.1.2 (p. 123). Following HPLC purification,
the identity of the product was confirmed by LC-MS and MS (Fig. 5.20).
Figure 5.20: Mass spectrum of the synthesised reference peptide - The identity
of the product was confirmed by MS. Expected mass: 3091.4 g/mol.
5.3.3.2 Optimisation of the tryptic digestion
Proteins need to be denaturated before digestion to expose the cleavage sites to the pro-
teases. Even if the reference peptide was not expected to assume secondary structures
which could disturb cleavage, it was important to test the whole process, to make sure
that the denaturation conditions would non inhibit the subsequent digestion. Thus,
various conditions were tested for denaturation and digestion of the peptide.
Denaturation in 0.1 % SDS with subsequent digestion with 1:100 w/w trypsin gave
good results (Fig. 5.21) but has the disadvantage of SDS non being compatible with
reverse phase (RP) chromatography. Even though purification with ZipTip before
HPLC worked for the peptide, their use with ARNO-Sec7 was not satisfying.
Boiling in urea, was found to lead to modification of the peptide N-terminus. As
shown in Table 5.1, a difference of 42-43 Da between expected and measured mass was
detected both in the undigested reference peptide and in the N-terminal peptide. This
difference can be explained by the reaction of the free amine with urea or its decom-
positions products, as ammonium cyanate (Fig. 5.22a and b, respectively). Indeed,
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Figure 5.21: Total ion chromatogram of the trypsinated reference peptide -
The reference peptide was digested with trypsin and analysed by LC-MS. All the three
expected fragment could be identified (insert).
Table 5.1: Boiling in urea causes N-terminus modification - A difference of 42-43
Da was found for the N-terminal peptide.
m/z
Peptide z Expected Found ∆m [Da]
Undigested 3 1031.8 1045.7 41.6
4 774.1 784.6 41.9
FVAMNR 1 737.4 780.4 43.0
the formation of cyanic acid in aqueous urea at high temperatures, and the subse-
quent carbamylation of the N-terminus and lysine, arginine, and cysteine residues was
reported127–130. To prevent the side reactions, which can heavily disturb protein iden-
tification, one should reduce the denaturation temperature (and time) and use fresh
prepared urea solution, so as to reduce the presence of cyanic acid to a minimum.
As a third method, which does not require SDS nor urea, acetone precipitation was
tested. Addition of an excess of acetone denaturates and precipitates the proteins in
the sample. Digestion is then performed after (partial) reconstitution in ammonium
bicarbonate131. This approach was directly tested on ARNO-Sec7 and worked well
enough to allow to start with optimisation of the LC-MS conditions.
Particularly interesting for the analysis of SecinH3-TPD labelled samples, was the
digestion on filter129. This protocol, where the whole sample preparation process is
performed on common ultrafiltration devices, circumvents any solubility issue and offers
at the same time a nice method to get rid of excess compound. The proteins are
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Figure 5.22: Possible reactions of urea with the N-terminal amine - The reaction
in a leads to an increase in mass of 42 Da. Reaction b adds 43 Da to the peptide total
mass.
denatured and solubilised in 0.1 % SDS, which is then exchanged by urea on a standard
filtration device. At this stage, also unbound compound is washed away. Incubation
of a trypsin solution on the filters leads to digestion of the proteins and the resulting
peptides are then collected by centrifugation.
5.3.3.3 Optimisation of the LC-MS conditions
LC-MS analysis of the reference peptide digest was performed on a reversed-phase
chromatography C4 column and could be optimised as desired (Fig. 5.21). For better
separation of the more complex mixture obtained by digestion of ARNO-Sec7, the gra-
dient was extended to 60 min. Reduction of the flow rate from 0.4 ml/min to 0.2 ml/min
improved the separation further. The C4 column already allowed good separation of
the peptides, but since some were coeluting, a C18 column was then used, with which
good chromatograms could be acquired (Fig. 5.23). At the end of the optimisation pro-
cess, I was able to identify 17 of the 21 expected completely digested tryptic peptides,
with a sequence coverage of 92 % (Fig. 5.24).
5.3.3.4 Tandem LC-MS measurements
The LC-MS measurements were analysed manually and are only suited for samples with
limited complexity, such as digests of purified proteins. For the analysis of more complex
samples from multiple and unknown proteins, I tested the conditions for tandem LC-
MS. As tandem MS delivers sequence information additionally to the peptide mass, it
is more powerful in the automated analysis of unknown samples. After optimisation of
87
5. CAPTURE COMPOUND MASS SPECTROMETRY
Figure 5.23: Total ion chromatogram of an ARNO-Sec7 digest - ARNO-Sec7 was
digested with trypsin after acetone precipitation. Separation on a RP C18 column with a
60 min gradient lead to good separated peaks.
Figure 5.24: ARNO-Sec7 was analysed with good sequence coverage - Sequence
of ARNO-Sec7 with the peptides found in the LC-MS run (Fig. 5.23) highlighted. Black:
completely digested peptides; blue: peptides with one missed cleavage.
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the separation gradient and the MS/MS parameters, good peptides scores and sequence
coverage were obtained for both BSA and ARNO-Sec7 samples.
5.3.4 Detection of modified proteins and fragments by LC-MS
To test if the analytical conditions enable in principle the identification of protein
modification, I alkylated some ARNO-Sec7 with iodoacetamide (IAA).
5.3.4.1 Analysis of iodoacetamide modified ARNO-Sec7
IAA reacts with the side chain of cysteine leading to a mass increase of 57 Da (Fig. 5.25).
Since ARNO-Sec7 sequence has three cysteines, a mass difference of 171 Da is expected
for the fully alkylated protein.
Figure 5.25: Reaction of iodoacetamide with cysteine side chains - A mass increase
of 57 Da is observed upon alkylation with IAA.
Indeed, LC-MS analysis of non digested ARNO-Sec7, revealed a mass increase of
∼182 Da in the sample treated with IAA (Fig. 5.26) and confirmed that the method
was suitable for the identification of small modifications. The small deviation between
the theoretical and experimental mass lies in the resolution of the instrument.
The same samples were then analysed after digestion. All cysteines in ARNO-
Sec7 are found in the same tryptic peptide, for which a mass difference of 171 Da
is again expected. As visible in Figure 5.27, some additional peaks appeared in the
chromatogram after alkylation. Some of them were peptides which occurred in higher
amount without carrying any alkylation, perhaps due to improved digestion of the
alkylated sample. More interestingly, the peak at 44 min could be attributed to the
three-times alkylated peptide (Fig. 5.28b). As a proof of the sensitivity of the system,
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Figure 5.26: The mass increase upon alkylation can be identified in the non
digested ARNO-Sec7 - ARNO-Sec7 was alkylated with IAA and analysed by LC-MS
(lower panel). The average mass spectrum at the protein elution time is shown. The
mass spectrum of unmodified ARNO-Sec7 is shown as reference (upper panel). The mass
difference observed is in the range expected for a three-time alkylation.
Figure 5.27: Total ion chromatogramm of alkylated ARNO-Sec7 - Comparison of
LC-MS analyses of alkylated and unmodified digested ARNO-Sec7. Some additional peaks
were observed in the alkylated sample (blue).
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Figure 5.28: Additional peaks correspond to three- and two-times alkylated
peptides - a. Magnification of the 44-47 min window of the chromatogram in Figure 5.27.
b, c. The mass spectra relative to the two peaks identify a three- (b) and two-times (c)
alkylated peptide. d. Sequence of the alkylated peptide and mass differences measured.
a low intensity peak at 45 min, which corresponded to a small amount of two-times
alkylated peptide, was also identified (Fig. 5.28c).
5.3.4.2 Analysis of SecinH3-TPD-labelled ARNO-Sec7
Since detection of protein alkylation was successful, I tested if it was possible to de-
tect labelling by SecinH3-TPD. ARNO-Sec7 was incubated either with SecinH3-TPD,
the negative control compound BA103, or DMSO before irradiation with UV. Sample
preparation was performed both with the acetone precipitation and the digestion on
filter methods. Unfortunately, no relevant difference was seen between the SecinH3-
TPD samples and the negative controls (data not shown). It is possible that SecinH3
was bound to a fragment which is not detected with the analysis conditions or, more
probably, that the portion of labelled peptide was to low to be detected.
5.3.5 Enrichment of biotinylated ARNO
A strategy to improve detection of the labelled protein, is to selectively enrich it. Since
SecinH3-TPD carries a biotin, covalently bound protein can be fished with streptavi-
dine conjugated beads. This method allows enriching biotinylated protein from very
complex sample, and is therefore ideal to test labelling specificity in cell lysate, too (see
Section 5.1, p. 65, for explanation of the CCMS strategy). The enrichment protocol
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was adapted from Weerapana et al.92 and first tested with prebiotinylated ARNO-Sec7
(bio-Sec7).
Table 5.2: Enrichment and identification of bio-Sec7 - bio-Sec7 (250 nM), pure or
mixed to 2 mg/ml H460 proteome, was enriched with streptavidine beads, analysed by
LC-MS/MS and the data searched against the SwissProt database using Mascot. Samples
containing non biotinylated ARNO-Sec7 served as control for unspecific binding to the
beads. ARNO was only identified in samples containing bio-Sec7. No other proteins were
identified. The proteome did not disturb identification.
Sample Proteins identified Score
ARNO-Sec7 none -
bio-Sec7 ARNO 90
Proteome + ARNO-Sec7 none -
Proteome + bio-Sec7 ARNO 100
5.3.5.1 Determination of the detection limit
Streptavidine beads were incubated with samples containing either bio-Sec7 or ARNO-
Sec7 only, or in combination with cell lysate. After intensive washing, the enriched
proteins were digested on the beads. The supernatant was analysed by LC-MS/MS
and the data searched against the SwissProt database using Mascot132.
Table 5.3: Determination of the detection limit for bio-Sec7 - The experiment
in Table 5.2 was repeated with decreasing concentrations of bio-∆PBR. Identification of
ARNO was possible even with the lowest starting concentration (50 nM). Again, the pro-
teome did not disturb identification.
Sample Proteins identified Score
250 nM bio-∆PBR ARNO 459
100 nM bio-∆PBR ARNO 192
50 nM bio-∆PBR ARNO 136
Proteome + 1µM ∆PBR none -
Proteome + 100 nM bio-∆PBR ARNO 252
Indeed, ARNO was only identified in the samples containing bio-Sec7 and the pres-
ence of lysate did not disturb identification (Tab. 5.2). Unfortunately, it was not pos-
sible to detect the biotinylated peptide after elution from the beads (data not shown).
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The first enrichment experiment was performed with relatively high concentration
of bio-Sec7 (250 nM). To check the detection limit of the method with respect to the
start concentration of labelled protein, the procedure was repeated with a dilution
series. For this experiment, prebiotinylated ∆PBR (bio-∆PBR) between 250 and 50
nM to was used. Even in the 50 nM bio-∆PBR sample (which corresponds to around
5 % labelling of 1µM ARNO), it was still possible to identify ARNO and again, the
presence of lysate did not influence the detection in the 100 nM sample (Tab. 5.3).
This shows that the protocol is suitable to selectively enrich biotinylated proteins even
in relatively low concentration and in complex samples.
5.3.6 Specificity of labelling in cell lysate
Having a method to analyse tagged proteins in cell lysate, I moved to the determination
of specificity of SecinH3-TPD labelling in cell lysate. For this, it was necessary to find
lysis conditions which do not disturb the labelling reaction.
5.3.6.1 Determination of lysis conditions compatible with labelling
Triton X-100 and digitonin, two detergents which are often used for cell lysis, were
tested in the labelling assay. As evident in Figure 5.29, Triton completely blocks
labelling, while digitonin does not affect the reaction. Thus, I decided to prepare
the proteome by permeabilising the cells with 25µg/ml digitonin133.
Figure 5.29: Digitonin is compatible with SecinH3-TPD labelling - Triton X-100
and digitonin were added to the labelling buffer in the indicated concentrations and the
labelling assay performed as usual. Triton inhibits while digitonin does not affect labelling.
5.3.6.2 Analysis of specificity by Western blot
To test if ARNO-Sec7 is labelled by SecinH3 also in cell lysate, HEK (Human Embryonic
Kidney 293) cells were harvested, permeabilised and the soluble proteins collected by
centrifugation. The labelling reaction was performed in diluted proteome (1.1 mg/ml
total protein) with or without addition of purified ARNO-Sec7 (1µM) and with 20µM
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SecinH3-TPD in 20 % diglyme. Promisingly, a band was detected at the right size
(Fig. 5.30a, lane 6). Few additional bands were detected at higher size. In particular,
a strong signal at ∼70 kDa was present only in the sample where no ARNO-Sec7 was
added (lane 8).
As a second experiment, I looked if labelling of ARNO could be competed by the
addition of unmodified SecinH3. H460 cells were prepared as above and the labelling
reaction was done in proteome diluted to 2 mg/ml total protein. 1µM ∆PBR, 5µM
SecinH3-TPD and 15µM SecinH3 in 10 % DMSO were used. Again, labelling of ∆PBR
was possible also in cell lysate (Fig. 5.30b, lane 14). Interestingly, like in the precedent
experiment with no ARNO addition, competition with SecinH3 reduced drastically the
amount of labelled ∆PBR and a new strong band at ∼80 kDa was observed (lane 16).
Surprisingly, this band was not present in the sample without ∆PBR (lane 12).
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Figure 5.30: ARNO can be labelled with SecinH3-TPD in cell lysate - Both
ARNO-Sec7 and ∆PBR were labelled by SecinH3-TPD in cell lysate (lanes 6 and 14,
respectively). Interestingly, when no ARNO-Sec7 was added (lane 8) or binding to ∆PBR
was competed with unmodified SecinH3 (lane 16), a band at around 70-80 kDa appeared
instead of the ARNO band. a. The standard labelling reaction (lane 2) was compared with
reactions were lysis buffer (Lys.B., lane 4) or cell lysate (Proteome, lane 6) were added.
Labelling of proteome without addition of purified ARNO-Sec7 (1µM) is visible in lane 8.
After separation on a 10 % SDS-PAGE and Western blotting, the labelled proteins were
visualised with horseradish peroxidase streptavidin conjugate. 20µM SecinH3-TPD in
20 % diglyme were used. C: ARNO-Sec7. b. Labelling by SecinH3-TPD in cell lysate, was
competed with underivatised SecinH3. After separation on a 7.5 % SDS-PAGE and Western
blotting, the labelled proteins were detected with NeutrAvidin DyLight 800 fluorescent
conjugate. 1µM ∆PBR, 5µM SecinH3-TPD and 15µM SecinH3 in 10 % DMSO were
used. J: ∆PBR.
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Table 5.4: Human proteins binding biotin - Database search revealed three biotin-
binding proteins with size similar to that of the unknown protein labelled by SecinH3-TPD.
UniProt Protein Size
accession number (kDa)
P50747 Biotin–protein ligase 80.8
Q96RQ3 Methylcrotonoyl-CoA carboxylase 80.5
subunit alpha, mitochondrial
P05165 Propionyl-CoA carboxylase 80.1
alpha chain, mitochondrial
When proteome analysis with photoreactive probes are performed, competition is
used to select which bands to analyse87,134–136. Indeed, a main disadvantage of pho-
toreactive affinity based probes over activity based probes is the higher background
labelling which mostly leads to detection of multiple bands even for specific inhibitors.
The idea behind the competition experiments is that only specific labelling will be dras-
tically reduced by the unmodified inhibitor. Thus, often only the bands with reduced
labelling are analysed further87,134–136.
The experiment in Figure 5.30b clearly shows that labelling of ∆PBR is indeed
due to interaction with SecinH3. However, some other bands are present which are
competed by SecinH3. The MS analysis of all labelled proteins is described in next
Section.
The ∼70-80 kDa band is an unexpected result. Indeed, I am not aware of compe-
tition experiments with photoreactive probes which lead to such a drastic increase of
signal. Since the labelling is higher in the presence of unmodified SecinH3, it can not
be attributed to a specific interaction with the inhibitor. However, binding is strong
enough to lead to very high signal. In fact, the interaction between SecinH3-TPD and
the unknown protein, could also be mediated by the photoreactive moiety or the linked
desthiobiotin. In this case, SecinH3 would not disturb the binding.
Since biotin is naturally present in cells, SecinH3-TPD could possibly interact via its
reporter group with some biotin binding protein. Searching the UniProtKB database
for human proteins with a biotinyl-binding domain gave 5 hits, two of which with size
in the right range. The QuickGO∗ browser delivered an additional ∼80 kDa human
∗QuickGO is a fast web-based browser for Gene Ontology terms and annotations, which is
provided by the UniProtKB-GOA group at the European Bioinformatics Institute (EBI). Adress:
http://www.ebi.ac.uk/QuickGO/
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Table 5.5: Identification of ARNO by CCMS - ∆PBR was labelled with SecinH3-
TPD, enriched, and analysed by LC-MS/MS. Data base search with Mascot identified one
relevant peptide. When the same experiment was performed in the presence of proteome,
ARNO was not identified.
Experimental Calculated
Name m/z z m m ∆m Score Sequence
CYH2 HUMAN 756.5 2 1511.0 1510.8 0.2 53 GINEGGDLPEELLR
Cytohesin-2
Mass: 46859
Score: 66
protein with biotin binding function (search ID: GO:0009374). These proteins are
shown in Table 5.4. It is therefore possible that SecinH3-TPD, when displaced from
ARNO by SecinH3, or when only very low amounts of ARNO are present, binds and
labels biotin-binding proteins through its reporter group. However, this hypothesis has
not been verified.
5.3.6.3 Identification of interacting proteins by MS
To identify the proteins labelled by SecinH3-TPD, the complete CCMS procedure was
followed (see Section 5.3.5, p. 91). The labelling reaction was performed with or without
proteome from H460 cells, with the addition of 1µM ∆PBR.
Table 5.6: Identification of tubulin by CCMS - H460 proteome was labelled with
SecinH3-TPD, enriched, and analysed by LC-MS/MS. Data base search with Mascot iden-
tified various tubulin isotypes with good scores and sequence coverage. The identified
proteins and peptides are listed with the relative scores.
Experimental Calculated
Name m/z z m m ∆m Score Sequence
TBB5 HUMAN 566.0 2 1130.0 1129.6 0.4 32 FPGQLNADLR
Tubulin 572.5 2 1143.0 1142.6 0.4 55 LAVNMVPFPR
beta chain 615.5 2 1229.0 1228.6 0.4 87 ISEQFTAMFR
Mass: 50095 651.5 2 1301.0 1300.6 0.4 53 ISVYYNEATGGK
Score: 431 660.5 2 1319.0 1318.7 0.3 61 IMNTFSVVPSPK
723.9 2 1445.8 1445.7 0.1 58 EVDEQMLNVQNK
808.6 2 1615.2 1614.8 0.4 40 AILVDLEPGTMDSVR
830.7 2 1659.4 1658.9 0.5 35 ALTVPELTQQVFDAK
608.5 3 1822.5 1821.9 0.6 34 EIVHIQAGQCGNQIGAK
653.8 3 1958.4 1958.0 0.4 35 GHYTEGAELVDSVLDVVR
933.6 3 2797.8 2797.3 0.4 33 SGPFGQIFRPDNFVFGQS-
GAGNNWAK
Continued on Next Page. . .
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Table 5.6 – Continued
Experimental Calculated
Name m/z z m m ∆m Score Sequence
TBB2C HUMAN 566.0 2 1130.0 1129.6 0.4 32 FPGQLNADLR
Tubulin 572.5 2 1143.0 1142.6 0.4 55 LAVNMVPFPR
beta-2C chain 615.5 2 1229.0 1228.6 0.4 87 ISEQFTAMFR
Mass: 50255 660.5 2 1319.0 1318.7 0.3 61 IMNTFSVVPSPK
Score: 427 664.9 2 1327.8 1327.6 0.1 62 INVYYNEATGGK
723.9 2 1445.8 1445.7 0.1 58 EVDEQMLNVQNK
801.6 2 1601.2 1600.8 0.4 33 AVLVDLEPGTMDSVR
846.6 2 1691.2 1690.9 0.3 37 ALTVPELTQQMFDAK
608.5 3 1822.5 1821.9 0.6 34 EIVHLQAGQCGNQIGAK
653.8 3 1958.4 1958.0 0.4 35 GHYTEGAELVDSVLDVVR
933.6 3 2797.8 2797.3 0.4 33 SGPFGQIFRPDNFVFGQS-
GAGNNWAK
TBB3 HUMAN 566.0 2 1130.0 1129.6 0.4 32 FPGQLNADLR
Tubulin 572.5 2 1143.0 1142.6 0.4 55 LAVNMVPFPR
beta-3 chain 615.5 2 1229.0 1228.6 0.4 87 ISEQFTAMFR
Mass: 50856 660.5 2 1319.0 1318.7 0.3 61 IMNTFSVVPSPK
Score: 302 808.6 2 1615.2 1614.8 0.4 40 AILVDLEPGTMDSVR
846.6 2 1691.2 1690.9 0.3 37 ALTVPELTQQMFDAK
608.5 3 1822.5 1821.9 0.6 34 EIVHIQAGQCGNQIGAK
653.8 3 1958.4 1958.0 0.4 35 GHYTEGAELVDSVLDVVR
TBA1B HUMAN 1015.5 1 1014.5 1014.6 -0.1 11 DVNAAIATIK
Tubulin 543.5 2 1085.0 1084.6 0.4 50 EIIDLVLDR
alpha-1B chain 625.4 2 1248.8 1248.5 0.2 50 YMACCLLYR
Mass: 50804 793.0 2 1584.0 1583.7 0.2 42 SIQFVDWCPTGFK
Score: 277 851.6 2 1701.2 1700.9 0.3 46 AVFVDLEPTVIDEVR
573.7 3 1718.1 1717.9 0.2 17 NLDIERPTYTNLNR
879.1 2 1756.2 1756.0 0.2 47 IHFPLATYAPVISAEK
913.2 2 1824.4 1824.0 0.4 38 VGINYQPPTVVPGGDLAK
933.0 2 1864.0 1863.9 0.1 47 AVCMLSNTTAIAEAWAR
1004.5 2 2007.0 2006.9 0.1 88 TIGGGDDSFNTFFSETGAGK
TBA1A HUMAN 1015.5 1 1014.5 1014.6 -0.1 11 DVNAAIATIK
Tubulin 543.5 2 1085.0 1084.6 0.4 50 EIIDLVLDR
alpha-1A chain 625.4 2 1248.8 1248.5 0.2 50 YMACCLLYR
Mass: 50788 800.0 2 1598.0 1597.8 0.2 31 TIQFVDWCPTGFK
Score: 263 851.6 2 1701.2 1700.9 0.3 46 AVFVDLEPTVIDEVR
573.7 3 1718.1 1717.9 0.2 17 NLDIERPTYTNLNR
879.1 2 1756.2 1756.0 0.2 47 IHFPLATYAPVISAEK
913.2 2 1824.4 1824.0 0.4 38 VGINYQPPTVVPGGDLAK
933.0 2 1864.0 1863.9 0.1 47 AVCMLSNTTAIAEAWAR
1004.5 2 2007.0 2006.9 0.1 88 TIGGGDDSFNTFFSETGAGK
Continued on Next Page. . .
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Table 5.6 – Continued
Experimental Calculated
Name m/z z m m ∆m Score Sequence
TBA1C HUMAN 1015.5 1 1014.5 1014.6 -0.1 11 DVNAAIATIK
Tubulin 543.5 2 1085.0 1084.6 0.4 50 EIIDLVLDR
alpha-1C chain 625.4 2 1248.8 1248.5 0.2 50 YMACCLLYR
Mass: 50548 800.0 2 1598.0 1597.8 0.2 31 TIQFVDWCPTGFK
Score: 244 851.6 2 1701.2 1700.9 0.3 46 AVFVDLEPTVIDEVR
573.7 3 1718.1 1717.9 0.2 17 NLDIERPTYTNLNR
879.1 2 1756.2 1756.0 0.2 47 IHFPLATYAPVISAEK
913.2 2 1824.4 1824.0 0.4 38 VGINYQPPTVVPGGDLAK
1004.5 2 2007.0 2006.9 0.1 88 TIGGGDDSFNTFFSETGAGK
922.2 3 2763.6 2763.3 0.3 8 AYHEQLTVAEITNACFEPA-
NQMVK
Surprisingly, ARNO was not identified. Actually, even in absence of proteome it
was difficult to detect the ∆PBR signal. In fact, only in one of two experiments it
was possible to unambiguously identify one ∆PBR peptide in the enriched sample
(Table 5.5). Since the signal intensity was already particularly low, it was improbable
to find ARNO signals in the proteome sample, where other (biotinylated) proteins are
competing.
Furthermore, in the same experiment, an unexpected observation was made. In fact,
labelling of proteome with SecinH3-TPD resulted in identification of various tubulin
isotypes. For example, more than 10 peptide matches with good scores were found
for “Tubulin beta chain” (Table 5.6). With a sequence coverage of 35 %, this hit can
definitely be trusted. Thus, I decided to investigate the interaction of SecinH3-TPD
with tubulin in more detail.
5.3.7 Investigation of the SecinH3/tubulin interaction
The identification of tubulin raised various questions. Is the interaction specific or
simply an artefact due to the high concentration of tubulins in cells? Is the binding
specific to SecinH3 or amenable to the photoreactive unit? And finally, is the interaction
biologically relevant? To solve this questions, some informations about tubulin biology
are needed.
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Figure 5.31: Microtubules in the cell - a. An in-
terphase cell stained with an antibody to tubulin. Mi-
crotubules extend from the centrosome throughout the
cell. b. A schematic diagram of the cell. Centrioles are
shown in the centrosome (yellow). Red circles denote
vesicles moving to the outside of the cell. Green circles
denote vesicles moving to the centrosome.137 Reprinted by
permission from Macmillan Publishers Ltd: Nature (Ref. 137),
copyright 2003.
5.3.7.1 Tubulin and the microtubules
Tubulin is the heterodimeric building block of microtubules and, as such, involved
in various essential cell functions. Microtubules, as part of the cytoskeleton, offer
mechanical support for the cell shape and provide tracks for transport of vesicle and
organelles (Fig. 5.31). Moreover, the mitotic spindle they form during cell division is
required for the correct segregation of chromosomes.
These various functions are highly regulated at different levels. Additionally to the
transcription of different tubulin isotypes, post-translational modifications (PTMs) and
interaction with microtubule-associated proteins (MAPs) further tune the nucleotide
regulated microtubule dynamics138.
Microtubules dynamic instability
By head-to-tail association of the α-β tubulin dimers, linear protofilaments are formed,
which, in turn, lead to the formation of the cylindric microtubules by lateral association.
The polarity of the dimer is maintained during the polymerisation process and mirrored
in the microtubules polarity137 (Fig. 5.32a). In animal cells, the minus end, which
is terminated by the α subunit, is generally anchored at centrosomes and the plus
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end grows toward the periphery, resulting in the characteristic radiating pattern137,139
(Fig. 5.31).
Figure 5.32: Microtubule structure and dynamics. - a. A microtubule lattice. The
beta-subunit of tubulin is on the plus end. b. Dynamic instability of microtubules. Micro-
tubules growing out from a centrosome switch between phases of growing and shrinking.
The figure shows a hypothetical aster at two different times. The different colours represent
different microtubules. The red and yellow microtubules are shrinking at both times. The
blue microtubule is growing at both times. The green microtubule, growing at the first
time, has undergone a catastrophe by the second time. The brown microtubule, shrinking
at the first time, has undergone a rescue by the second time.137 Reprinted by permission from
Macmillan Publishers Ltd: Nature (Ref. 137), copyright 2003.
Microtubules polymerisation is a highly dynamic process. In fact, microtubules are
subject to stochastic switch between growing and shrinking phases (Fig. 5.32b). This
property, called dynamic instability140, is essential to their function and depend on the
GTPase activity of tubulin141.
Indeed, each heterodimer subunit carries a guanine nucleotide. While GTP in the
α unit is buried at the monomer-monomer interface within the dimer, and is thus non-
exchangeable (N-site), in β tubulin it sits on the dimer surface and is fully exchangeable
(E-site)142. For polymerisation to occur, the E-site has to be GTP-loaded, but, at the
same time, binding of a new dimer triggers hydrolysis in the adjacent E-site. As a result,
the microtubule body is composed of GDP-tubulin subunits and is in an energetically
unfavorable state141 which favours shrinking events (Fig. 5.33b). In fact, GDP-tubulin
is thought to have a bent conformation which places stress on the microtubules lattice.
During depolimerisation the ends curls, releasing the strain137,141 (Fig. 5.33d).
An additional level of regulation is offered by MAPs. By interacting with the solu-
ble, non-polymerized tubulin subunits, the microtubule wall lattice and/or microtubule
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Figure 5.33: Model for how the GTP hydrolysis cycle is coupled to structural
changes in the microtubule. - a. Atomic structure of the tubulin dimer as seen in
the wall of the protofilament. b. Docking of the alpha-beta subunit to the microtubule
end. Residues from the incoming alpha-subunit trigger hydrolysis of the GTP bound to
the lattice-attached beta-subunit. c, d. Microtubules at growing ends contain sheets of
protofilaments while microtubules at shrinking ends curl. The straight-bent transition is
also shown in panel d. The GTP dimer is thought to have a straight conformation that fits
nicely into the straight wall of the microtubule. Hydrolysis of GTP induces a bend in the
subunit, but this bend is constrained within the lattice. The constraint places stress on the
lattice, which is released during depolymerization, allowing the protofilament to adopt a
curled conformation.137 Reprinted by permission from Macmillan Publishers Ltd: Nature (Ref. 137),
copyright 2003.
ends, they regulate microtubule stability and dynamics (See Refs. 143 and 144 for re-
view).
When it comes to assigning a specific function to a microtubule, PTMs play a
prominent role. In fact, a considerable number of reversible PTMs, such as acetylation,
polyglycylation, polyglutamylation, tyrosination/detyrosination, phosphorylation, and
palmitoylation contribute to microtubules diversity145. Most PTMs occur on micro-
tubules rather than on unpolymerized tubulin and stable microtubules accumulate more
modifications than dynamic microtubules146. Since differences in PTM patterns can
be seen between stable microtubules, the PTMs are postulated to play a role in their
specific functions (see Refs. 145 and 146 for review).
Microtubule-targeting drugs
Since during mitosis highly coordinated microtubule dynamics is required, compounds
which interfere with microtubule dynamics limits proliferation and have been used as
anticancer drugs for years. They are classified as microtubule stabilizers or destabilizers
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but both classes inhibit mitosis through a similar mechanism of slowing microtubule
dynamics, resulting in mitotic arrest and apoptosis147.
An additional classification is done by the binding site on tubulin. Indeed, desta-
bilising drugs are usually binding to the vinca- and colchicine-sites, while microtubule
stabilisers mostly bind the taxane-site (but inhibitors binding at other sites were re-
cently discovered). For a detailed explanation of the mechanisms of action, please read
Ref. 147.
5.3.7.2 Labelling of purified tubulin
Figure 5.34: SecinH3-TPD binds ∆PBR preferentially over tubulin - Labelling of
purified tubulin was tested in the standard labelling assay (1µM protein, 20µM SecinH3-
TPD in 10 % DMSO). After separation on a 7.5 % SDS-PAGE and Western blotting, the
labelled proteins were detected with a NeutrAvidin DyLight 800 fluorescent conjugate. The
total amount of protein was detected by Coomassie staining of gel. The strong tagging of
tubulin is competed by ∆PBR.
Because of the essential role of tubulin in cells, it was particularly important to
investigate if SecinH3 is specifically binding to tubulin and interfering with its functions.
As a first control, purified tubulin was analysed in the standard labelling assay. As
evident in Figure 5.34, SecinH3-TPD strongly labelled tubulin, but the binding was
competed by ∆PBR. Indeed, while labelling of tubulin was drastically decreased in the
presence of ∆PBR, ARNO signal remained stable. This result shows that SecinH3-TPD
interacts with tubulin but, in vitro, SecinH3-TPD preferentially binds ARNO.
5.3.7.3 Competition with SecinH3
To exclude that SecinH3-TPD interaction with tubulin is mediated by the photoreactive
or desthiobiotin moieties, a competition experiment was performed. Labelling was
carried out in the presence of non derivatised SecinH3 in excess. The clear inhibition of
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Figure 5.35: SecinH3 competes labelling of both tubulin and ∆PBR - Non
derivatised SecinH3 was added in excess to labelling reactions with 2.5µM SecinH3-TPD.
After separation on a 7.5 % SDS-PAGE and Western blotting, the labelled proteins were
detected with a NeutrAvidin DyLight 800 fluorescent conjugate. Tagging of both tubulin
and ∆PBR was significantly reduced by the competitor.
labelling visible in Figure 5.35 in the competed sample, accords binding to the SecinH3
core.
5.3.7.4 Analysis of SecinH3 effect on microtubules structure
The most difficult question to answer was if the SecinH3-tubulin interaction is of bi-
ological relevance. To analyse a possible effect of SecinH3 on microtubule structure,
immunofluorescence was used. H460 cells were treated overnight with SecinH3 or the
microtubule-targeting drugs demecolcine and paclitaxel prior fixation in methanol. Mi-
crotubules were visualized by immunofluorescence using a FITC conjugated monoclonal
anti-α-tubulin antibody.
In Figure 5.36, two representative views for each condition are shown. It is read-
ily visible that mitosis is heavily impaired in the demecolcine and paclitaxel treated
cells (these drugs binds the colchicine- and taxane-site, respectively). Additionally,
in the lower paclitaxel panel, bundling of interphase microtubules, a typical effect of
taxane147,148, is apparent. In contrast, in SecinH3 treated cells the mitotic spindle is
still formed (upper panel) and no grave defect is visible in the interphase cells. This
results exclude a major impact of SecinH3 on microtubules dynamic. Possible smaller
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effects, for example on PTMs or interaction with MAPs, can not be ruled out.
Figure 5.36: SecinH3 has no evident effect on microtubules structure - H460
cells were treated with SecinH3, demecolcine or paclitaxel, fixed in metanol and the micro-
tubules structure visualized with a FITC conjugated monoclonal anti-α-tubulin antibody
by immunofluorescence. In the demecolcine and paclitaxel treated cells, impairment of
mitotic spindle formation is evident. The tipical bundling of interphase microtubules is
evident for paclitaxel treated cells (lower panel). In contrast, no evident defect is visible
in SecinH3 treated cells and the mitotic spindle is still formed (upper panel).
5.3.8 Discussion
The implementation of a CCMS protocol is a technically challenging task which requires
separate optimisation of the single methods, as just described in this chapter. The
first stage was the synthesis of the trifluorophenyl diazirine derivatised SecinH3 probe
SecinH3-TPD. Because of the high costs of the TPD acid needed in the last step, the
synthesis was first carried out with the non photoreactive 4-ethylbenzoic acid. This way,
we could successfully adapt the procedure to reduce light exposition of the photoreactive
moiety to a minimum.
At the stage of labelling of ARNO with the SecinH3 probe, solubility was the
limiting factor. Indeed, Figure 5.11 (p. 78) shows that considering a SecinH3 maximal
solubility of ∼15µM (in 10 % DMSO) and an estimated KD in the same range, a
maximum of 50 % SecinH3/ARNO complex over total ARNO can be achieved. With
the intent to improve SecinH3 solubility, diglyme was tested as an alternative solvent.
Although solubility was improved (100µM in 20 % diglyme), diglyme could not be used
in the assay because it seemed to affect ARNO activity.
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In fact, the solubility difficulties were not restricted to the compound. Figure 5.18
(p. 83) shows that under the labelling conditions most of ARNO was found in the
pellet after centrifugation, indicating aggregation or coating of the protein. Addition
of 0.005 % Triton X-100 to the buffer, allowed to recover ARNO back in solution.
Under this conditions it was possible to detect labelling of ARNO by SecinH3-TPD
and labelling of various mutants was tested.
Interestingly, ∆PBR, a construct lacking the polybasic region at the C-terminus,
was more strongly labelled that the Sec7 domain and the full length ARNO was labelled
similarly to the ∆PBR (Fig. 5.19). This is surprising because SecinH3 was identified
using the Sec7 domain only of cytohesin-117 and, although selected on the full length
protein, its parent aptamer M69 is a pure cytohesin Sec7-domain binder, since the same
KD was measured for the full length protein and the Sec7-domain alone
32. There is
thus no evident reason, why full length ARNO should bind SecinH3 better than ARNO-
Sec7. Experiments like those described in Figures 5.14 (p. 80) and 5.34 (p. 102), where
preference of SecinH3-TPD for ARNO over other proteins is clearly shown, exclude
increased unspecific binding due to the bigger protein size. It should however be noted
that variability in labelling in different purification charges of ∆PBR was noted and
for the comparison a single charge of both constructs was used. It would therefore be
worth to analyse if better labelling of ∆PBR is given for all purification batches.
Having shown that SecinH3-TPD retains its binding capacity and is able to label
ARNO, the next step was the analysis of the binding site by MS. As the expertise
for analysis of proteins and peptides by MS was lacking in our group, the reference
peptide synthesised for the establishment of the measuring protocol offered fundamental
help. Indeed, it did not only allowed successful optimisation of sample preparation and
analysis conditions but it was also essential in fixing and setting the MS instrument.
Analysis by LC-MS was a good training, but the use of tandem LC-MS emerged as
necessary for unambiguous identification of the peptides. Indeed, tryptic digestion of
ARNO gives various peptides with similar masses which can not be discerned without
some sequence data. Moreover, analysis of LC-MS/MS data by specific software was
easier and allowed identification of unknown proteins. This was particularly important
in the second part of this study: the analysis of SecinH3 specificity in proteome.
The amount of labelling of ARNO by SecinH3-TPD turned out not to be sufficient
for identification of the modified peptide. Indeed, in contrast with the analysis of
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the almost 100 % modification of cysteines with iodoacetamide (Fig. 5.27, p. 90), no
difference could be detected between the chromatograms of labelled and non labelled
ARNO. Possible explanations are that SecinH3-TPD labels either multiple peptides
nearby the binding site (and thus leads to a complex distribution of various modified
peptides in the sample) or one of the few peptides which are not identified under the
analysis conditions. However, it is more probable that the amount of labelled protein
is simply too low with respect to the total protein to allow its detection in a complex
sample.
Enrichment of the modified proteins or fragments with streptavidine before or af-
ter digestion, respectively, could allow their detection even with low labelling yield.
Unfortunately, experiments in that direction where not successful. Indeed, although
prebiotinylated ARNO could be selectively enriched with streptavidine-beads, digested
on beads and identified in MS (Tab. 5.2 and 5.3, p. 92), it was not possible to detected
the biotinylated peptide after elution from the beads. It was not possible to define if
this was because of poor elution from the beads, coelution of contaminants disturbing
analysis or perhaps degradation of the petides during elution. Application of the same
protocol to SecinH3-labelled ARNO lead to identification of a single relevant peptide
with Mascot (Tab. 5.5, p. 96). The signal was very weak and thus also in this case the
modified peptide could not be identified.
Yet, the fact that not only prebiotinylated but also SecinH3-labelled ARNO was
identified after the whole CCMS procedure confirms that the protocol was successfully
established. While prebiotinylated ARNO could be enriched and identified also out
of complex samples (i.e. cell lysate) the same was not possible for labelling reactions
in cell lysate, even when purified ARNO was added to the sample before irradiation.
Considering the weak signal in the analysis above with purified ARNO, the result is
not surprising. Indeed, in cell lysate both the labelling reaction and the enrichment
are complicated by the high amount of protein material present in the sample. Here,
again, more efficient labelling could significantly improve the results, but this can only
be achieved with higher concentrations or a better binding probe. In fact, the use of
photoreactive affinity probes is mostly reported for inhibitors with affinities in the nM
range87,93,134. For less tight interactions, high concentrations and excess of probe (up
to low mM concentrations) were used86,136.
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Western blot analysis of labelling in cell lysate, demonstrated that SecinH3-TPD
is able to label ARNO even in complex samples and competition experiments showed
that labelling can be reduced by the addition of unmodified SecinH3 (Fig. 5.30). In-
terestingly, disruption of the SecinH3-TPD/ARNO complex favoured labelling of (an)
other unknown protein(s) (Fig. 5.30b, lane 16). Since the signal at ∼80 kDa is much
stronger in the presence of SecinH3, the interaction can not be ascribed to the SecinH3
core but rather to the photoreactive or reporter groups. The fact that at least three
biotin-binding proteins around 80 kDa in size are known (Tab. 5.4, p. 95), seems to
support this hypothesis which, however, was not tested so far. CCMS analysis of a
sample labelled in the presence of SecinH3 could reveal the identity of the protein.
However, should the binding to desthiobiotin be very tight, this could complicate the
enrichment step and possibly prevent identification of the protein.
The identification of tubulins by CCMS experiments in cell lysate (Tab. 5.6, p. 96)
is an additional proof of the successful implementation of this method. Indeed, this
result shows, that selectively labelled protein can be identified out of cell lysate with
my protocol. Interaction of tubulin and SecinH3 was confirmed in vitro, although
SecinH3-TPD was shown to preferentially bind ARNO (Fig. 5.34, p. 102) and compe-
tition with non derivatised SecinH3 excluded that the interaction was mediated by the
photoreactive moiety or the photoreactive tag (Fig. 5.35, p. 103).
Still, this finding poses some questions. First of all: why only tubulin is found if
affinity for ARNO is higher? One could argument that the purified ARNO used for the
comparison is actually a recombinantly expressed protein and could thus have a slightly
different folding as the native protein in cell lysate. However, samples spiked with equal
concentration of recombinant ARNO neither allowed its identification. Furthermore,
it was shown that the lysis buffer does not derange the labelling reaction (Fig. 5.29,
p. 93). It could also be, that tubulin is actually not labelled stronger than ARNO in
cell lysate but it is simply better digested by trypsin or the petides are more efficiently
ionised during MS. Both cases would lead to higher signals for tubulin but, in fact,
MS analysis of simple samples of both protein gave comparable results. That ARNO
can be actually detected by CCMS was shown with prebiotinylated ARNO, excluding
loss of the peptides during work up due to low solubility or other effects. Thus, at this
stage I can not offer any conclusive explanation for the identification of tubulin instead
of ARNO.
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A second question concerns the biological relevance of the tubulin/SecinH3 inter-
action: does binding of SecinH3 to tubulin affect any cellular process? As described
in Section 5.3.7.1 (p. 99), the microtubules, and thus their building blocks tubulins,
play an important role in the control of cell function and morphology. Their involve-
ment in the most disparate processes like mitosis and exo/endocytosis makes answering
this question quite laborious, but a first help comes from the SecinH3 literature. Mi-
crotubules are known to be essential for maintaining structure and function of the
Golgi complex: although the effect of microtubule-targeting drugs is less drastic than
that of, e.g., brefeldin A, depolymerization of microtubules leads to separation and
redistribution of the Golgi subcompartments139. However, already the first publication
about SecinH3 showed that no significant disturbance of Golgi integrity is observed
upon SecinH3 treatment17. Moreover, Figure 5.36 (p. 104) shows that, in contrast to
the microtubule-targeting drugs demecolcine and paclitaxel, SecinH3 treatment had no
dramatic effect of microtubules structure. So far, thus, nothing indicates a major effect
of SecinH3 on microtubules function. Possible minor effects, for example at the level
of post-translational modifications or interaction with microtubule-associated proteins,
can not be excluded at this stage but their investigation is far beyond the scope of this
project.
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During this PhD project, very diverse methods for interaction analysis were imple-
mented and applied to the investigation of the activity mechanisms of cytohesins and
their small molecule inhibitors. Cytohesin were chosen because the discovery of their
dual function as both guanine nucleotide exchange factors (GEFs) and ErbB recep-
tor activators raised the question on how these relatively small proteins regulate their
different roles.
The main focus of this work was on the establishment of the new methodologies.
These are of particular interest for a group like ours, where high throughput screenings
deliver not only new small molecules but from time to time also unexpected new target
proteins.
6.1 BRET
The first technique which had to be established was a cellular BRET assay. In a first
approach, a possible interaction between EGFR and ARNO was tested by analysis of
energy transfer from EGFR-Luc to ARNO-GFP. The observation that C-terminal GFP
labelling affects ARNO functionality (A. Bill, J. Theis, unpublished results) explains
why no binding was detected, although we showed later on by a different method, that
ARNO directly interacts with the EGFR50.
Since in the meanwhile the question if ARNO interacts with the EGFR was an-
swered, BRET with N-terminally labelled ARNO, which had already been shown to be
active29–31,53–59, was not tested. This experiment could be of interest only if additional
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analyses of the EGFR-ARNO interaction are planned. For example, a screening for
inhibitors of this interaction could be envisaged: the assay would have the advantage
over standard in vitro assays of selecting only inhibitors which are active in cell culture.
The generation of a cell line which stably expresses EGFR-Luc and ARNO-GFP would
be necessary for high throughput screening and probably solve some of the problems
encountered during analysis with cells transiently expressing the two proteins.
Although the analyses above did not deliver an answer to the biological question
if ARNO interacts with the EGFR, I could establish a set of control proteins and
experiments which proved important in the subsequent measurements. Moreover, some
important defects of the Mithras LB 940 plate reader used were identified and adjusted.
In the second BRET approach, the possible interaction between EGFR and ARNO
was observed indirectly by monitoring the evolution of energy transfer from EGFR-Luc
to EGFR-GFP upon coexpression of unlabelled ARNO. Starting from an already rela-
tively high BRET-signal, expression of ARNO increased further the measured BRET-
ratio (Fig. 3.4, p. 21). An increase in signal can be explained by either an induction of
dimerisation or a conformational change of the receptors (clustering had at that time
already been excluded by superresolution light microscopy experiments50).
To verify the BRET system, I analysed the effect of EGF stimulation on the BRET-
ratio of the EGF receptors. Since upon stimulation important changes happens both
in the conformation and the amount of dimerised receptors, a change in BRET-signal
was expected. Yet, no difference was detected.
Later on, I observed that our EGFR constructs, which lacked the exon 4 in the
extracellular EGF binding domain, did actually not respond to stimulation (Fig. 3.8,
p. 23). Accordingly, Wang et al. reported very recently the identification of an exon
4-deletion variant of the EGFR which displayed only minimal EGF binding activity
and underwent ligand-independent autophosphorylation and self-dimerisation52.
Given the observations above, no change in BRET-signal could be expected upon
stimulation. Moreover, since the ARNO overexpression experiments were performed
with dimeric EGFR, the experiments above shows that ARNO acts on already dimerised
receptor. That A. Bill demonstrated the same with anisotropy microscopy experiments50,
can be taken as a validation of the results.
Still, it should be stressed out that the established BRET system was not optimal.
In particular, the very low signals detected and the limitations due to transfection made
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the measured BRET-ratio quite variable. Especially the analyses with overexpressed
ARNO would need further validation, in particular with respect to receptor expression.
Some stimulation experiments were also performed with full length receptor con-
structs. However the variation in luminescence and fluorescence signal was too high to
allow analysis of the acquired data. Particularly problematic was the use of DeepBlueC
as a substrate for the luciferase, since due to the rapid decays of its luminescence, it is
not possible to measure more than one time point per sample. Moreover, DeepBlueC
itself decayed rapidly in the injection system making time-dependent measurement very
difficult. The use of Coelenterazine h or EnduRen as substrates and the respective flu-
orophores (BRET1 and eBRET combinations), which allow detection for up to one to
several hours46, would have been better suited. Since Coelenterazine h has over 100-fold
higher quantum yield than DeepBlueC, its use could have solved also the problem of
low luminescence.
Looking back at the ensemble of the BRET experiments it is clear that the initial
choice of the protein constructs and the BRET combination was unpropitious. Adopt-
ing the BRET plasmids and system that were already partially established at the start
of my thesis was an unfavourable decision, which I should have questioned earlier in
the project. Nevertheless some promising results could be recorded.
6.2 SPR
The SPR analysis of the EGFR/ARNO interaction lead to suboptimal binding data due
to complex responses in all the tested conditions. However, the intimacy developed with
the Biacore machine was of undeniable value for the subsequent experiments. Having
already seen a comprehensive set of possible problems, allowed to quickly recognise and
correct technical irregularities.
The measurements on immobilised GST-EGFR provided promising data. With
the knowledge of the subsequent experiments, it is now possible to suggest measuring
parameters for clean binding curves. Low concentrations of ARNO (< 1µM) and new
coupling reagents should be used. If the KD should be higher than 1µM, it is worth
trying the inverse setup with coupled ARNO to see if the EGFR can be used in higher
concentration. This would allow a preciser determination of the binding parameters.
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In the second measurements group, we observed binding of ARNO-Sec7 to immo-
bilised second generation cytohesin inhibitor Secin16 with a dissociation constant of
∼150 nM (Fig. 4.24, p. 57). The data was reproducible and measurements at different
surface densities lead to comparable results. Note that high Sec7 concentrations of
above 500 nM lead to complex binding behaviour and should therefore not be taken
into consideration.
Positively, no binding was detected to the negative control compound XH1009
(Fig. 4.26, p. 59). Since GST turned out to be an unsuitable negative control, some
more control proteins are currently being measured. Preliminary data seems to confirm
the specificity of the measured interaction.
Unfortunately, it was not possible to determine the binding parameters to SecinH3
because of unpredictable behaviour of the SecinH3 derivatised surface. The use of
SecinH3 with propanolamine instead of ethanolamine linker could possibly solve this
problem. Indeed, both Secin16 and XH1009 had this (longer) linker. SecinH3 binding
data would permit direct comparison of the affinities of the new inhibitors with that of
the parent molecule.
In conclusion, an SPR method for the analysis of small molecule/protein interaction
was successfully implemented and delivered meaningful kinetic parameters. However,
I would only recommend this method if kinetic parameters are needed and not if only
a quick answer about binding/non binding is desired. Indeed, the system has to be
fine tuned in an extremely time-consuming procedure not only for every protein, but
also for the single compounds . Moreover, with the actual setup, every inhibitor has
to be derivatised and its activity confirmed separately. Since the behaviour of the
compound on the chip cannot be predicted, coupling of many derivatisations of a single
compound can be necessary and would increase drastically the costs of analysis. SPR
measurements are also particularly buffer dependent, especially with regard of the
protein. In absence of an adequate positive control (which is mostly not available at
the early stage of drug discovery), the identification of the right buffer could prove
very challenging. For all these reasons I recommend using SPR only if kinetic data are
needed and only for a limited amount of inhibitors.
A positive feature of this system was the stability of the derivatised chips. In fact, we
were able to reproduce binding experiments on the same chip after 3 months of storage
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at 4◦C. This could be particularly interesting as a routine test of protein activity, since
every new purified charge could be easily tested by looking at the binding affinity.
6.3 CCMS
The first stage of the CCMS protocol was the synthesis of the photoreactive probe
SecinH3-TPD. The coupling of the commercially available diazirine benzoic acid via the
active benzoyl chloride to BA99, as done in the synthesis of SecinH3-TPD (Fig. 5.9,
p. 75), can in principle be applied to any other compound where a primary amine is
available. For example, since changes at the tert-butyl substituent of Secin16 were
shown not to influence its activity (J. S. Hannam, unpublished), the reaction in Fig-
ure 6.1 could be envisaged for introduction of the photoreactive diazirine moiety in
Secin16.
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Figure 6.1: Possible reaction for the introduction of the diazirine moiety in
Secin16 - Coupling of the commercially available diazirine benzoic acid via the active
benzoyl chloride is in principle possible for every primary amine containing molecule.
SecinH3-TPD was shown to selectively label ARNO in vitro (Fig. 5.14, p. 80). The
addition of 0.005 % Triton X-100 was necessary to keep ARNO in solution and did not
disturb the labelling reaction (Figs. 5.18 and 5.19, p. 83). Unfortunately, the labelling
yield was limited by the low solubility and relatively high KD of SecinH3 and was too
low to allow identification of the labelling site by MS. In an analysis where the cysteines
of ARNO where modified with iodoacetamide, I was able to detect the modification
both in the complete protein and in the digested sample (Fig. 5.28, p. 91). This was not
the case for ARNO labelled with SecinH3-TPD. Of course, alkylation was a best case
sample, since the reaction had almost 100 % yield and only three possible reaction sites.
In the case of photoreactive labelling the conditions are more complex. Indeed, the
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photoreactive group can covalently insert into any amino acid in the binding region. If
these are distributed on more than a single tryptic peptide a mixture of labelled peptides
is obtained. When additionally the labelling yield is strongly limited by solubility, the
amount of every single modified peptide could be below the detection limit. Since the
solubility of SecinH3 could not be increased, the only possibility to obtain a simpler
sample would be to use an enzyme which cuts less frequently than trypsine for the
digestion (e.g. LysC). The longer fragments could reduce the complexity of the sample
and lead to less modified samples in higher amounts. However, the separation step
could become more challenging.
By Western blot analysis of labelling in cell lysate I showed that SecinH3-TPD labels
ARNO even in complex samples and competition experiments revealed that labelling
is reduced by the addition of unmodified SecinH3 (Fig. 5.30, p. 94) and could thus be
used for the analysis of specificity.
The CCMS protocol for the analysis of binding specificity consists in labelling in cell
lysate and enrichment of the labelled proteins via the reporter group before digestion,
LC-MS analysis and data base search. The procedure was optimised with success on
prebiotinylated ARNO added to cell lysate (Tab. 5.2, p. 92). Concentrations down to
50 nM bio-∆PBR lead to identification of ARNO by Mascot search and the lysate was
shown not to interfere with the enrichment (Tab. 5.3).
Application of CCMS to a ∆PBR labelling reaction identified a single ARNO frag-
ment (Tab. 5.5, p. 96). The very low signal measured for this fragment was not present
when the labelling was performed in cell lysate, even when purified ∆PBR was added
before irradiation. Instead, tubulins, the building monomers of microtubules, were
enriched in the SecinH3-TPD labelled proteome sample (Tab. 5.6, p. 96).
Interaction of SecinH3 with tubulins was confirmed by labelling in vitro. SecinH3-
TPD labelled the purified tubulins and binding was competed by unmodified SecinH3.
Still, SecinH3-TPD preferentially labelled ARNO (Figs. 5.34 and 5.35, p. 102). It is
not clear why only tubulins are identified, although ARNO is, at least in vitro, the
preferred binding partner of SecinH3-TPD.
The discovery that SecinH3 binds to tubulins lead to the question if SecinH3 influ-
ences the microtubules activity. By immunofluorescence with FITC conjugated mon-
oclonal anti-α-tubulin antibody, I showed that SecinH3 does not seriously affect the
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microtubules organisation. The microtubule-targeting drugs demecolcine and pacli-
taxel were used as control (Fig. 5.36, p. 104). Moreover, it is known that inhibition of
microtubules leads to separation and redistribution of the Golgi subcompartments139.
Yet, Hafner et al. showed that SecinH3 treatment does not affect Golgi integrity17.
Thus, I can exclude a major effect of SecinH3 on microtubules. Still, minor effects
on interaction with microtubule-associated proteins or post-translational modifications
are possible. Their investigation, however, is far beyond the scope of this project.
6.4 Solubility
All the methods implemented were tested on ARNO and its small molecule inhibitors
SecinH3 and Secin16. Now I know that these are by far not optimal testing samples,
as they share a disadvantageous quality: bad solubility. The problem was particularly
evident in the in vitro analysis.
In CCMS ARNO could be kept in solution by the addition of 0.005 % Triton X-100
to the buffers. Since relatively diluted solution were used, ARNO solubility was not
particularly problematic in this assay. However the issue was evident in the Biacore
measurements. Biacore depends on high quality reagents and even partial aggregation
of the analyte is often detectable in the sensorgrams. Poor solubility of ARNO could
account for the complex binding behaviour detected in both setups. The upper con-
centration limit I had to define, affected the quality of the measurements, since for the
determination of precise binding parameters measurements at concentrations above the
KD are needed. All Biacore buffers contained 0.005 % Tween-20 as detergent. So far,
we have not tested if Triton X-100 can improve the measurements.
With regard to the compounds, the situation is even more difficult. SecinH3 has a
KD of around 15 µM for ARNO and solubility of 15-20 µM. Since the KD is by definition
the concentration at which half of the protein is in complex with the compound∗, there
is no chance to have more than ∼50 % of ARNO bound to SecinH3. This is of course a
difficult starting point for assays like CCMS, where the interest is in labelling as much
ARNO as possible to improve detection, as well as for activity and cellular assays
∗With AB −−⇀↽ − A + B, then KD = [A] [B]
[A B]
. If [B] = KD, then [A] = [A B].
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The second generation cytohesin inhibitor Secin16 has better IC50 and KD values.
However, this improvement is countered by diminished solubility. Thus, its use would
not help improving the labelling efficiency.
The solubility problem accompanied most of the experiments with the cytohesin
inhibitors in the last years. The efforts up to now were mainly concentrated on im-
proving the activity. However, a compound with similar activity but marked better
solubility would be of much higher value for our research. Thus the directed insertion
of solubility-improving modifications should be pursued.
6.5 Outlook
In this thesis three methods for binding analysis were presented. The BRET assay al-
ready require a relatively high amount of information on the mechanism and/or targets
of the interaction to be investigated to be successfully implemented. Instead SPR and
CCMS can be applied at earlier stage of hit characterisation after an high throughput
screening. These last two methods are complementary in the information they deliver.
After identification of the interaction partner(s) by CCMS, the binding characteristics
could be determined by SPR. As both methods require modification of the inhibitor,
it would be useful to have a common derivatisation for both systems. This would
reduce the synthetic efforts and the time spent in activity analysis of the derivatised
compound. An interesting step in this direction would be the use of “click” chemistry.
“Click” chemistry is a general term introduced by Sharpless149 to describe chemical
reactions which can be efficiently used for modular synthesis, have very high chemical
yields and selectivity and can be preferably performed in water. The best known and
mostly used “click” reaction is the Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition
between azides and alkynes.
The use of “clickable” probes has already been reported for CCMS where alkynyl
ABPP probes are used for proteome labelling and the azide bound reporter group is
added only afterwards90,135 (Fig. 6.2). This strategy often offers improved specificity
as the bulky reporter group is not present during labelling.
The same “click” strategy could be used to immobilise the small molecule on a
“clickable” SPR chip. A quick literature survey revealed that the preparation of a “click-
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Figure 6.2: Example of “click” chemistry in CCMS - The labelling reaction is
performed with an alkynyl probe before the reporter group is added by “click” chemistry.
Modified with permission from JACS (Ref. 90). Copyright 2005 American Chemical Society.
able” SPR surface has already been reported for “Clicked” carbohydrate self-assembled
monolayers150 and should thus be feasible.
Moreover one could use “clickable” fluorophores, which are commercially available,
to rapidly obtain fluorescently labelled inhibitors. These could be used in further assays
like microscale thermophoresis151 or fluorescence polarisation. The use of “clickable”
inhibitors would thus allow to rapidly switch from an assay to another and reduces the
time spent in the development of new synthetic routes.
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7Materials and methods
7.1 Methods
7.1.1 Organic synthesis
Chemicals were purchased from Alfa Aesar, Aldrich, Bachem and Fluka and used with-
out further purification. For synthesis, solvents were obtained from Fluka, Merck and
Riedel de Haen in ‘per analysis’ grade.
For column chromatography, solvents of technical grade were distilled before use
and silica gel from Acros, with a particle dimension of 35-70 µm, was utilized. Thin
layer chromatography was performed on aluminium plates of silica gel 60 F254 from
Merck. Detection was done with ultraviolet (UV) light at 254 nm.
Nuclear magnetic resonance (NMR) spectra were measured on Bruker AM 400 (1H:
400 MHz, 13C: 100 MHz) and Bruker AM 300 (1H: 300 MHz) spectrometers at room
temperature. The chemical shifts are given in ppm relative to tetramethylsilane and the
spin multiplicity as s = singulet, d = doublet, t = triplet, br = broad, m = undefined
multiplet.
Mass spectrometry (MS) measurements were done on a Bruker esquire HCT spec-
trometer with atmospheric pressure interface-electrospray ionisation (API-ESI).
7.1.1.1 Synthesis of SecinH3-TPD
(2-(2-[5-Benzo[1,3]dioxol-5-yl-1-(4-nitro-phenyl)-1H-[1,2,4]triazol-3-yloxy]-
ethoxy)-ethyl)-carbamic acid tert-butyl ester (BA91)
BS-1 (2-(2-(Benzo[1,3]dioxole-5-carbonylthiocarbamoyloxy)-ethoxy)-ethyl)-carbamic acid
tert-butyl ester, 1.6 g, 3.9 mmol, 1.0 eq.) and 4-nitrophenylhydrazine (0.7 g, 4.74 mmol,
1.2 eq.) were suspended in EtOH (22 ml) and stirred at 80◦C under reflux for 8 h. The
reaction mixture was evaporated under vacuum and purified by column chromatogra-
phy on silica gel (EtOAc/cyclohexane 100:0 – 45:55 gradient) to give the desired product
(1.2 g, 58 %). Rf (EtOAc/cyclohexane 1:1): 0.83. 1H NMR (CDCl3): δ ppm 1.46 (s,
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Figure 7.1: BA91 - Chemical formula: C19H19N5O6. Molecular weight: 413.4.
9 H) 1.87 (br. s., 2 H) 3.36 (t, J =4.53 Hz, 2 H) 3.63 (t, J =5.04 Hz, 2 H) 3.84 - 3.90
(m, 2 H) 4.50 - 4.56 (m, 2 H) 4.96 (br. s., 1 H) 6.06 (s, 2 H) 6.82 (d, J =7.81 Hz, 1 H)
6.95 (s, 1 H) 6.96 - 7.00 (m, 1 H) 7.57 (d, J =9.06 Hz, 2 H) 8.28 (d, J =8.81 Hz, 2 H).
2-2-[5-Benzo[1,3]dioxol-5-yl-1-(4-nitro-phenyl)-1H -[1,2,4] triazol-3-yloxy]-
ethoxy-ethylamine (BA94)
O
O
N
N
N
NO2
O
O
NH2
Figure 7.2: BA94 - Chemical formula: C19H19N5O6. Molecular weight: 413.38.
BA91 (800 mg, 1.6 mmol, 1 eq.) was dissolved in formic acid (14.5 ml) and stirred
at room temperature for 2.5 h. The reaction was evaporated under vacuum, redissolved
in formic acid (4 ml) and evaporated again. The residue was co-evaporated twice with
toluene. Purification by column chromatography on silica gel (25VC MeOH/CH2Cl2
1:99, each 5VC MeOH/CH2Cl2/Triethylamine 1:98:1 – 3:96:1) gave the desired product
(433 mg, 67 %). 1H NMR (CDCl3): δ ppm 3.17 (br. s., 2 H) 3.80 (br. s., 2 H) 3.86
(br. s., 2 H) 4.47 (br. s., 2 H) 6.01 (s, 2 H) 6.77 (d, J =8.06 Hz, 1 H) 6.89 (s, 1 H) 6.89
- 6.94 (m, 1 H) 6.99 - 7.41 (m, 4 H) 7.27 - 7.30 (m, 1 H) 7.53 (d, J =8.81 Hz, 2 H) 8.21
(d, J =9.06 Hz, 2 H).
6-(5-Methyl-2-oxo-imidazolidin-4-yl)-hexanoic acid (2-(2-[5-benzo[1,3]dioxol-
5-yl-1-(4-nitro-phenyl)-1H -[1,2,4]triazol-3-yloxy] -ethoxy)-ethyl)-amide (BA96)
N -Ethyldiisopropylamine (830µl , 4.8 mmol, 5.1 eq.) was added to a solution of HBTU
(359 mg, 0.9 mmol, 1 eq.) and desthiobiotin (223 mg, 1.0 mmol, 1.1 eq.) in DMF (4 ml).
The mixture was stirred for 10 min at room temperature. A solution of BA94 in DMF
(10 ml) was added dropwise and the reaction stirred for 1 h. The reaction mixture
was partitioned between brine and CH2Cl2. The organic layer was dried over MgSO4
120
7.1 Methods
O
O
N
N
N
NO2
O
O
N
H
O
H
N
N
H
O
Figure 7.3: BA96 - Chemical formula: C29H35N7O8. Molecular weight: 609.63.
and evaporated. The resulting residue was purified by column chromatography (9VC
MeOH/CH2Cl2 2:98, 4VC MeOH/CH2Cl2 10:90) to give the desired product (698 mg,
quantitative) 1H NMR (CDCl3): δ ppm 1.12 (d, J =6.55 Hz, 3 H) 1.18 - 1.54 (m, 9 H)
1.66 (quin, J =6.86 Hz, 2 H) 2.21 (t, J =7.30 Hz, 2 H) 3.48 (q, J =5.04 Hz, 2 H) 3.65
(t, J =5.04 Hz, 2 H) 3.68 - 3.74 (m, 1 H) 3.80 - 3.85 (m, 1 H) 3.85 - 3.89 (m, 2 H) 4.50
- 4.54 (m, 2 H) 6.05 (s, 2 H) 6.51 (t, J =4.78 Hz, 1 H) 6.82 (d, J =7.81 Hz, 1 H) 6.94
(s, 1 H) 6.96 (d, J =1.26 Hz, 1 H) 7.56 (d, J =9.06 Hz, 2 H) 8.27 (d, J =8.81 Hz, 2 H).
6-(5-Methyl-2-oxo-imidazolidin-4-yl)-hexanoic acid (2-2-[1-(4-amino-phenyl)-
5-benzo[1,3]dioxol-5-yl-1H -[1,2,4]triazol-3-yloxy] -ethoxy -ethyl)-amide (BA99)
O
O
N
N
N
NH2
O
O
N
H
O
H
N
N
H
O
Figure 7.4: BA99 - Chemical formula: C29H37N7O6 Molecular weight: 579.6.
BA96 (530 mg, 0.9 mmol) was mixed with 10 % palladium on carbon (126 mg),
THF (10 ml) and EtOH (10 ml) and added to a stirred autoclave. The reactor was
purged with argon and pressurised with hydrogen (9 bar). After 2 h the reaction was
filtered over celite and evaporated under vacuum. Purification by column chromatog-
raphy on silica gel (MeOH/CH2Cl2 2:98 – 5:95 gradient) gave the desired product
(235 mg, 50 %). Rf (MeOH/CH2Cl2/triethylamine 10:89:1) 0.66.
N -(4-[5-Benzo[1,3]dioxol-5-yl-3-(2-(2-[ 6-(5-methyl-2-oxo-imidazolidin-4-yl)-
hexanoylamino]-ethoxy)-ethoxy)-[1,2,4]triazol-1-yl] -phenyl)-4-ethyl-benza-
mide (BA103)
4-Ethylbenzoic acid (16.3 mg, 0.1 mmol, 1 eq.) was dissolved in THF (225µl), and
1 droplet of DMF added. The reactor was flushed with argon and a solution of ox-
alylchloride (69µl, 0.5 mmol, 5 eq.) in THF (225µl) added dropwise. The reaction
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Figure 7.5: BA103 - Chemical formula: C38H45N7O7. Molecular weight: 711.81
mixture was stirred for 2.5 h at room temperature and the solvent evaporated under
vacuum. The oxalyl chloride was removed by coevaporation with once THF and twice
toluene. The crude product was dissolved in CH2Cl2 (500µl) and the reactor purged
with argon. BA99 (64.6 mg, 0.1 mmol, 1 eq.) and N -Ethyldiisopropylamine (38µl,
0.2 mmol, 2 eq.) in CH2Cl2 (1.8 ml) were added dropwise and the reaction stirred for
2 h. The reaction mixture was concentrated under reduced pressure. Purification on
TLC plates (MeOH/CH2Cl2 10:90) gave the desired product (22 mg, 28 %).
N -4-[5-Benzo[1,3]dioxol-5-yl-3-(2-(2-[ 6-(5-methyl-2-oxo-imidazolidin-4-yl)-
hexanoylamino]-ethoxy-ethoxy)-[1,2,4]triazol-1-yl] -phenyl)-4-(3-trifluoro-
methyl-3H -diazirin-3-yl)-benzamide (SecinH3-TPD)
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Figure 7.6: SecinH3-TPD - Chemical formula: C38H40F3N9O7. Molecular weight:
791.8
4-(1-Azi-2,2,2-trifluoroethyl)benzoic acid (25 mg, 0.1 mmol, 1 eq.) was dissolved in
THF (300µl), and 2 drops of DMF added. The reactor was flushed with argon and a
solution of oxalylchloride (92µl, 1.0 mmol, 10 eq.) in THF (250µl) added dropwise.
The mixture was stirred for 2.5 h at room temperature and the solvent evaporated under
vacuum. The oxalylchloride was removed by coevaporation with once THF and twice
toluene. The raw product was dissolved in CH2Cl2 (500µl) and the reactor purged
with argon. BA99 (63.2 mg, 0.1 mmol, 1 eq.) and N -ethyldiisopropylamine (38µl,
0.2 mmol, 2 eq.) in CH2Cl2 (1.3 ml) were added dropwise and the reaction stirred
for 2 h. The reaction mixture was concentrated under reduced pressure. Purification
on TLC plates (MeOH/CH2Cl2 10:90) gave the desired product (35 mg, 41 %). Rf
(MeOH/CH2Cl2/triethylamine 10:89:1) 0.66.
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7.1.1.2 Solid-phase peptide synthesis
To get used to the LC-MS system a reference peptide was synthesised by solid-phase
peptide synthesis on a PS3 peptide synthesiser (Protein technologies, Inc.). A 27 amino
acids long subsequence of ARNO-Sec7 with two tryptic cleavage sites was chosen (“‖”
denotes a tryptic cleavage site):
H2N− FVAMNR ‖ GINEGGDLPEELLR ‖ NLYDSIR− CO2H
Fmoc (fluorenylmethyloxycarbonyl chloride) protected amino acids and 0.4 mmol
Rink Resin (PS3-RK-1) from Protein technologies, Inc. were used for the synthesis
following the manufacturer instructions.
Deprotection
Various deprotection conditions were tested on aliquots. Then, the complete synthesis
was deprotected following this protocol:
1. Prepare the deprotection solution: 82.5 % TFA, 2.5 % DTT, 5 % water,
5 % phenol, 5 % thioanisol.
2. Add 5 ml deprotection solution to 1 ml resin. Incubate 2 h at RT.
3. Filtrate over silica cotton.
4. Precipitate with diethylether.
5. Wash with diethylether.
6. Add 5 ml deprotection solution. Incubate 2 h at RT.
7. Precipitate with diethylether.
8. Wash 3-times with diethylether.
9. Dry on SpeedVac.
The peptide was then purified on a semipreparative HPLC. Column: Multo high bio
300–5 C4. Gradient: 30 % (FA/H2O 0.1 % v/v)/CH3CN to 100 % CH3CN in ∼30 min.
Injections: 50µl, 1 mM. The collected fractions were pooled, shock frozen and dried on
SpeedVac.
The purified peptide was analysed by LC-MS on the same column and with the
following gradient:
min FA/H2O [%] CH3CN [%]
0 100 0
20 0 100
24 0 100
26 100 0
The peptide eluted at 15.5 min. Observed peaks: 773 and 1031 m/z.
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7.1.2 Handling of nucleic acids
7.1.2.1 Agarose gel electrophoresis
Agarose gel electrophoresis was used to analyse the outcome of PCR reactions and
enzymatic digestions. Concentrations of agarose varying from 0.5 to 2 % were used,
depending on the expected DNA size. The desired amount of agarose was dissolved
in 25 ml 0.5 X TBE-buffer by heating in a microwave oven and poured into the gel
chamber. In order to detect the oligonucleotides bands, ethidium bromide at a final
concentration of 0.5µg/ml was added to the solution. After solidification, 5µl of a
5:1 mixture of sample and 6 X agarose gel loading buffer were loaded and the gel run
at 150 V in 0.5 X TBE-buffer. The oligonucleotide bands were then visualized on a
transilluminator.
7.1.2.2 Determination of the concentration
The concentration of double stranded DNA solutions was determined from the absorp-
tion at 260 nm using the conversion rule: 1 OD260 ≡ 50µg/ml DNA.
7.1.2.3 Molecular cloning
For cloning of new plasmid constructs the coding sequence of the protein of interest
was amplified by PCR from a template plasmid. Both the amplified insert and a vector
plasmid were digested with appropriate enzymes, mixed and ligated. The ligation
reaction was used to transform ultracompetent cells which were cultured on antibiotic-
containing plates. Then, colonies were picked an screened by PCR to verify the presence
of the plasmid of interest.
Amplification of the insert
The inserts were amplified by PCR in 100µl reactions:
Pipetting schema Cycling parameters
Water to 100µl 95◦ 60 s
10 X Pfu rection buffer 10µl 95◦ 30 s e
25 mM MgCl2 8µl 60
◦ 30 s 28 X
plasmid 2-10 ng 72◦ 90 s c
25µM 5’-primer 2µl 72◦ 180 s
25µM 3’-primer 2µl 4◦
dNTP-Mix, 25 mM each 1µl
2.5 U/µl Pfu polymerase 4µl
The PCR products were analysed by agarose gel electrophoresis, then purified with a
PCR purification kit (Macherey-Nagel) and eluted in 30µl 10 mM Tris, pH 8.0. The
concentration was determined photometrically.
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Enzymatic digestion of insert and vector
Vector Insert
water to 20µl to 40µl
10 X Fast Digest buffer 2µl 4µl
Vector 1µg -
PCR-product - 850 ng
1 FDU/µl enzyme 1 0.5 1.5
1 FDU/µl enzyme 2 0.5 1.5
The reactions were incubated for 45 min at 37◦C. Then, 0.2µl CIP (Calf intestinal
alkaline phosphatase, Promega) were added and the reaction incubated for further
15 min before purification with a MinElute Reaction Cleanup Kit (Qiagen).
Ligation
The digested samples were mixed in ratio of 3 mol insert to 1 mol vector. The whole
insert sample was used. The mixture was incubated for 5 min at 45◦C and then trans-
ferred directly on ice. 1/10 volume of 10 X ligation buffer (Fermentas) and 1µl T4 DNA
Ligase (Fermentas) were added and the reaction was incubated for 3 h at RT. The lig-
ation reaction was used to transform XL10-Gold ultracompetent cells (Stratagene).
Transformation of XL10-Gold ultracompetent cells
Procedure:
1. Gently thaw the XL10-Gold ultracompetent cells on ice.
2. Add 1.25µl of β-mercaptoethanol to 25µl of the supercompetent cells.
3. Incubate on ice for 10 min (swirl gently every 2 min).
4. Transform with 10µl of the ligation reaction.
5. Incubate for 30 min on ice.
6. Heat-pulse for 60 at 42◦C.
7. Incubate on ice for 2 min.
8. Add 500µl of preheated SOC medium to each tube and incubate for ∼60
min (depending on the antibiotic) at 37◦C with shaking (Thermomixer,
2 ml, 1000 rpm)
9. Centrifuge the cells for 3 min, 3000 rpm, discard ∼450µl of the supernan-
tant.
10. Plate the cells (∼75µl) on agar plates with the right antibiotic and
incubate o.n. at 37◦C.
Usually, 10 colonies were picked, boiled for 5 min in 25µl water and centrifuged at
15 000 rpm for 3 min. 5µl of the supernatant were mixed to 5µl of master mix and
used for colony PCR. A primer was chosen to be in the vector and the other in the
insert. The clones whih resulted positive in the colony PCR, were inoculated in 5 ml LB
medium with appropriate antibiotic and grown o.n. The plasmid were minipreparated
and the coding sequence verified by sequencing (GATC Biotech).
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Master mix for 11 PCRs Cycling parameters
Water 42.5µl 95◦C 60 s
10 X Taq buffer 12µl 94◦C 30 s e
dNTP mix, 25 mM each 0.96 60◦C 30 s 25 X
25µM 5’primer 0.96µl 72◦C 60 s c
25µM 3’primer 0.96µl
5 U/µl Taq 2.4µl
7.1.2.4 Mutagenesis
The QuikChange lightning site-directed mutagenesis kit was used to obtain plasmids
encoding the GEF inactive ARNO mutant E156K.
Plasmids used (10 ng/µl): ARNO GFP K7 (Resistance: zeocin)
pCMV-FLAG Cyt2 Full (Resistance: kanamycin)
pCMV-FLAG Cyt2 Sec7 (Resistance: kanamycin)
5’-Primer: ARNO-E156K sp, 15µM
3’-Primer: ARNO-E156K ap, 15µM
Pipetting schema: Cycling parameters:
water 34.5µl 95◦C 120 s
10 X reaction buffer 5µl 95◦C 30 s e
Plasmid 5µl 60◦C 60 s 18 X
5’-Primer 1µl 68◦C 165 s c
3’-Primer 1µl 4◦C
dNTP mix 1µl
QuickSolution 1.5µl
Lightning Enzyme 1µl
2µl DpnI were added and the reaction incubated at 37◦C for 30 min before purification
with a PCR purification kit (Qiagen). The whole reaction was used to transform XL10-
Gold ultracompetent cells (Stratagene).
7.1.3 Protein methods
7.1.3.1 Determination of protein concentration
The concentration of purified protein solutions was measured by UV absorption at
280 nm and calculated according to the Beer-Lambert law
A =  ` c
where c is the concentration in mol/l, A the absorbance, ` the path length of the
sample in cm. The molar extinction coefficient  at 280 nm is given in l mol−1 cm−1
and calculated with VectorNTI, based on the content of tyrosine, tryptophan, and
cysteine residues.
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Bradford assay
The protein concentration in complex samples (e.g. cell lysate) was determined by
Bradford assay152. This colorimetric assay bases on the binding of the Coomassie
Brilliant Blue dye to basic and aromatic amino acids which leads to an absorbance
shift of the absorption maximum to λ = 595 nm. The assay was measured in 96-well
microtiter plates. BSA dilutions (333, 500, 666, 1000, 1500, 2000 and 3000 µg/ml)
were used to build a calibration curve. Each 2µl of the sample of interest and the
BSA dilutions were dispensed in the wells (in triplicates and duplicates, respectively)
and then 150µl of 1:6 diluted Bradford solution (Bio-rad) were added. The absorption
at 595 nm was measured in a Varioskan plate reader and the samples concentration
derived from the calibration curve.
7.1.3.2 SDS-PAGE
For the analysis of protein purity, expression or labelling, the protein samples were
separated according to their size by discontinuous SDS-PAGE (sodium dodecyl sulfate
polyacrylamid gel electrophoreses) according to Laemmli153.
The gels were prepared by polymerisation of acrylamide and N,N’ -methylene-bis-
acrylamide initiated with ammonium persulfate (APS) and N,N,N’,N’ -tetramethyl-
ethylenediamine (TEMED) according to the following schema:
Separating gel Stacking gel
7.5 % 10 % 4 %
(Bis)-acrylamide 1250µl 1667µl 213µl
Water 2462µl 2045µl 975µl
Separating gel buffer (4x) 1250µl 1250µl -
Stacking gel buffer (4x) - - 400µl
TEMED 8µl 8µl 2µl
APS 30µl 30µl 10.4µl
The indicated reactions were mixed and the gels were cast between two thin glass
slides. The concentration of the separating gel was chosen depending on the size of the
investigated protein. Usually 7.5 % gels were used for the analysis of ARNO∆PBR and
10 % gels for the analysis of ARNO-Sec7 and the EGFR. A stacking gel, poured on top of
the separating gel, was used to focus the proteins in a thin starting zone. The samples
were boiled in 1 X loading buffer (p. 148) loaded on the gel and separated for ∼1 h
at 200 V in cold Tris glycine running buffer (p. 147). Page Ruler Prestained Protein
Marker (Fermentas) was loaded as a size standard. The gels where then either stained
with Coomassie or transferred on a nitrocellulose membrane by Western blotting.
7.1.3.3 Western blotting and immunodetection
Discontinuous blotting according to Kyhse-Andersen154 was used to transfer proteins
separated by SDS-PAGE on nitrocellulose membranes. The gel was piled between
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different layers of filter papers equilibrated for some minutes in different buffers (p. 148)
as following:
Cathode
3 filter papers in cathode buffer
Gel in Cathode buffer
Nitrocellulose membrane in anode II buffer
2 filter paper in anode II buffer
1 filter paper in anode I buffer
Anode
A constant power of 2 mA/cm2 gel was applied for 45 min. Then, the membrane
was blocked by incubation in 5 % w/v milk powder or BSA in 1 X TBS-T for at least
45 min at RT, rinsed 3-times with 1 X TBS-T and incubated with dilutions of primary
antibody either for 1 h at RT or o.n. at 4◦C. The membranes were washed 3-times
in 1 X TBS-T and then incubated in horseradish peroxidase (HRP)- or near infrared
(NIR) dye-coupled secondary antibody diluted 1:10 000-1:20 000 in 5 % w/v BSA in 1 X
TBS-T for 1 h at RT. NIR dye coupled antibodies were incubated in the dark.
Visualisation was done by enhanced chemiluminescence on a VersaDoc 5000 CCD
camera (BioRad) or by NIR immunofluorescence on an Odyssey scanner (Licor). The
bands were quantified with the QuantityOne software (BioRad).
7.1.4 Cell culture
Cells were grown at 37◦C and 5 % CO2 in the following media and splitted every 2-3
days, when they reached a maximal confluency of ∼80 %.
HEK293T DSMZ Cell DMEM, High Glucose, with PAA/Lonza
Lines Bank phenol red and 10 % FBS
H460 ATCC Cell Bio- RPMI (PAA) with 10% FBS PAA/Lonza
logy Collection
7.1.4.1 Preparation of cell lysates
For the analysis of EGF stimulation, the transfected HEK cells (in 6-wells plates)
were serum-starved overnight in DMEM, 0.1 % FBS and stimulated for 5 min with
50 ng/ml EGF (Peprotech). The medium was discarded and the cells harvested in
cold 1 X PBS, 5 mM EDTA on ice. After centrifugation (500 rpm, 5 min, 4◦C) the
supernatant was decanted, the pellets resuspended in ∼30µl lysis buffer supplemented
with protease-inhibitor-mix HP (Serva) and incubated for 15 min on ice. Cell debris
were separated by centrifugation at 12 000 rpm for 20 min at 4◦C) and the protein
content of the supernatant determined by Bradford assay. The samples were diluted in
water and 6 X Loading buffer to ∼3µg/µl in 1 X Loading buffer and boiled. 40-50µg
proteins were loaded for SDS-PAGE.
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1 X Lysis buffer 20 mM Tris, pH 7.5
150 mM NaCl
1 mM EDTA
1 mM EGTA
2.5 mM sodium pyrophosphate
1 mM β-glycerophosphate
1 mM sodium vanadate
1 % (v/v) Triton X-100
7.1.5 BRET
For BRET, HEK cells transiently expressing the fluorophore/enzyme-tagged proteins
were used. The plasmids transfected for each kind of experiment were:
Experiment Donor Acceptor Ratio Additional plasmid
Direct pEGFR-RLucd4 pARNO-GFP2 1:20
Indirect pEGFR-RLucd4 pEGFR-GFP2d4 1:20 pCMVTag2-ARNO
pHER2-Luc pHER3-GFP 1:20 pCMVTag2-ARNO
Control pGST-Rluc pGST-GFP2 1:20 pCMVTag2-ARNO
7.1.5.1 Transfection
3.5× 106 HEK293T cells were seeded in a 10-cm plate in 10 ml DMEM with 10 % FBS
and without phenol red. Metafectene (Biontex) (3µl per µg of DNA was premixed
with serum free media. Maximally 6µg total DNA (transfections with less DNA were
filled up with empty vector) were diluted in serum free medium and then added to
the metafectene solution without mixing. After 20-30 min the cells were transfected by
addition of the transfection mixture. The cells were then incubated for ∼40 h at 37◦C
and 5 % CO2.
7.1.5.2 Measurement
Solutions needed:
BRET-buffer: add 0.55 g glucose to 500 ml DPBS (PAA), warm up to 37◦C
Luciferase substrate: 15µM DeepBlueC in PBS. Dilute from the stock solution
(1 mM in ethanol) only at the moment of use∗. 50µl/well + 600µl for priming
are needed.
5 mM EDTA in PBS to detach the cells.
Before start:
warm up the BRET-buffer and a white 96-wells plate to 37◦C.
Start the instrument to allow warming up, open the parameters file to set the
temperature to 37◦.
Wash the injector with water (’Instrument – Wash’, tick ’injector 3’, press
∗DeepBlueC decays quickly. Keep the time between dilution and injection as short as possible.
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’next’ twice).
1. Take the cells from the incubator and remove the medium.
2. Detach the cells with 1 ml DPBS/EDTA and transfer into a 15 ml-Falcon.
3. Wash the plate with 6 ml BRET-Buffer and add to the Falcon. Take an
aliquot to count the cells.
4. Centrifuge at 400 rcf, 37◦C, for 5-7 min. Meanwhile, count the cells.
5. Decant the supernatant.
6. Add BRET-Buffer to a final concentration of 3.2× 106 cells/ml.
7. Mix and transfer in 8-ates (in columns) into a white 96-well plate (100µl/well,
keep warm)
8. Dilute the luciferase substrate. Connect to the instrument.
9. Prime the instrument (’Instrument – Prime’, tick ’injector 3’, press ’next’
twice).
10. Select ’Platte einstellen’ (bottom left), tick ’by rows’, select the wells.
11. Write a filename.
12. Press Start to insert the plate.
13. After the measurement: ’Datei – Export’, ’Matrix export’. The report
is saved in ’Dokumente – Mithras Datei – Transfer’.
14. Give two aliquots of the cells in a black plate and measure total GFP.
15. ’Instrument – unload plate’.
16. Substitute the luciferase substrate with water. ’Instrument – wash’,
select 40 cycles, ’next’.
7.1.5.3 Evaluation
1. Check that luciferase signal is over 1000.
2. Subtract background from non trasfected cells.
3. Calculate ratio GFP/Luc
4. Subtract ratio of cells transfected with Luciferase only.
7.1.6 SPR
7.1.6.1 Maintenance routines
SPR machines are particularly sensitive to impurities and especially proteins tend to
adsorb to the tubing. To ensure optimal performance of the machine, the following
working rules were defined:
• Buffers are always filtered and degassed and possibly stored at 4◦C. Check reg-
ularly that nothing is growing in the buffer. Consider making aliquots of your
buffers to reduce contaminations.
• Execute a DESORB routine at least once a month and before every chip coupling.
If a new interaction is studied, it is worth running a DESORB routine before start.
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! Never run a DESORB, SANITIZE or SUPERCLEAN procedure on
your working chip as this could be destroyed. Use the maintenance chip
instead.
• Run a SANITZE routine at least every three months. Always execute a DESORB
prior a SANITIZE.
! After SANITIZE a longer rinsing time is needed. It is worth planning
the routine at the end of the day.
• From time to time run a SUPERCLEAN by priming the system four times in a
row with each of the following reagents: 0.5 % SDS, 6 M urea, 1 % acetic acid and
0.2 M NaHCO3.
• Run on occasion a SYSTEMCHECK to verify the condition of the IFC.
• Prime the system three times at every buffer change (it is time well invested!).
• Let the chips ad buffers warm up to RT for ∼30 min before use.
• Store your ligand coupled chips wet (especially if protein is coupled). I.e. after
undocking the chip remove the chip carrier slide from its sheath and insert it in
a 50 ml Falcon tube filled with your running buffer. Store at 4◦C.
• Clean your chip before redocking. I.e. wash the plastic slide and the gold surface
with water and dry it with compressed air. Make sure that no salts deposit are
visible on the gold surface.
• If possible, test the solubility of the molecules before injecting them. If your
analyte aggregate/precipitate in the system, you can spend the rest of the day
with cleaning procedures!
7.1.6.2 Analysis of protein/inhibitor interactions
The SPR measurements of the ARNO/inhibitor interaction were performed by Esteban
Gutierrez during his Master thesis76. An adaptation of his methods description is
reported here for completeness.
Preconditioning of SPR chips
The CM5 chip for the second coupling (Fig. 4.24) was preconditioned before covalent
coupling of the small molecules. The chip was docked in and the system primed with
water. A new sensorgram was started, with a flow rate of 100µl/min. 100 mM HCl,
50 mM NaOH, 0.5 % SDS w/v and water were injected sequentially for 10 s each. The
sequence was repeated once. Water injections where repeated until a stable baseline
was observed.
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Coupling of small molecules
For the coupling of small molecules on CM5 sensor chips standard EDC/NHS coupling
was used following the manufacturer instructions. The compounds were derivatized
with amine linkers as described in Section 4.3.2.3 (p. 55). A sodium hydrogenocarbon-
ate buffer (pKa 10.3) was used to ensure that the primary amines (pKa 9-10) were not
protonated. 5 % DMSO were added to avoid solubility problems. As running buffer
HBS-P (Biacore) was used.
Coupling protocol:
1. Allow the CM5 chip and all buffers to warm up to RT.
2. Prepare fresh EDC (0.4 M in water) and NHS (0.1 M in water) solutions
or thaw up frozen aliquots.
3. Dock the chip and prime with HBS-P.
4. Start a new sensorgram on Fc2 (Fc1 is used as reference cell). Flow rate:
5µl/min .
5. Activate the surface by a 7 min injection of a 1:1 mixture of the EDC/NHS
solutions.
6. Immobilize the first small molecule: 10 min injection (150µM in 10 mM
Na2CO3, pH 10.5, 5 % DMSO).
7. Deactivate the surface with a 7 min injection of ethanolamine solution.
Stop the sensorgram.
8. Repeat steps 4.-7. for Fc2 and Fc3 with the other small molecules. Stop
the sensorgram.
9. Start a new sensorgram on Fc1 (reference cell).
10. Activate the surface with a 7 min injection of EDC/NHS 1:1.
11. Inject buffer (10 mM Na2CO3 pH 10.5, 5 %DMSO) for 5 min.
12. Deactivate with a 7 min injection of ethanolamine solution. Stop the
sensorgram.
With this protocol 2 000-3 000 RU of small molecule where coupled on the untreated
CM5 chip and around 800 RU on the preconditioned chip.
Acquisition of binding sensorgrams
Before every interaction kinetic measurements, after docking the ligand-coupled chip
and priming the system with running buffer, the UNCLOG and RINSE routines (Bia-
core control software - working tools) were used. This reduces artifacts from air bubbles
and contaminations of IFC, injection needle or chip.
To monitor the surface and injection stability, a sensorgram was started on the
desired flow cells (reference and ligand-bound Fcs) and run with a flow rate of 50-
100µl/min for 5-15 minutes. The slope of the baseline was determined by setting
report point. Baselines with slopes lower than 0.02 RU/s were considered as stable. If
stronger drifting was observed, the systems working tools were used (CLEAN, RINSE,
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UNCLOG) and, if necessary, regeneration solutions injected (5 mM NaOH, 1 M NaCl,
0.5 % SDS or 5 mM glycine, depending on the sensitivity of the ligand).
We frequently observed irregularities in the first few injections. Therefore, after ob-
serving baseline stability, we executed several buffer injections (INJECT or KINJECT
mode, 60 s injections) until a clean injection sensorgram (square shaped or flat) was
observed.
The kinetic measurements were performed in the KINJECT mode, at a flow rate
of 30µl/min with ARNO buffer (p. 148) as running buffer. The KINJECT injection
routine avoids pumps filling during the dissociation phase (pump filling often lead to
sensorgram jumps which disturb analysis). 250µl of protein solution were injected
and then the dissociation monitored for 5 min. For double referencing66, two buffer
injections with the same parameters were acquired before protein injection on one
again at the end of the measurement series. Two injections of buffer were also done
(INJECT, 60 seconds) before each injection of analyte sample, to avoid irregularities
at the start of the sensorgram (due to residual regeneration solution in the needle).
Five concentrations (50 nM, 100 M, 250 nM, 500 nM, 1µM , 1.5µM ) of protein
solution (ARNO-Sec7 and GST) were injected. Every sample injection was followed by
3 regeneration injections (5 mM NaOH and 500 mM NaCl; 0.5 % SDS; 5 mM glycine),
and a new cycle was started between the regeneration phase and the following analyte
injection.
Protocol used:
1. Change running buffer to ARNO buffer.
2. Start a new sensorgram: mode “FC1,2,3,4”, flow rate 30µl/min. Wait
until a stable baseline is reached.
3. Set data collection rate to high.
4. INJECT running buffer to test surface stability.
5. Acquires two KINJECT with buffer for double referencing.
6. Start a new cycle. INJECT buffer for twice 60 s
7. Use KINJECT for injections. Set the association time to 250µl and the
dissociation time to 5 min.
8. KINJECT the first concentration of protein.
9. INJECT the regeneration solutions. Try different regeneration conditions
until the baseline is back at the level measured before analyte injection.
10 Repeat steps 6.-9. for the remaining concentrations.
11. Acquire a KINJECT with buffer for double referencing.
Data processing and analysis
Sensograms obtained from kinetic interaction measurements were double referenced66.
An example of data processing is shown in Figure 7.7.
First, the response in the few seconds just before injection was set to zero (y-axis)
and the start of the injection was set to zero by eye for each each Fc (Fig. 7.7b).
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Then, the reference surface data is subtracted from the reaction surface data to
remove the refractive index change and injection noise (Fig. 7.7c). The sharp spikes
at either the beginning or end of the association phase are due to differences in the
position of the reaction and reference Fcs and should be removed during data analysis.
The reference subtracted response and the blank injections (buffer KINJECTions)
are overlaid (Fig. 7.7d) and the response from the blank injections subtracted (Fig. 7.7e)
and, at the end, the responses from the different analyte concentrations are overlaied
(Fig. 7.7f).
At this point the dissociation is determined with the program BIAevaluation (Bia-
core) by global kinetic curve fitting to a 1:1 interaction model or equilibrium analysis.
Figure 7.7: Example of data processing - a. Raw data from biosensor for 233 nM
IL-2 injected over a receptor surface (top trace) and reference surface (bottom trace). b.
Data sets were zeroed on the y and x axis just prior to the start of the injection. c. Data
from the reference surface was subtracted from the data from the reaction surface. d.
Overlay of four replicate injections of 233 nM IL-2 as well as a running buffer blank. e.
After subtracting the average of the blank injections from both the sample and blank data.
f. Overlay of a series of IL-2 injections (233, 78, 26, 8.6, 2.9 and 0 nM) replicated four times
each.66 Adapted from Journal of Molecular Recognition (Ref. 66), copyright 1999, with permission from
John Wiley and Sons, Inc.
7.1.6.3 Analysis of protein/protein interactions
Loading of the NTA/NiP chips
NTA chips were first washed with 0.5 M EDTA, pH 8.4, to get rid of Ni 2+ ions and
then loaded with 20 mM NiCl2. To avoid carry-over of nickel, 3 mM EDTA was added
to the dispenser buffer (p. 148) (connected to pump B and used for sample preparation
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and washing of the injection needle) and another rinsing programs ‘EXTRACLEAN’
or ‘WASH Needle’ were used (the routine ‘WASH IFC’ has increased risk of carryover).
The His-tagged protein was injected and NTA running buffer flown, till a stable
signal was observed. Then, the analyte was KINJECTected at 30µl/min . The KIN-
JECT injection routine avoids pumps filling during the dissociation phase (pump filling
often leads to sensorgram jumps which disturb analysis).
The chip was regenerated by repeated injections of NTA regeneration buffer (p. 148)
and 0.5 % SDS in 10 mM HEPES, pH 7.0, 150 mM NaCl and 0.005 % Tween-20. High
salt buffers were used to reduce electrostatic interaction of the proteins with the chip
surface.
Covalent immobilisation on NTA chips
The NTA chip was first washed with 0.5 M EDTA, pH 8.4, to get rid of Ni 2+ ions. The
cell of interest was loaded with 20 mM NiCl2 (2 min) and activated with a fresh 1:1
mixture of 0.4 M EDC in water and 0.1 M NHS in water (3 min). Then, 100 nM His-
EGFR in NTA running buffer were injected (10 min) and the surface was deactivated
by a 3 min injection of 1 M ethanolamine hydrochloride/NaOH pH 8.5. The Ni 2+ ions
and the non covalently bound receptor were washed away with NTA regeneration buffer
(3 min).
The analyte was KINJECTected in different running buffer at 30µl/min as de-
scribed in Section 4.3.1.3 (p. 44). Various regeneration solutions were used as described
in the previous section.
Covalent coupling to CM5 chips without preconcentration
The CM5 chip was activated with a fresh 1:1 mixture of 0.4 M EDC in water and 0.1 M
NHS in water (6 min). Then, 100 nM GST-EGFR in NTA running buffer were injected
(15 min) and the surface was deactivated by a 2 min injection of 1 M ethanolamine
hydrochloride/NaOH pH 8.5. The analyte was KINJECTected at 30µl/min in HBS-P.
The most promising regeneration solution was 0.1 % SDS/1 % Triton X-100 in HBS-P,
but still complete regeneration was not possible.
7.1.7 MS and LC-MS analysis
7.1.7.1 Maintenance routines
To ensure optimal performance of the machine the following should be respected:
• Leave the system running with nitrogen: ≥ 5 l/min of dry gas flow. Switch
the instrument to ’Shutdown’ for maintenance only. When not in use keep in
’Standby’.
• Control regularly the nitrogen and helium pressure.
• Check detector calibration at least one a month.
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• Note in the logbook:
- the dates of detector calibration and current multiplier voltage.
- the vacuum values at least once a month and before and after system venting.
- the Accu Time (right click in the MS spectrum on the right, select ’Eigen-
schaften’ and tick ’Show Accu Time’) and capillary current (visible in the ’Tune’
tab under ’Capillary’) at every detector check.
- the dates of maintenance and other actions.
• Measure regularly a standard sample with a standard LC-MS method to test the
whole set up.
• Clean the spray chamber and spray shield weekly.
• Use acetonitrile (ACN) of at least HPLC grade and water of MilliQ quality.
• Avoid tubes containing plasticiser. Do not wash the bottles in the dish washer,
rinse them with clean solvents instead.
Cleaning
Clean the spray chamber and spray shield weekly with isopropanol/water.
If the accumulation times in MS mode increase (check during calibration) and the
signal intensities drop, the system is probably contaminated and needs cleaning. A
longer run with alternating polarity can help cleaning the system:
Wash o.n. with 200µl/min 80 % ACN/H2O. Untick ’HV’, set the ’Dry
gas’ to 10 l/min and the ’Nebulizer’ to 30 psi. Thick ’Alternating’ under
’Polarity’.
If the signal does not improve, manual cleaning is needed. Refer to the manual.
Adjusting the spray needle
For best ESI performance and MS sensitivity the tip of the nebulizer should be checked
from time to time for correct position, damage and contamination:
1. Switch the ’Neb Gas’ off.
2. Detach the gas inlet and open the spray chamber.
3. Take out the nebulizer and place it in the support block.
4. Position the magnifier so that you can see the nebulizer tip.
5. If necessary, loosen the needle holder locknut.
6. Adjust the needle until it sticks out about 1/2 of its own diameter.
7. Tighten the locknut while making sure that the position of the needle
does not change.
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! Be careful with the tip of the nebulizer needle. It is very sensitive and
can be damaged when touched.
If the needle need to be cleaned or replaced, please refer to the manual.
Calibration
The detector calibration was checked weekly and recalibration performed when neces-
sary:
1. Dilute 10µl ’ES tuning mix’ (Agilent) with 190µl acetonitrile and 10µl
water.
2. Inject by infusion at 240µl/min.
3. Set the default method for MS acquisition (press Ctrl+N in the esquire-
Control window to open the default method).
4. Wait till a stable signal is observed. If the signal does not stabilise flush
with 50 acetonitrile/water at higher flow rate (by hand).
5. In the ’Calibration’ tab, press ’Detector...’. Select ’ES Tuning Mix Pos’
as ’Mass list’ and 1521.97 m/z as ’Mass’.
6. Press check and wait till the results windows pops up
7. If the program ask for recalibration, press ’Calibrate’ in the ’Detector’
window.
8. ’Check’ again after calibration.
9. Note the dates of detector calibration, current multiplier voltage, Accu
Time, capillary current and intensity of the signal at 1522 m/z in the
logbook.
Calibration of the masses is usually not necessary. If you notice a mass shift when
measuring the standard sample, perform a Scan calibration with the same calibration
solution:
1. Follow steps 1.-4. of the detector calibration protocol.
2. In the ’Calibration’ tab, select ’Auto’ and then press ’Start’. Follow the
instructions.
Standard sample
The whole set up should be checked regularly with a standard sample. I used 5 pmol
of trypsin-digested BSA separated on C18-column with the LCMS-BSA-2-40-30min
(p. 138) method.
The digested BSA was either bought from BioLabs or prepared by digestion in
solution (p. 143) of BSA.
7.1.7.2 LC-MS programs
For LC-MS analysis the following 125× 4 mm columns from CS-Chromatographie Ser-
vice GmbH were used:
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MultoHigh-Bio 300 – C4 5µ, Art.-Nr. 584 1177, Column-Nr. 3303-10 (Analysis of non
digested proteins)
MultoHigh 100 RP 18 – 5µ, Art.-Nr. 582 1172, Column-Nr. 12911-05 (Analysis of di-
gested proteins)
The following parameters were used for MS acquisition:
Scan modus Standard-Enhanced, positive
Neb 30 psi
Dry gas 10 l/min
Dry temp 330◦C
Smart Target 200 000
Scan 300 to 1500 m/z
Averages 5
Target mass 900
Auto MS(2) acquisition parameters:
Scan 100 to 2300 m/z
Averages 3
Frag Ampl 0.5 V
Active exclusion: Excluded after 3 spectra
Release after 0.5 min
LC gradient for protein analysis
Undigested proteins were diluted in 30 % isopropanol in 0.1 % FA/H2O and analysed
with the following gradient on the C4 column:
min 0.1 % FA/H2O [%] Isopropanol [%]
0 70 30
3 70 30
23 40 60
24 0 100
29 0 100
30 70 30
MS spectra were acquired without MSMS between 5 and 25 min from gradient start.
Peptide mixtures analysis
Digested samples of purified proteins were usually analysed with the following 30 min
gradient on the C18 column:
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min 0.1 % FA/H2O ACN
0 98 2
30 60 40
31 10 90
36 10 90
37 98 2
60 98 2
MS or MSMS spectra were acquired between 3 and 18 min from gradient start.
Instead, digested samples from the enrichment experiments were analysed with a 60 min
gradient on the C18 column:
min 0.1 % FA/H2O ACN
0 98 2
3 98 2
40.2 53 47
42 0 100
47 0 100
49 98 2
70 88 2
MS or MSMS spectra were acquired between 8 and 40 min from gradient start.
7.1.8 CCMS
7.1.8.1 Labelling reactions
Alkylation with iodoacetamide
Alkylation with iodoacetamide (IAA) routinely used in protein digestion protocols to
avoid reformation of disulfide bonds after denaturing and reduction. In this case we
were interested in introducing a modification in ARNO which could be detected by MS.
ARNO-Sec7 has 3 cysteines, which are all found on the same tryptic peptide.
The protocols for alkylation found in literature use highly different incubation times
and temperatures. Since many side reactions are possible155, I decided to use a short
alkylation time at room temperature. The protocol was adapted from Ref. 91:
Solutions needed: 12 M urea in water. Warm up to 50 ◦C to dissolve.
1 M IAA in water.
1. Dilute ARNO-Sec7 to 10µM in 50 mM Tris pH 8.5 (total volume 50µl).
2. Add 50µl 12 M urea and 1µl 1 M DTT.
3. Incubate 25 min at 65 ◦C.
4. Add 4.2µl fresh 1 M IAA.
5. Incubate 15 min at 25 ◦C in the dark.
6. Buffer exchange with centrifugal filters (Amicon Ultracell 10 K - 0.5 ml)
(see next section for an example).
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7. Dilute to 5µM with 10 mM NH4HCO3.
8. Add 0.4µl trypsine (1 µg/µl) and incubate for 13 h at 37◦C.
9. Dilute to 1µM with 0.1 % formic acid/water.
For LC-MS analysis of the undigested protein, an aliquot from step. 6. was diluted
to 0.1µM with 0.1 % formic acid/water and 10 % Isopropanol were added. 35µl were
injected on a C4 column as described in Section 7.1.7.2. The digested sample was
analysed by injection of 60µl of the step 9. dilution on a C18 column with the 60 min
programm (p. 138).
Biotinylation with PEG2-biotin
EZ-link iodoacetyl-PEG2-biotin (IAA-biotin) was used to biotinylate ARNO which was
used as reference in western blot and for the optimisation of the enrichment procedure.
An example of an ARNO-Sec7 biotinylation protocol is given:
1. Dilute ARNO-Sec7 to 10µM in 50 mM Tris pH 8.5 (total volume 65µl ).
2. Add 65µl 12 M urea and 1 µl 1 M DTT.
3. Incubate 25 min at 65 ◦C.
4. Add crumb∗ of IAA-biotin.
5. Incubate 20 min at 25 ◦C in the dark.
6. Buffer exchange with centrifugal filter (Amicon Ultracell 10 K - 0.5 ml)
to labelling buffer without glycerol:
Fill up the sample to 500µl and transfer to the filter.
Centrifuge at 11 000 g, 5 min.
Add ∼400µl buffer, centrifuge at 11 000 g, 5 min. Repeat 3 times.
Invert the filter in a new tube. Elute by centrifuging at 1020 g, 3 min.
SecinH3-TPD labelling of purified protein
SecinH3-TPD was conserved dried at 4◦C in the dark. Aliquots reconstituted to 25 mM
in DMSO were conserved at room temperature for several months. Further dilutions
were done directly prior usage and discarded after the experiment.
! Avoid light exposition of SecinH3-TPD.
All the labelling reactions were performed on ice with prechilled labelling buffer
(50 mM Tris pH 7.65, 300 mM NaCl, 3 mM MgCl2, 10 % Glycerol) with or without
0.005 % Triton X-100 as indicated. The proteins were prediluted in labelling buffer and
aliquoted in 1.5 ml test tubes. The compounds were prediluted in DMSO or Diglyme,
added to the protein dilution and mixed by pipetting
! Pipetting order: to avoid compound precipitation it is important to add
the compound dilution to the protein solution.
∗The amount needed is far too low to be weighted. If you can see it, it is enough.
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The samples were incubated in the dark for 10 min and then irradiated for 10
min with UV light at 365 nm (3UV Lamp, bulb power 8 W, UVA output at 1 cm
2800µW/cm2).
For western blot analysis aliquots were taken before and after irradiation, mixed
with 1/6 volume of 6X loading buffer (p. 148) and boiled for 5 min. The samples were
separated by PAGE and transferred on membrane by western blotting (p. 127). The
membrane was blocked for 1 h with 5 % BSA/TBS-T w/v (p. 148).
! Do NOT use milk to block the membrane if biotin detection is following.
For detection of total protein, the membrane was incubated with His5-antibody
(diluted 1:2 000 in 5 % BSA/TBS-T w/v with 0.02 % thimerosal) for 1 h, washed 3-
times 5 min with TBS-T and then incubated for 30-60 min with near infrared (NIR)
dye or horseradish peroxidase (HRP) coupled secondary antibody. After washing 3-
times 5 min with TBS-T, visualisation was done by enhanced chemiluminescence on a
VersaDoc 5000 CCD camera or by NIR immunofluorescence on an Odyssey scanner.
For detection of labelled protein, the membrane was incubated with either NeutrA-
vidin DyLight 800 (1:40 000 in 5 % BSA/TBS-T w/v) for 30-60 min or HRP coupled
streptavidine (1:10 000 in 5 % BSA/TBS-T w/v), washed at least 4-times 5 min with
TBS-T and visualised as above. If the NeutrAvidin DyLight 800 treated blot showed
high background an additional washing step of up to 2 h was done.
! Incubate NIR dyes dilutions in the dark.
Example of a standard labelling reaction
End concentrations: 1µM ARNO∆PBR, 20µM SecinH3-TPD, 10 % DMSO.
1. Dilute ARNO to 1.1µM in labelling buffer with 0.005 % Triton X-100.
Keep on ice.
2. Aliquot 49.5µl in a new cold tube. Keep on ice.
3. Dilute SecinH3-TPD to 125µM in DMSO at room temperature.
4. Add 5.5µl of the dilution in 3. to the aliquot in 4. Mix well by pipetting.
Incubate on ice for 10 min.
5. Transfer 25µl in a new cap, add 5µl 6X loading buffer. Boil 5 min.
6. Irradiate for 10 min at 365 nm on ice.
7. Transfer 25µl in a new cap, add 5µl 6X loading buffer. Boil 5 min.
8. Load each 12µl on a 7.5 % polyacrylamide gel.
SecinH3-TPD labelling in proteome
To test the binding and labelling specificity of SecinH3-TPD, labelling reactions in were
performed in cell lysate. Lysis of HEK or H460 cells followed this protocol:
Lysis buffer: 50 mM Tris pH 7.65, 300 mM NaCl, 3 mM MgCl2, 25µg/ml
digitonin (mix 40µl 10X labelling buffer (p. 149), 11.1µl digitonin (0.9 mg/ml
in water) and 349µl water).
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1. Collect cells grown to confluency in a 150 cm2-flask (often, frozen pellets
were used).
2. Resuspend the cells in 200µl lysis buffer.
3. Incubate 1 h on ice. Mix by vortexing from time to time.
4. Centrifuge 30 min at 4◦C, maximal speed, to separate the cell debris.
5. Transfer the supernatant in a new tube and measure the protein concen-
tration by Bradford assay (p. 127).
6. Use in the labelling reaction at a final concentration of 2 mg/ml. If the
sample is needed for the enrichment experiment (next section), use 1µg
proteome/sample.
The labelling reaction was performed as described above. The samples for enrichment
were aliquoted in 2 2-ml tubes (500µl each) before irradiation and irradiated for 15 min
instead of 10 min. Labelling buffer without glycerol and with 0.005 % Triton X-100 was
used.
7.1.8.2 Enrichment of labelled proteins and digestion on beads
Biotinylated proteins were enriched by precipitation with streptavidine beads (Pierce
Streptavidin UltraLink Resin) starting from labelled proteome (Section 7.1.8.1) or cell
lysate with added prebiotinylated protein. Trypsin digestion was done on the beads
and the supernatant collected for MS-analysis. The biotinylated peptides were eluted
from the beads with acetonitrile/water. The protocol was adapted from Ref. 92.
! Do not use Dynabeads M-280 Streptavidin. Since they are conserved in a
BSA containing buffer, high BSA signals are disturbing the MS analysis. If
working with magnetic beads is preferred, BSA free beads should be used
(e.g. Dynabeads MyOne Streptavidin C1, Invitrogen).
Solutions needed: PBS
1.2 % SDS/PBS
6 M urea/PBS (prepare fresh daily)
6 M Urea/PBS with 10 mM DTT (prepare fresh before use)
440 mM IAA in water (prepare fresh before use)
100 mM CaCl2 in water
Enrichment
1. Pool the labelling reaction (1 ml) in a 15 ml Falcon tube.
2. Add 4 ml of cold (-80◦C) acetone. Incubate at -80◦C overnight (shorter
time can be used).
3. Centrifuge at maximal speed at 0◦C for 45 min.
4. Discard the supernatant. Let the pellet dry for ∼15 min at RT.
5. Dissolve in 1 ml 1.2 % SDS/PBS by repeated cycles of sonication and
boiling.
6. Add PBS to 12 ml.
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7. Wash 100µl of beads slurry 3-times with PBS (collect the beads by cen-
trifugation at 1400 g, 3 min !Always use the soft brake function when
centrifuging the beads!).
8. Resuspend in 50µl PBS and transfer in the Falcon.
9. Incubate 3 h at RT on an overhead tumbler.
10. Centrifuge at 1400 g, 3 min. Discard the supernatant.
11. Transfer into 1.5 ml caps and wash
3-times with 1.5 ml 0.2% SDS/PBS (washing time: 0, 5 and 20 min)
3-times with 1.5 ml PBS (washing time: 0, 5 and 10 min)
3-times with 1.5 ml water (washing time: 0-1 min).
Digestion
12. Discard supernatant. Add 500µl of 6 M Urea/PBS, 10 mM DTT.
13. Incubate at 65◦C, 15 min, allow to cool down to RT.
14. Add IAA to 40 mM (45µl of 440 mM IAA in water).
15. Incubate 15 min at 37◦C on over-head tumbler.
16. Dilute the reaction to 1.5 ml with PBS, centrifuge and discard the su-
pernatant.
17. Add a solution of 100µl 2 M urea/PBS, 2µl 100 mM CaCl2, 2µg trypsin.
18. Incubate o.n. at 37◦C on an overhead tumbler.
19. Transfer the supernatant into 1.5 ml caps. Wash the beads 2-times with
25µl water and combine with the supernatant.
20. Freeze the supernatant in liquid nitrogen and dry on SpeedVac.
21. For LC-MS analysis, dissolve in 110µl 0.1 % formic acid/water and inject
100µl on a C18 column.
Elution of the labelled fragment
22. Wash the beads from step 19. with 1 ml 0.2 % SDS/PBS.
23. Wash 2-times with 1 ml PBS and once with 1 ml water.
24. Add 300µl 50 % acetonitrile/water.
25. Incubate 15 min at 65◦C.
26. Centrifuge at 1400 g, 3 min. Transfer the supernatant in a new cap,
freeze in liquid nitrogen and dry on SpeedVac.
7.1.8.3 Enzymatic digestion
Digestion of proteins was performed either in solution, on column or on beads. Digestion
on beads is described in the previous section.
Digestion in solution
Digestion in solution was mostly used during the optimisation phase.
Solutions needed: 50 mM Tris, pH 8.0
6 M urea in 50 mM Tris, pH 8.0, 10 mM DTT (prepare fresh before use)
50 mM NH4HCO3 in water (prepare fresh daily)
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440 mM IAA in 50 mM Tris, pH 8.0 (prepare fresh before use)
1 M DTT
1. Dilute the protein to 5µM with 6 M urea.
2. Incubate at 65◦C for 15 min. Allow the reaction to cool down.
3. Add 440 mM IAA to a final concentration of 40 mM.
4. Incubate at 25◦C for 15 min.
5. Add 1 M DTT to a final concentration of 30 mM.
6. Incubate at 25◦C for 15 min.
7. Dilute to 0.6 M urea with 50 mM NH4HCO3.
8. Add trypsin in 1:50 w/w ratio over protein weight.
9. Incubate at 37◦C for 4 h.
Digestion on column
The protocol of protein digestion on column was developed by Wisniewski et al. for
proteins difficult to solubilise129. Here, it offers the additional advantage of getting rid
of unbound compound and concentrating the protein.
Solutions needed: 1 M DTT in water
2 % SDS in 100 mM Tris, pH 8.0
Buffer UA: 8 M urea in 100 mM Tris, pH 8.5 (prepare fresh daily)
Buffer UB: 8 M urea in 100 mM Tris, pH 8.0 (prepare fresh daily)
50 mM IAA in buffer UA (prepare fresh before use)
Buffer ABC: 50 mM NH4HCO3 in water (prepare fresh daily)
1. To 100µl of 1µM protein solution, add 5.9µl 2 % SDS and 11.7µl 1 M
DTT (final concentrations: 0.1 % SDS, 100 mM DTT).
2. Incubate at 95◦C for 5 min.
3. Add 382.4µl buffer UA to the filter unit and mix with the protein solu-
tion.
4. Centrifuge at 14 000 g, 20◦C for 40 min.
5. Discard the flow-through.
6. Add 200µl buffer UA to the unit and centrifuge at 14 000 g, 20◦C, 40 min.
Discard the flow-through.
7. Add 100µl IAA solution and mix at 600 rpm in a thermo-mixer at 20◦C
for 1 min. Incubate without mixing for 5 min.
8. Centrifuge at 14 000 g, 20◦C, 30 min.
9. Add 100µl of buffer UB and centrifuge at 14 000 g, 20◦C, 40 min. Repeat
once.
10. Add 100µl of buffer ABC and centrifuge at 14 000 g, 20◦C, 40 min. Trans-
fer to a new collection tube.
11. Add 80µl buffer ABC with trypsin in 1:10 w/w ratio over protein weight.
Mix at 600 rpm for 1 min.
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12. Incubate the units at 37◦C o.n. in a wet chamber.
13. Centrifuge at 14 000 g, 20◦C, 40 min.
14. Add 50µl buffer UB and centrifuge the filter units at 14 000 g, 20◦C,
20 min.
7.1.8.4 Data analysis
LC-MS data were opened with Compass DataAnalysis for compound detection. The
compounds were then imported in BioTools and searched against the Mascot database.
Compound detection in Compass
1. Open the analysis file in Compass DataAnalysis.
2. Go to ’Edit’ - ’Chromatograms...’ (F7).
3. Choose Type: ’Base Peak Chromatogram’ - ’Add’.
4. The Base Peak Chromatogram (BPC) signal should be similar to the
Total Ion Chromatogramm of MSMS (TIC +All MSn). If not, the ion
selection for MSMS failed. Check you measuring parameters and if nec-
essary recalibrate the system.
5. Go to ’Find’ - ’Parameters’. In the ’AutoMS(n) tab’ set the intensity
threshold and the maximum number of compounds according to your
spectrum and sample. Tick ’Fragments
qualified by’ and choose amino acids. Press ’OK’.
6. Select ’Find’ - ’Compounds - AutoMS(n)’.
7. Export the compounds: ’File’ - ’Export’ - ’Compounds...’. Choose ’Com-
pound XML File’ as file type.
BioTools – Mascot search
1. Go BioTools and open your exported compounds.
2. Select ’View’ - ’Activate MS/MS view’.
3. Select ’Search’ - ’Mascot MS/MS ion search’.
4. Use the URL: http://www.matrixscience.com/cgi/nph-mascot.exe?1.
5. Select ’Carbamidomethyl (C)’ as ’Global Modifications’ and ’Oxidation
(M)’ as ’Variable Modifications’.
6. Choose ’SwissProt’ as database and ’Trypsin’ as enzyme.
7. Use a ’Mass Tol. MS’ of 400 ppm and ’MS/MS Tol’ of 0.5 Da. ’Charge
State’: ’1+. 2+ and 3+’. Press ’start’.
8. Look at the results and download the hits of interest with the button
’Get Hit(s)’.
9. Check the errors on the ions mass. If you are measuring the standard
sample and you notice an high deviation, it could be necessary to per-
form a ’Scan calibration’ (p. 137).
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7.1.9 Immunofluorescence
1. Sterilise the coverslips with ethanol and lay one in each well of a 6-well
culture plate.
2. Dilute the poly-L-lysine solution (0.1 % w/v in H2O, Sigma) to 0.1 mg/ml
and sterilise by filtration.
3. Dispense on the coverslips and incubate for 30 min at 37◦C.
4. Wash 2-times with water and dry on air.
5. Seed 150 000 H460 cells pro well in DMEM with 10 % FCS.
6. Incubate 24 h at 37◦C, 5 % CO2.
7. Remove the medium and add new medium with either
15µM SecinH3 in 0.4 % DMSO/DMEM
0.4 % DMSO/DMEM
50 nM demecolcine in DMEM
100 nM taxol in 0.4 % DMSO/DMEM
or DMEM
8. Incubate o.n. at 37◦C, 5 % CO2.
9. Remove medium and add new medium as in step
10. Take the coverslip, dip it in PBS and transfer it in cold (-20◦C methanol).
11. Incubate at -20◦C for at least 20 min.
12. Take the coverslip, dip it in PBS an transfer on parafilm. Cover directly
with PBS.
13. Wash 3-times with PBS.
14. Dilute the FITC coupled DM1A antibody 1:100 in 5 % BSA/TBS. Add
to the coverslips and incubate for 1 h at RT in the dark.
15. Wash 3-times with PBS and once with 0.5X PBS.
16. Dip in water and mount with VECTASHIELD mounting medium with
DAPI (Vectorlabs).
7.2 Materials
7.2.1 Special chemicals and materials for synthesis
4-Bromomethyl benzoic acid Alfa Aesar
4-(1-Azi-2,2,2-trifluoroethyl)benzoic acid (TPD-COOH) Bachem (Q-1540)
D-Desthiobiothin IBA (2-1000-002)
HPLC column: MultoHigh-Bio 300-5 C4, 125× 4 mm CS-Chromatographie Service
(Column-Nr. 2512-07) (Art.-Nr. 584 1177)
HPLC system Agilent, 1100 serie
PS3 peptide synthesiser Protein technologies, Inc.
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7.2.2 Nucleic acids
7.2.2.1 Primers
Primers were bought from Metabion deprotected and desalted. Following primers were
used:
ARNO-E156K ap tctgggcctttccgggtaggcgaaagc
ARNO-E156K sp gctttcgcctacccggaaaggcccaga
ARNOpbr ap gagatgctggcagcgtgaaagaagcggatttca
ARNOpbr sp tgaaatccgcttctttcacgctgccagcatctc
BamHI/EspI-EGFR sp ccgtctcggatcccggaagcgcacgctgcg
C-FLuc-XbaI atgtctagattacttgccgcccttcttggccttaatgag
Cyh2-KpnI taggtaccgggctgctcctgcttcttcttgactga
EcoRI-ARNO-S7 aggaattctgatatggccaatgagggcagtaagaccttgcaac
GST sp tgttcgaagatcgtttatgtcataaaacatatttaaat
GST-BamHI ap ggttccgcgtggatccccggg
GST-BamHI sp ggttccgcgtggatccccggg
GST-EGFR ap tgcgaattcgagacgtcatgctccaataaattcactgctttgtgg
GST-EGFR sp ccgtctcggatcccgaaggcgccacatcgttcg
KpnI-C-FLuc atggtaccatgagcggctacgttaacaaccccga
KpnI-Grb2 cggtaccatggaagccatcgccaaatatgacttc
KpnI-Grb2 cggtaccatggaagccatcgccaaatatgacttc
KpnI-N-FLuc atggtaccgaagatgccaaaaacattaagaagggccca
mmCyh3-XhoI atcctcgagctatttcttattggcaatcctcctt
mmCyh3pbr ap acatgttggccacgtgaaaaaggaggattgccaataagaaatag
N-FLuc-XbaI atgtctagattagccgtccttgtcgatgagagcgtt
PstI-GST sp cactgcagcatgtcccctatactaggttattggaaaattaagg
Shc-XhoI ctctcgagggattggagggcatcttctggaa
7.2.2.2 Plasmids
The plasmid cloned during this thesis are listed in Table 7.3 (p. 151). The parent
plasmids, primers, vectors and enzymes used are given.
7.2.3 Buffers for SDS-PAGE
4 X Separating gel buffer Tris pH 8.8 1.5 M
SDS 0.4 % w/v
4 X Stacking gel buffer Tris pH 6.8 500 mM
SDS 0.4 % w/v
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5 X Running buffer Tris pH 8.2 125 mM
glycine 960 mM
SDS 0.5 % w/v
6 X Loading buffer Tris pH 6.8 49.5 mM
DTT 600 mM
SDS 15 % w/v
glycerin 30 %
bromophenolblue
7.2.4 Buffers and materials for Western blotting
Cathode buffer Tris pH 9.4 25 mM
glycine 40 mM
Anode I buffer Tris pH 10.4 300 mM
Anode II buffer Tris pH 10.4 25 mM
10 X TBS buffer Tris pH 7.6 200 mM
NaCl 1.36 M
TBS-T buffer Tris pH 7.6 20 mM
NaCl 136 mM
Tween-20 0.1 % v/v
Odyssey scanner Licor
VersaDoc 5000 CCD camera BioRad
7.2.5 Buffers and materials for BRET
DMEM PAA
DPBS PAA
Metafectene Biontex
Plate reader Mithras LB 940 (Berthold technologies)
7.2.6 Buffers and materials for SPR
NTA running buffer HEPES, pH 7.4 10 mM
NaCl 300 mM
EDTA 50 µM
Tween-20 0.005 %
NTA dispenser buffer HEPES, pH 7.4 10 mM
NaCl 300 mM
EDTA 3 mM
Tween-20 0.005 %
NTA regeneration buffer HEPES, pH 7.4 10 mM
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NaCl 500 mM
EDTA 0.5 M
Tween-20 0.005 %
NiCl2 solution HEPES, pH 7.0 10 mM
NiCl2 20 mM
NaCl 150 mM
Tween-20 0.005 %
A-buffer Tris, pH 7.8 50 mM
NaCl 300 mM
EDTA 50 µM
Tween-20 0.005 %
ARNO buffer Tris pH 7.4 50 mM
NaCl 300 mM
MgCl2 3 mM
Tween-20 0.005 %
DMSO 0.5 %
Small molecule coupling buffer Na2CO3, pH 10.5 10 mM
DMSO 5 %
HBS-P (Biacore) HEPES pH 7.4 10 mM
NaCl 150 mM
Surfactant P20 0.005 %
NB: Surfactant P20 is commonly known as Tween 20.
Both chips from Biacore (GE Healtchare Life Sciences) and Xantec (XanTec bioana-
lytics GmbH, Du¨sseldorf) were used. In the following table the notation is compared:
Coating of the SPR sensor chip Notation
Biacore Xantec
Carboxymethyldextran CM5 CMDP
NTA derivatised carboxymethyldextran NTA NiP
All measurements were performed on a Biacore 3000.
7.2.7 Buffers and materials for CCMS
10 X Labelling buffer Tris pH 7.65 500 mM
NaCl 3 M
MgCl2 30 mM
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1 X Labelling buffer Tris pH 7.65 50 mM
NaCl 300 mM
MgCl2 3 mM
glycerol 10 %
Amicon Ultra-0.5 mL Centrifugal Filters Millipore
BSA Calbiochem
ESI ion trap Bruker Daltonics Esquire HCT
EZ-link iodoacetyl-PEG2-biotin Piercenet (#21334)
HPLC system Agilent, 1100 serie
Iodoacetamide Sigma
Trypsin Gold, Mass Spectrometry Grade Promega (#TB309)
Trypsin-digested BSA (CAM-modified) New England BioLabs (#P8108S)
Tubulin (porcine) Cytoskeleton (#T240)
ES tuning mix Agilent (# G2421A)
3UV ultraviolet lamps Thermo Scientific Pierce (producer: UVP)
7.2.8 Materials for immunofluorescence
Demecolcine (10µg/ml in HBSS) Sigma (#D1925)
Digitonin Sigma (#D141)
poly-L-lysine solution (0.1 % w/v in H2O) Sigma (#P8920)
Taxol (paclitaxel) Sigma (#T7191)
Monoclonal anti-α-tubulin, DM1A FITC conjugate Sigma (#F2168)
Pierce Streptavidin UltraLink Resin Thermo Scientific (#53114)
VECTASHIELD Mounting Medium with DAPI Vectorlabs (#H-1200)
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Plasmid Primer Enzymes
Cloned Template Vector (Resistance) Sense Antisense
pARNOdCC-GFP2 pARNO-RLuc pGFP2-N2 (ZEO) EcoRI-ARNOS7 cyh2-KpnI EcoRI, KpnI
pARNO(E156K)-GFP2 pARNO-GFP2 (ZEO) ARNO-E156K sp ARNO-E156K ap (QuickChange)
pCMVTag2-ARNO(E156K) pCMVTag2-ARNO(KAN) ARNO-E156K sp ARNO-E156K ap (QuickChange)
pCMVTag2-ARNO-Sec7(E156K) pCMVTag2-ARNO-Sec7 ARNO-E156K sp ARNO-E156K ap (QuickChange)
pASK-IBA-Grb2 cDNA pASK-IBA 43 plus (Amp) KpnI-Grb2 Grb2-XhoI KpnI, XhoI
pASK45-Cyt2-∆CC pCMVTag2-ARNOdCC pASK-IBA 45 plus (Amp) nonea EcoRI, HindIII
pASK45-Cyt2-∆PH pCMVTag2-ARNO-CC-Sec7 pASK-IBA 45 plus (Amp) nonea EcoRI, HindIII
pASK45-Cyt2-Full pCMVTag2-ARNO pASK-IBA 45 plus (Amp) nonea EcoRI, HindIII
pASK45-Cyt2-Full(E156K) pCMVTag2-ARNO(E156K) pASK-IBA 45 plus (Amp) nonea EcoRI, HindIII
pASK45-Cyt2-Sec7 pCMVTag2-ARNO-Sec7 pASK-IBA 45 plus (Amp) nonea EcoRI, HindIII
pASK45-Cyt2-Sec7(E156K) pCMVTag2-ARNO-Sec7(E156K) pASK-IBA 45 plus (Amp) nonea EcoRI, HindIII
pCMVneo-EGFR-NLuc pGL4.12[luc2CP] pEGFR-RLuc (KAN)b KpnI-N-FLuc N-FLuc-XbaI KpnI, XbaI
pCMVzeo-EGFR-CLuc pGL4.12[luc2CP] pEGFR-GFP2 (ZEO)b KpnI-C-FLuc C-FLuc-XbaI KpnI, XbaI
pCMVzeo-EGFR-FLuc pGL4.12[luc2CP] pEGFR-GFP2 (ZEO)b KpnI-N-FLuc C-FLuc-XbaI KpnI, XbaI
pET11-ARNOpbr pET11-ARNO (Amp) ARNOpbr sp ARNOpbr ap (QuickChange)
pET15b-mmCyh3pbr pET15b-mmCyh3 (Amp) mmCyh3pbr sp mmCyh3pbr ap (QuickChange)
pGEX-GST-EGFR pEGFR-RLuc pGEX-2T (Amp) BamHI/EspI-EGFR GST-EGFR ap Esp3I (insert)
BamHI, EcoRI
(vector)
pGST-GFP2 pGEX-2T pGFP2-N2 (ZEO) PstI-GST sp GST-BamHI ap PstI, BamHI
pGST-RLuc pGEX-2T pRLuc-N2 (KAN) PstI-GST sp GST-BamHI ap PstI, BamHI
Table 7.3: Plasmid constructs cloned - ZEO: Zeocin; KAN: kanamycin; Amp: Ampicillin.
aThe inserts were obtained by digestion of the template plasmid.
bXbaI is methylation sensitive. The vectors were purified from Dam− E.Coli.
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